HYPERTROPHIC CARDIOMYOPATHY: MODERN APPROACHES TO DIAGNOSIS AND TREATMENT

Συγγραφείς: Elena S. Eniseeva

Πηγή: Байкальский медицинский журнал, Vol 3, Iss 3, Pp 11-24 (2024)

Θεματικοί όροι: гипертрофическая кардиомиопатия, гены саркомерных белков, внезапная сердечная смерть, диастолическая дисфункция, эхокардиография, магнитно-резонансная томография, септальная миэктомия, алкогольная аблация перегородки, Medicine (General), R5-920

Περιγραφή αρχείου: electronic resource

Relation: https://www.bmjour.ru/jour/article/view/242; https://doaj.org/toc/2949-0715

Σύνδεσμος πρόσβασης: https://doaj.org/article/c95568ac32ac4492bd7f906ab7742b49

The Sudden Cardiac Death Continuum. Message 3 ; Континуум внезапной сердечной смерти. Сообщение 3

Συγγραφείς: A. Yu. Lazutkina, А. Ю. Лазуткина

Συνεισφορές: The study has no sponsorship

Πηγή: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 14, № 2 (2025); 294-310 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 14, № 2 (2025); 294-310 ; 2541-8017 ; 2223-9022

Θεματικοί όροι: кардиоренальный синдром, chronic kidney disease, continuum, sudden cardiac death, endothelial dysfunction, forecasting, cardiorenal syndrome, хроническая болезнь почек, континуум, внезапная сердечная смерть, эндотелиальная дисфункция, прогнозирование

Περιγραφή αρχείου: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/2174/1592; Омельяненко М.Г., Шумакова В.А., Урусова Е.В., Манжос А.П. Дисфункция эндотелия как маркер прогрессирования хронической болезни почек. В кн.: Криштоп В.В. (ред.) Актуальные вопросы профилактики, ранней диагностики, лечения и медицинской реабилитации больных с неинфекционными заболеваниями и травмами. Материалы III Межрегиональной научно-практической конференции врачей Центрального федерального округа с международным участием, посвященной 85-летию Ивановской государственной медицинской академии (Иваново, 23–24 ноября 2015 г.). Иваново: ИвГМА; 2015. с.131-132. https://www.elibrary.ru/download/elibrary2540731233493935.pdf [Дата обращения 28.05.25 г.]; Шумакова В.А., Омельяненко М.Г., Пахрова О.А., Гринева М.Р., Томилова И.К. Особенности гемореологии и системы NO-эндотелий у больных с хронической почечной недостаточностью. Вестник Ивановской медицинской академии. 2009;14(S):55.; Макарова Т.П., Мельникова Ю.С. Эндотелиальная дисфункция и элементный статус при хронической болезни почек у детей. Российский вестник перинатологии и педиатрии. 2018;63(2):48–52. https://doi.org/10.21508/1027-4065-2018-63-2-48-52; Schachinger V, Britten MB, Zeiger AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899–1906. PMID: 10779454 https://doi.org/10.1161/01.cir.101.16.1899; Лазуткина А.Ю., Горбунов В.В. Континуум внезапной сердечной смерти. Хабаровск: ДВГМУ; 2017.; Лазуткина А.Ю. Кардиореноцереброваскулярный континуум (Континуум хронических облитерирующих заболеваний артерий нижних конечностей & Возвращение к внезапной сердечной смерти и хронической болезни почек). Хабаровск: ДВГМУ; 2019.; Aird WC. Endothelium as an organ system. Crit Care Med. 2004;32(5 Suppl):S271–S279. PMID: 15118530 https://doi.org/10.1097/01.ccm.0000129669.21649.40; Heil SG, De Vriese AS, Kluijtmans LA, Mortier S, Den Heijer M, Blom HJ. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor. (EDHF)-mediated vasodilatation. Cell Mol Biol (Noisy-le-grand). 2004;50(8):911–916. PMID: 15704255; Евдокименко А.Н. Ультраструктурные изменения эндотелия в области нестабильных атеросклеротических бляшек каротидного синуса. Международный журнал прикладных и фундаментальных исследований. 2015;(11-5):639–647.; Омельяненко М.Г., Суховей Н.А., Назаров С.Б., Плеханов В.Г. Клиническое значение эндотелиальной дисфункции при остром коронарном синдроме без подъёма сегмента ST у лиц в возрасте до 55 лет. Российский кардиологический журнал. 2003;8(4):36–40.; Drexler Н. Nitric oxide and coronary endothelial dysfunction in humans. Review Cardiovasc Res. 1999;43:572–579. PMID: 10690329 https://doi.org/10.1016/s0008-6363(99)00152-2; Vanhoutte PM. Endothelial dysfunction and atherosclerosis. Eur Heart J. 1997;18(Suppl E):E19–29. PMID: 9402468 https://doi.org/10.1016/s0195-668x(97)90005-1; Volpe M, Cosentino F. Abnormalities of endothelial function in the pathogenesis of stroke: the importance of endothelin. J Cardiovasc Pharmacol. 2000;35(Suppl 2):S45–S48. PMID: 10976781 https://doi.org/10.1097/00005344-200000002-00011; Климов В.А. Стадии эндотелиальной дисфункции в фето-плацентарном комплексе при осложненном течении беременности. Вопросы гинекологии, акушерства и перинатологии. 2008;7(4):25–28.; Жевак Т.Н., Чеснокова Н.П., Шелехова Т.В., Бизенкова М.Н. Роль нарушения функциональной активности эндотелия в патогенезе хронического лимфолейкоза на различных стадиях его развития. Фундаментальные исследования. 2015;(1–6):1156–1160.; Олжаев С.Т., Карибаев К.Р. Эндотелиальная дисфункция у больных раком желудка: зависимость от стадии образования. Вестник Новгородского государственного университета. 2017;106(8):32–36.; Zhang J, Bottiglieri T, McCullough PA. The Central Role of Endothelial Dysfunction in Cardiorenal Syndrome. Cardiorenal Med. 2017;7:104–117. PMID: 28611784 https://doi.org/0.1159/000452283; Бойцов С.А., Драпкина О.М. Современное содержание и совершенствование стратегии высокого сердечно-сосудистого риска в снижении смертности от сердечно-сосудистых заболеваний. Терапевтический архив. 2021;93(1):4–6. https://doi.org/10.26442/00403660.2021.01.200543; Лазуткина А.Ю. Предикторы микроальбуминурии у работников локомотивных бригад: проспективное наблюдательное исследование. CardioСоматика. 2023;14(1):27–36. https://doi.org/10.17816/CS321275; Лазуткина А.Ю. Предикторы сниженной скорости клубочковой фильтрации. Патогенез. 2023;21(2):55–61. https://doi.org/10.25557/2310-0435.2023.02.55-61; Лазуткина А.Ю. Предикторы креатининемии у работников локомотивных бригад: проспективное наблюдательное исследование. Терапия. 2024;10(3):52–60. https://doi.org/10.18565/therapy.2024.3.52-60; Лазуткина А.Ю. Происхождение ретинопатии I-II степени. Аспирантский вестник Поволжья. 2023;23(4):38–43. https://doi.org/10.55531/2072-2354.2023.23.4.38-43; Лазуткина А.Ю. Патогенетические механизмы сниженной скорости клубочковой фильтрации. Патогенез. 2023;21(3):19–27. https://doi.org/10.25557/2310-0435.2023.03.19-27; Лазуткина А.Ю. Происхождение и формирование ранних изменений сетчатки глаза под воздействием факторов атеросклероза. Атеросклероз. 2023;19(4):385–403. https://doi.org/10.52727/2078-256X-2023-19-4-385-403; Лазуткина А.Ю. Формирование и прогрессирование микроальбуминурии. Артериальная гипертензия. 2024;30(6):562–576. https://doi.org/10.18705/1607-419X-2024-2418; Лазуткина А.Ю. Происхождение и прогрессирование креатининемии у мужчин трудоспособного возраста, работников локомотивных бригад. Терапия. 2024;10(9):88–101. https://doi.org/10.18565/therapy.2024.9.88-101; Дзугкоев С.Г., Можаева И.В., Такоева Е.А., Дзугкоева Ф.С., Маргиева О.И. Механизмы развития эндотелиальной дисфункции и перспективы коррекции. Фундаментальные исследования. 2014;(4–1):198–204.; Лазуткина А.Ю. Прогнозирование сердечно-сосудистых заболеваний и их исходов у работников локомотивных бригад Забайкальской железной дороги (Результаты 6-летнего проспективного наблюдения): автореф. дис. . канд. мед. наук. Чита; 2017.; Приказ Минздравсоцразвития РФ № 796 от 19.12.2005 г. «Об утверждении перечня медицинских противопоказаний к работам, непосредственно связанным с движением поездов и маневровой работой». URL: https://normativ.kontur.ru/document?moduleId=1&documentId=89575 [Дата обращения 28.05.2025 г.]; Бритов А.Н., Поздняков Ю.М., Волкова Э.Г., Драпкина О.М., Еганян Р.А., Кисляк О.М., и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6S2):2–64.; Подзолков В.И., Перепеч Н.Б., Перепеч Н.Б., Ощепкова Е.В., Остроумова О.Д., Оганов Р.Г. и др. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваскулярная терапия и профилактика. 2008;7(6 S2):1–32.; Гржибовский А.М. Анализ номинальных данных (независимые наблюдения). Экология человека. 2008;(6):58–68.; Медицинская статистика. Критерий Хи-квадрат Пирсона. URL: https://medstatistic.ru/methods/methods4.html [Дата обращения 23.06.2025]; Петри М.А., Сэбин К. Наглядная медицинская статистика. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа; 2010.; Шарашова Е.Е., Холматова К.К., Горбатова М.А., Гржибовский А.М. Применение множественного линейного регрессионного анализа в здравоохранении с использованием пакета статистических программ SPSS. Наука и здравоохранение. 2017;(3):5–31.; Анализ выживаемости и регрессия для цензурированных данных. В кн.: StatSoft: Statistica. Официальное руководство: в 5 томах. StatSoft; 1995. Т. 3, Гл. 10. с. 3473–3534.; Румянцев П.О., Саенко В.А., Румянцева У.В., Чекин С.Ю. Статистические методы анализа в клинической практике. Часть II. Анализ выживаемости и многомерная статистика. Проблемы эндокринологии. 2009;55(6):48–56. https://doi.org/10.14341/probl200955648-56; DATAtab: Online Statistics Calculator. 2025. Аvailable at: https://datatab.net [Accessed May 28, 2025].; Богуш Т.А., Башарина А.А., Романов И.П., Гришанина А.Н., Богуш Е. А., Щербаков А.М., и др. Иммунофлуоресцентный анализ экспрессии эстрогеновых рецепторов альфа в ткани немелкоклеточного рака легкого». Вестник Московского университета. Серия 2. Химия. 2024;65(3):218–227. https://doi.org/10.55959/MSU0579-9384-2-2024-65-3-218-227; Лазуткина А.Ю. Четыре вида деструктивного влияния конфаундинг-эффектов кардиоренального континуума. Медицина. 2024;12(2):25–47. https://doi.org/10.29234/2308-9113-2024-12-2-25-47; Корнышева Е.А., Платонов Д.Ю., Родионов А.А., Шабашов А.Е. Эпидемиология и статистика как инструменты доказательной медицины. 2-е изд., испр. и доп. Тверь: ТГМА; 2009.; Заболотских В.В., Васильев А.В., Терещенко Ю.П. Синергические эффекты при одновременном воздействии физических и химических факторов. Известия Самарского научного центра Российской академии наук. 2016;18(5–2):290–294.; Ласт Д.М. (ред.) Эпидемиологический словарь. [4-е изд.]. Москва: Глобус; 2009.; Черток В.М., Черток А.Г. Регуляторный потенциал капилляров мозга. Тихоокеанский медицинский журнал. 2016;(2):72–80.; Васина Л.В., Власов Т.Д., Петрищев Н.Н. Функциональная гетерогенность эндотелия (обзор). Артериальная гипертензия. 2017;23(2):88–102. https://doi.org/10.18705/1607-419X-2017-23-2-88-102; Саттарова Ф.Ф. Категориальный аспект проблемы синтеза научного знания. Актуальные вопросы современной науки. 2010;(16):272–280.; Чернова И.М., Лукьянов М.М., Сердюк С.Е., Бойцов С.А. Особенности факторов риска, механизмов развития, клинического течения и поражения органов-мишеней у больных артериальной гипертензией молодого возраста. Системные гипертензии. 2012;9(3):60–65.; Лазуткина А.Ю. Континуум внезапной сердечной смерти. Сообщение 1. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2024;13(4):578–589. https://doi.org/10.23934/2223-9022-2024-13-4-578-589; Лазуткина А.Ю. Континуум внезапной сердечной смерти. Сообщение 2. Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь». 2025;14(1):23–36. https://doi.org/10.23934/2223-9022-2025-14-1-23-36; Резник Е.В., Никитин И.Г. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (Часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019;9(1):5–22. https://doi.org/10.20514/2226-6704-2019-9-1-5-22; Ланг Т., Сесик М., Леонова В.П. (пер.) Как описывать статистику в медицине. Москва: Практическая медицина; 2011.; Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S.; Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23(1):7–17. PMID: 15643116 https://doi.org/10.1097/00004872-200501000-00004; Лазуткина А.Ю. Старение сетчатки глаза. Сообщение 1. Национальный журнал Глаукома. 2025;24(1):15–23. https://doi.org/10.53432/2078-4104-2025-24-1-15-23; Лазуткина А.Ю. Старение сетчатки глаза. Сообщение 2. Национальный журнал Глаукома. 2025;24(2):16–28. https://doi.org/10.53432/2078-4104-2025-24-2-16-28; Бабайлов В.К. Теория метода. Харкiв: ХНАДУ; 2011.; Бабайлов В.К. Анализ и синтез. Бизнес-Информ. 2012;(4):16–19.; Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: Патогенетические основы превентивной нефрологии. Нефрология. 2005;9(3):7–15.; Шутов А.М., Серов В.А. Кардиоренальный континуум или кардиоренальный синдром? Клиническая нефрология. 2010;(1):44–48.; Кобалава Ж.Д., Дмитрова Т.Б. Кардиоренальный синдром. Русский медицинский журнал. 2003;11(12):699–702.; Комаров А.Л., Шахматова О.О., Илющенко Т.А. и др. Факторы, определяющие прогноз у больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология. 2012;(1):4–14.; Филиппов А.Е., Ханджян А.М., Солодухин К.А., Никифоров В.С., Бобкова О.А. Дисфункция эндотелия и факторы риска при ишемической болезни сердца. Клиническая медицина. 2006;84(2):28–32.; Мухин Н.А. (ред.) Нефрология: национальное руководство. Москва: ГОЭТАР-Медиа; 2009.; Сигитова О.Н., Бикмухамметова Э.И., Надеева Р.А. Микроальбуминурия – диагностическое и прогностическое значение при артериальной гипертонии. Артериальная гипертензия. 2009;15(6):627–632.; Kasumovic A, Matoc I, Rebic D, Avdagic N, Halimic T. Assessment of Retinal Microangiopathy in Chronic Kidney Disease Patients. Med Arch. 2020;74(3):191–194. PMID: 32801434 https://doi.org/10.5455/medarh.2020.74.191-194; Balmforth C, van Bragt JJ, Ruijs T, Cameron JR, Kimmitt R, Moorhouse R, et al. Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. JCI Insight. 2016:1(20): e89173. PMID: 27942587 https://doi.org/10.1172/jci.insight.89173; Фурсова А.Ж., Васильева М.А., Дербенева А.С., Тарасов М.С., Чубарь Н.В., Никулич И.Ф., Гусаревич О.Г. Оптическая когерентная томография-ангиография в диагностике микроваскулярных изменений сетчатки при хронической болезни почек (клинические наблюдения). Вестник офтальмологии. 2021;137(3):97–104. https://doi.org/10.17116/oftalma202113703197; Кутырина И.М. Лечение артериальной гипертонии при хронических заболевания почек. РМЖ. 1997;5(23):7.; Weber JA, van Zanten AP. Interferences in current methods for measurements of creatinine. Clin Chem. 1991;37(5):695–700. PMID: 2032322; Коротаева Н.В., Настаушева Т.Л., Ипполитова Л.И. Функциональное состояние почек в неонатальном периоде у детей с очень низкой и экстремально низкой массой тела. Нефрология. 2022;26(4):89–96. https://doi.org/10.36485/1561-6274-2022-26-4-89-96; Янин В.Л., Углева Т.Н., Петухова С.Н., Биктимиров Т.Р., Алексеенко Л.А., Хадиева Е.Д. Функциональная и морфологическая характеристика почек новорожденных с экстремально низкой массой тела. FORCIPE. 2020;3(3):5–12.; Родригес Д.Э., Боброва Л.А., Козловская Н.Л., Столяревич Е.С. Тромботическая микроангиопатия у пациента с генетической формой тромбофилии как фактор риска прогрессирования IgA-нефропатии. Клиническая нефрология. 2017;(4):66–71.; Трифаненкова И.Г., Терещенко А.В. Флюоресцентная иридоангиография в диагностике активной ретинопатии недоношенных. Офтальмохирургия. 2020;(4):67–72. https://doi.org/10.25276/0235-4160-2020-4-67-72; Рогозина Л.А., Давыдкин И.Л., Данилова О.Е., Фатенков О.В., Гиматдинова Г.Р., Хайретдинов Р.К. Атипичный гемолитико-уремический синдром в клинической практике. Ульяновский медико-биологический журнал. 2023;(1):6–13. https://doi.org/10.34014/2227-1848-2023-1-6-13; Байко С.В., Сукало А.В. Факторы риска неблагоприятного исхода гемолитико-уремического синдрома у детей. Нефрология и диализ. 2016;18(4):404–414.; Попа А.В. Роль тромбофилии в развитии тромботической микроангиопатии при гемолитико-уремическом синдроме у детей. автореферат дис. … к.м.н. Москва; 2014. URL: https://viewer.rsl.ru/ru/rsl01005552004?page=1&rotate=0&theme=white [Дата обращения 28.05.25 г.]; Боброва Л.А., Козловская Н.Л., Шкарупо В.В. и др. Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита. Нефрология и диализ. 2010;(1):25–33.; Loirat C. Post-diarrhea hemolytic-uremic syndrome: clinical aspects. Arch Pediatr. 2001;8(Suppl 4):776s–784s. PMID: 11582927 https://doi.org/10.1016/s0929-693x(01)80196-2; Raife T, Montgomery R. New aspects in the pathogenesis and treatment of Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Rev Clin Exp Hematol. 2001;5(3):236–261. PMID: 11703817 https://doi.org/10.1046/j.1468-0734.2001.00044.x; Макарова И.Н. Функциональные взаимосвязи и взаимоотношения различных систем в организме как основа реабилитации. Физиотерапия, Бальнеология и Реабилитация. 2008;(2):36–46.; Драпкина О.М., Дроздова Л.Ю., Калинина А.М., Ипатов П.В., Егоров В.А., Иванова Е.С. и др. Организация проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения. Методические рекомендации. 2-е изд. Москва: ФГБУ «НМИЦ ТПМ» Минздрава России; 2020.; Лазуткина А.Ю. Метод определения экспозиции латентного чрезмерного потребления алкоголя в коллективах операторских профессий, влияние этого фактора на сердечно-сосудистую заболеваемость и смертность. Медицина. 2024;12(3):25–44. https://doi.org/10.29234/2308-9113-2024-12-3-25-44; Ветлугина Т.П., Прокопьева В.Д., Епимахова Е.В., Мандель А.И., Бойко А.С. Провоспалительные цитокины, окисленные белки и липиды при алкогольной зависимости. Патогенез. 2022;20(3):73–74. https://doi.org/10.25557/2310-0435.2022.03.73-74; Чернов И.А., Кириллов Ю.А., Арешидзе Д.А., Козлова М.А., Макарцева Л.А., Штемплевская Е.В. Влияние этанола на развитие оксидативного стресса и эндотелиальной дисфункции. Медицинская наука и образование Урала. 2020;3(103):143–149. https://doi.org/10.36361/1814-8999-2020-21-3-143-149; Экспресс-диагностика (скрининг) хронической алкогольной интоксикации у больных соматического профиля. Методические рекомендации №99/174 (утв. Минздравом РФ 14.03.2000). URL: https://meganorm.ru/megadoc/norm/metodicheskie-rekomendacii/1/ekspress-diagnostika_skrining_khronicheskoy_alkogolnoy.html [Дата обращения 28.05.25 г.]; Медведев С.А., Зверев Ю.П. Распространённость употребления алкоголя и его негативных последствий среди спортсменов игровых видов спорта. Клиническая практика. 2011;3(7):24–28.; Деев Р.В., Кадыкова А.И., Шилова М.А., Шарова Е.И., Федюшкина И. В., Кулемин Н.А., и др. Внезапная сердечная смерть у молодых спортсменов: результаты экзомного секвенирования. Гены и клетки. 2024;19(1):169–180. https://doi.org/10.17816/gc569201; Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden death in young competitive athletes. Circulation. 2009;119(8):1085–1092. PMID: 19221222. https://doi.org/10.1161/CIRCULATIONAHA.108.804617; Domínguez F, Adler E, García-Pavía P. Alcoholic cardiomyopathy: an update. Eur Heart J. 2024;45(26):2294–2305. PMID: 38848133 https://doi.org/10.1093/eurheartj/ehae362; Ларинцева О.С. К вопросу о внезапной сердечной смерти у спортсменов: анализ литературы за 2016 год. Спортивная медицина: наука и практика. 2017;7(2):70–76. https://doi.org/10.17238/ISSN2223-2524.2017.2.70; Shuval K, Leonard D, Chartier KG, Barlow CE, Fennis BM, Katz DL, et al. Fit and Tipsy? The Interrelationship between Cardiorespiratory Fitness and Alcohol Consumption and Dependence. Med Sci Sports Exerc. 2022;54(1):113–119. PMID: 34431829 https://doi.org/10.1249/MSS.0000000000002777; Разводовский Ю.Е., Зотов П.Б. Алкоголь как фактор гендерной разницы уровня общей смертности в России. Сибирский вестник психиатрии и наркологии. 2018;3(100):16–20. https://doi.org/10.26617/1810-3111-2018-3(100)-16-20; Разводовский Ю.Е., Зотов П.Б. Потребление алкоголя и гендерный градиент уровня общей смертности в России. Сибирский вестник психиатрии и наркологии. 2019;1(102):56–61. https://doi.org/10.26617/1810-3111-2019-1(102)-56-61; https://www.jnmp.ru/jour/article/view/2174

Διαθεσιμότητα: https://www.jnmp.ru/jour/article/view/2174
https://doi.org/10.23934/2223-9022-2025-14-2-294-310

QTC INTERVAL PROLONGATION: ROLE OF POLYPHARMACY, DRUG INTERACTION AND CONSIDERATIONS FOR CLINICAL PRACTICE ; УДЛИНЕНИЕ ИНТЕРВАЛА QTC: РОЛЬ ПОЛИПРАГМАЗИИ, ЛЕКАРСТВЕННОЕ ВЗАИМОДЕЙСТВИЕ И РЕКОМЕНДАЦИИ ДЛЯ КЛИНИЧЕСКОЙ ПРАКТИКИ

Συγγραφείς: Vladimir P. Kuzmin, Irina A. Zolotovskaya, Svetlana P. Krivova, Rais K. Khayretdinov, Violetta A. Rodionova, Olesya A. Rubanenko, Igor L. Davydkin, Владимир Петрович Кузьмин, Ирина Александровна Золотовская, Светлана Петровна Кривова, Раис Катдусович Хайретдинов, Виолетта Анатольевна Родионова, Олеся Анатольевна Рубаненко, Игорь Леонидович Давыдкин

Συνεισφορές: The authors declare no research funding.

Πηγή: Complex Issues of Cardiovascular Diseases; Том 14, № 2 (2025); 127-135 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 14, № 2 (2025); 127-135 ; 2587-9537 ; 2306-1278

Θεματικοί όροι: Внезапная сердечная смерть, Drug-induced QT prolongation, Drug side effects, Torsades de pointes, Sudden cardiac death, Лекарственно индуцированное удлинение интервала QT, Побочные эффекты лекарственных средств, Тахикардия типа «пируэт»

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/1540/1031; https://www.nii-kpssz.com/jour/article/downloadSuppFile/1540/1792; Castiglione A., Odening K. QT-Zeit – Was fange ich eigentlich damit an? [QT Interval and Its Prolongation - What Does It Mean?]. Dtsch Med Wochenschr. 2020;145(8):536-542. doi:10.1055/a-0969-6312.; Uvelin A., Pejaković J., Mijatović V. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist. J Anesth. 2017;31(3):413-423. doi:10.1007/s00540-017-2314-6.; Beach S.R., Celano C.M., Sugrue A.M., Adams C., Ackerman M.J., Noseworthy P.A., Huffman JC. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105-122. doi:10.1016/j.psym.2017.10.009.; Урясьев О.М., Жукова Л.А., Глотов С.И., Алексеева Е.А., Максимцева Е.А Удлинение и укорочение интервала QT-предикторы внезапной сердечной смерти. Земский врач. 2020;1:27-32.; Остроумова О.Д., Голобородова И.В. Влияние отдельных групп лекарственных препаратов на риск удлинения интервала QTс. Consilium Medicum. 2019; 21 (10): 95–106. doi:10.26442/20751753.2019.10.190447; Marengoni A., Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059. doi:10.1136/bmj.h1059.; Marostica E., Van Ammel K., Teisman A., Boussery K., Van Bocxlaer J., De Ridder F., Gallacher D., Vermeulen A. Modelling of drug-induced QT-interval prolongation: estimation approaches and translational opportunities. J Pharmacokinet Pharmacodyn. 2015;42(6):659-79. doi:10.1007/s10928-015-9434-0.; Khatib R., Sabir F.R.N., Omari C., Pepper C., Tayebjee M.H. Managing drug-induced QT prolongation in clinical practice. Postgrad Med J. 2021;97(1149):452-458. doi:10.1136/postgradmedj-2020-138661.; Tan H., Yan X., Chen Y., Huang G., Luo L., Li W., Lan W., Chen C., Xi X. A real-world pharmacovigilance study of drug-induced QT interval prolongation: analysis of spontaneous reports submitted to FAERS. Front Cardiovasc Med. 2024;11:1363382. doi:10.3389/fcvm.2024.1363382.; Priori S.G., Blomstrom-Lundqvist C., Mazzanti A., Blom N., Borggrefe M., Camm J., Elliott P.M., Fitzsimons D., et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867. doi:10.1093/eurheartj/ehv316.; Al-Khatib S.M., Stevenson W.G., Ackerman M.J., Bryant W.J., Callans D.J., Curtis A.B., Deal B.J., Dickfeld T., et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2018; 72: e91-e220; Dahlberg P., Diamant U.B., Gilljam T., Rydberg A., Bergfeldt L. QT correction using Bazett's formula remains preferable in long QT syndrome type 1 and 2. Ann Noninvasive Electrocardiol. 2021;26(1):e12804. doi:10.1111/anec.12804.; Yazdanpanah M.H., Naghizadeh M.M., Sayyadipoor S., Farjam M. The best QT correction formula in a non-hospitalized population: the Fasa PERSIAN cohort study. BMC Cardiovasc Disord. 2022;22(1):52. doi:10.1186/s12872-022-02502-2.; Kallergis E.M., Goudis C.A., Simantirakis E.N., Kochiadakis G.E., Vardas P.E. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Scientific World Journal 2012; 2012: 212178. doi:10.1100/2012/212178.; Baracaldo-Santamaría D., Llinás-Caballero K., Corso-Ramirez J.M., Restrepo C.M., Dominguez-Dominguez C.A., Fonseca-Mendoza D.J., Calderon-Ospina C.A. Genetic and molecular aspects of drug-induced QT interval prolongation. Int J Mol Sci 2021; 22: 8090. doi:10.3390/ijms22158090.; Welten S.J.G.C., van der Heijden A.A., Remmelzwaal S., Blom M.T., Nijpels G., Rutters F., Beulens J.W.J., Elders P.J.M.; ESCAPE-NET investigators. Prolongation of the QTc interval is associated with an increased risk of cardiovascular diseases: The Hoorn study. J Electrocardiol. 2023;80:133-138. doi:10.1016/j.jelectrocard.2023.06.001.; Vandael E., Vandenberk B., Vandenberghe J., Willems R., Foulon V. Risk factors for QTc-prolongation: systematic review of the evidence. Int J Clin Pharm. 2017;39(1):16-25. doi:10.1007/s11096-016-0414-2.; Lopez-Medina A.I., Chahal C.A.A., Luzum JA. The genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants. Pharmacogenomics. 2022;23(9):543-557. doi:10.2217/pgs-2022-0027.; Valentin J.P., Hoffmann P., Ortemann-Renon C., Koerner J., Pierson J., Gintant G., Willard J., Garnett C., Skinner M., Vargas H.M., Wisialowski T., Pugsley M.K. The Challenges of Predicting Drug-Induced QTc Prolongation in Humans. Toxicol Sci. 2022;187(1):3-24. doi:10.1093/toxsci/kfac013.; Masnoon N., Shakib S., Kalisch-Ellett L., Caughey G.E. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17(1):230. doi:10.1186/s12877-017-0621-2.; Li D., Chai S., Wang H., Dong J., Qin C., Du D., Wang Y., Du Q., Liu S. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database. Front Pharmacol. 2023;14:1259611. doi:10.3389/fphar.2023.1259611.; Kahlon S.S., Sikandar R., Tejovath S., Nair S., Hassan D., Patel K., Peddemul A., Mostafa J.A. Diagnosing Torsades De Pointes Based on Correlation to QT Interval: A Systematic Review. Cureus. 2022;14(8):e27833. doi:10.7759/cureus.27833.; Berger F.A., van der Sijs H., van Gelder T., van den Bemt P.M.L.A. The use of a clinical decision support tool to assess the risk of QT drug-drug interactions in community pharmacies. Ther Adv Drug Saf. 2021;12:2042098621996098. doi:10.1177/2042098621996098.; Tay K.Y., Ewald M.B., Bourgeois F.T. Use of QT-prolonging medications in US emergency departments, 1995-2009. Pharmacoepidemiol Drug Saf. 2014;23(1):9-17. doi:10.1002/pds.3455.; Chaverri-Fernández J.M., Díaz-Madriz J.P., Zavaleta-Monestel E., Cordero-García E., Fallas-Mora A., Escalona-Rodríguez R. The risk of treatment-induced QT interval prolongation. Farm Hosp. 2022;46(3):116-120.; Mangona E., Sandonato E., Brothers T.N., Pawasauskas J. Drug-Induced QTc Prolongation: What We Know and Where We Are Going. Curr Drug Saf. 2022;17(2):100-113. doi:10.2174/1574886316666210922153059.; Wolfes J., Sörgel R., Ellermann C., Frommeyer G., Eckardt L. Mechanisms underlying spontaneous termination of Torsade de Pointes in an experimental model of long QT syndrome. Heart Rhythm. 2024:S1547-5271(24)03423-4. doi:10.1016/j.hrthm.2024.10.009.; Uchikawa M., Hashiguchi M., Shiga T. Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004-2021). Drugs Real World Outcomes. 2022;9(4):551-559. doi:10.1007/s40801-022-00328-0.; Tisdale J.E., Chung M.K., Campbell K.B., Hammadah M., Joglar J.A., Leclerc J., Rajagopalan B.; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905.; Giudicessi J.R., Noseworthy P.A., Friedman P.A., Ackerman M.J. Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19). Mayo Clin Proc 2020; 95: 1213-1221. doi:10.1016/j.mayocp.2020.03.024.; Thu Kyaw M., Maung Z.M. Hypokalemia-Induced Arrhythmia: A Case Series and Literature Review. Cureus. 2022;14(3):e22940. doi:10.7759/cureus.22940.; Vehmeijer J.T., Koyak Z., Leerink J.M., Zwinderman A.H., Harris L., Peinado R., Oechslin E.N., Robbers-Visser D., Groenink M., Boekholdt S.M., de Winter R.J., Oliver J.M., Bouma B.J., Budts W., Van Gelder I.C., Mulder B.J.M., de Groot J.R. Identification of patients at risk of sudden cardiac death in congenital heart disease: The PRospEctiVE study on implaNTable cardIOverter defibrillator therapy and suddeN cardiac death in Adults with Congenital Heart Disease (PREVENTION-ACHD). Heart Rhythm. 2021;18(5):785-792. doi:10.1016/j.hrthm.2021.01.009.; Robison L.B., Brady W.J., Robison R.A., Charlton N. QT interval prolongation and the risk of malignant ventricular dysrhythmia and/or cardiac arrest: Systematic search and narrative review of risk related to the magnitude of QT interval length. Am J Emerg Med. 2021;49:40-47. doi:10.1016/j.ajem.2021.05.032.; Santoro F., Monitillo F., Raimondo P., Lopizzo A., Brindicci G., Gilio M., Musaico F., Mazzola M., Vestito D., Benedetto R.D., Abumayyaleh M., El-Battrawy I., Santoro C.R., Di Martino L.F.M., Akin I., De Stefano G., Fiorilli R., Cannone M., Saracino A., Angarano S., Carbonara S., Grasso S., Di Biase L., Brunetti N.D. QTc Interval Prolongation and Life-Threatening Arrhythmias During Hospitalization in Patients With Coronavirus Disease 2019 (COVID-19): Results From a Multicenter Prospective Registry. Clin Infect Dis. 2021;73(11):e4031-e4038. doi:10.1093/cid/ciaa1578.; Shah S.R., Park K., Alweis R. Long QT Syndrome: A Comprehensive Review of the Literature and Current Evidence. Curr Probl Cardiol. 2019;44(3):92-106. doi:10.1016/j.cpcardiol.2018.04.002.; Velcea A.E., Mihaila Baldea S., Nicula A.I., Vinereanu D. The role of multimodality imaging in the selection for implantable cardioverter-defibrillators in heart failure: A narrative review. J Clin Ultrasound. 2022;50(8):1066-1072. doi:10.1002/jcu.23281.; Donnellan E., Wazni O.M., Hanna M., Saliba W., Jaber W., Kanj M. Primary prevention implantable cardioverter-defibrillators in transthyretin cardiac amyloidosis. Pacing Clin Electrophysiol. 2020;43(11):1401-1403. doi:10.1111/pace.14023.; Khan K., Kim J.A., Gurgu A., Khawaja M., Cozma D., Chelu M.G. Innovations in Cardiac Implantable Electronic Devices. Cardiovasc Drugs Ther. 2022;36(4):763-775. doi:10.1007/s10557-021-07163-5.; Biton Y., Rosero S., Moss A.J., Goldenberg I., Kutyifa V., McNitt S., Polonsky B., Baman J.R., Zareba W. Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients. Europace. 2019;21(2):339-346. doi:10.1093/europace/euy149.; Ahsan S., Tousoulis D., Papageorgiou N. Implantable cardioverter-defibrillators: The shock "Paradox". Hellenic J Cardiol. 2020;61(6):428-429. doi:10.1016/j.hjc.2020.12.005.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/1540
https://doi.org/10.17802/2306-1278-2025-14-2-127-135

The Sudden Cardiac Death Continuum. Message 2 ; Континуум внезапной сердечной смерти. Сообщение 2

Συγγραφείς: A. Yu. Lazutkina, А. Ю. Лазуткина

Πηγή: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 14, № 1 (2025); 23-36 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 14, № 1 (2025); 23-36 ; 2541-8017 ; 2223-9022

Θεματικοί όροι: ренокардиальный синдром, chronic kidney disease, continuum, sudden cardiac death, predictors, cardiorenal syndrome, risk factors, renocardial syndrome, хроническая болезнь почек, континуум, внезапная сердечная смерть, предикторы, кардиоренальный синдром, факторы риска

Περιγραφή αρχείου: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/2068/1564; https://www.jnmp.ru/jour/article/view/2068/1682; Шугаева С.Н., Савилов Е.Д. Риск в эпидемиологии: терминология, основные определения и систематизация понятий. Эпидемиология и вакцинопрофилактика. 2017;97(6):73–78. https://doi.org/10.31631/2073-3046-2017-16-6-73-78; Глобальные факторы риска для здоровья. Женева: ВОЗ; 2015. URL: https://apps.who.int/iris/bitstream/handle/10665/44203/9789244563878_rus.pd [Дата обращения 27.02.25]; Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease). Circulation. 2006;114(25):2850–2870. PMID: 17179034 https://doi.org/10.1161/circulationaha.106.655688; Степин В.С. (ред.) Новая философская энциклопедия в 4-х томах. Москва: Мысль; 2010. Т. 3. с. 73–76.; Chugh SS. Sudden cardiac death in 2017: spotlight on prediction and prevention. Int J Cardiol. 2017;237:2–5. PMID: 28365183 https://doi.org/10.1016/j.ijcard.2017.03.086; Бойцов С.А., Линчак Р.М., Недбайкин А.М., Семенцова Е.В., Юсова И.А., Струкова И.В. Эпидемиология внезапной сердечной смерти: что мы знаем сегодня? Клиническая практика. 2014;4(20):13–19. https://doi.org/10.17816/clinpract5413-19; Ардашев А.В., Арутюнов Г.П., Желяков Е.Г., Беленков Ю.Н. Механизмы и причины внезапной сердечной смерти. Факторы и стратификация риска в клинической практике. Основные определения и термины. Клиническая практика. 2014;4(20):3–12. https://doi.org/10.17816/clinpract543-12; Liew R. Sudden Cardiac Death Risk Stratification – An Update. Eur. Cardiol. 2015;10(2):118–122. PMID: 30310436 https://doi.org/10.15420/ecr.2015.10.2.118; Кэмм А.Д., Люшер Т.Ф., Серруис П.В. (ред.) Болезни сердца и сосудов. Руководство Европейского общества кардиологов. Москва: ГЭОТАР-Медиа; 2011.; Авдеева Д.К., Еньшин С.И., Иванов М.Л., Корниенко А.И., Турушев Н.В., Южаков М.М. и др. Стратифицирующие модели предсказания внезапной сердечной смерти: поиск повышения эффективности прогноза продолжается. Международный научно-исследовательский журнал. 2022;121(7–2):18–24. https://doi.org/10.23670/IRJ.2022.121.7.040; Филиппов Е.В., Якушин С.С. Внезапная сердечная смерть: проблема стратификации риска и выбора лекарственного препарата. Рациональная Фармакотерапия в Кардиологии. 2011;7(2):212–218. https://doi.org/10.20996/1819-6446-2011-7-2-212-218; Илов Н.Н., Пальникова О.В., Стомпель Д.Р., Николаева Е.В., Нечепуренко А.А. Стратификация риска внезапной сердечной смерти у пациентов с сердечной недостаточностью: достаточно ли одной фракции выброса левого желудочка? Российский кардиологический журнал. 2021;26(1):3959. https://doi.org/10.15829/1560-4071-2021-3959; Лазуткина А.Ю. Континуум внезапной сердечной смерти. Сообщение 1. Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2024;13(4):578–589. https://doi.org/10.23934/2223-9022-2024-13-4-578-589; Лазуткина А.Ю., Горбунов В.В. Континуум внезапной сердечной смерти. Хабаровск: ДВГМУ; 2017.; Лазуткина А.Ю. Кардиореноцереброваскулярный континуум (Континуум хронических облитерирующих заболеваний артерий нижних конечностей & Возвращение к внезапной сердечной смерти и хронической болезни почек). Хабаровск: ДВГМУ; 2019.; Лазуткина А.Ю. Прогнозирование сердечно-сосудистых заболеваний и их исходов у работников локомотивных бригад Забайкальской железной дороги (Результаты 6-летнего проспективного наблюдения): автореф. дис. . канд. мед. наук. Чита, 2017 URL: https://www.elibrary.ru/item.asp?id=30443563 [Дата обращения 27.02.25]; Приказ Минздравсоцразвития РФ № 796 от 19.12.2005 г. (с изм. от 27.04.2017) «Об утверждении перечня медицинских противопоказаний к работам, непосредственно связанным с движением поездов и маневровой работой». URL: https://www.consultant.ru/ [Дата обращения 27.02.25]; Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6S2):2–64.; Лазуткина А.Ю. Происхождение и формирование ранних изменений сетчатки глаза под воздействием факторов атеросклероза. Атеросклероз. 2023;19(4):385–403. https://doi.org/10.52727/2078-256X-2023-19-4-385-403; Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваскулярная терапия и профилактика. 2008;7(6S2):1–32.; Петри М.А., Сэбин К. Наглядная медицинская статистика. 2-е изд., перераб. и доп. Москва: ГЭОТАР-Медиа; 2010.; Лазуткина А.Ю. Предикторы креатининемии у работников локомо­тивных бригад: проспективное наблюдательное исследование. Терапия. 2024;10(3):52–60. https://doi.org/10.18565/therapy.2024.3.52-60; Лазуткина А.Ю. Предикторы микроальбуминурии у работников локомотивных бригад: проспективное наблюдательное исследование. CardioСоматика. 2023;14(1):27–36. https://doi.org/10.17816/CS321275; Лазуткина А.Ю. Предикторы сниженной скорости клубочковой фильтрации. Патогенез. 2023;21(2):55–61. https://doi.org/10.25557/2310-0435.2023.02.55-61; Лазуткина А.Ю. Происхождение ретинопатии I-II степени. Аспирантский вестник Поволжья. 2023;23(4):38–43. https://doi.org/10.55531/2072-2354.2023.23.4.38-43; Шарашова Е.Е., Холматова К.К., Горбатова М.А., Гржибовский А.М. Применение регрессии Кокса в здравоохранении с использованием пакета статистических программ SPSS. Наука и Здравоохранение. 2017;6:5–27.; Анализ выживаемости и регрессия для цензурированных данных. В кн.: StatSoft: Statistica. Официальное руководство: в 5 томах. StatSoft; 1995. Т. 3, Гл. 10. с. 3473–3534.; Лазуткина А.Ю. Патогенетические механизмы сниженной скорости клубочковой фильтрации. Патогенез. 2023;21(3):19–27. https://doi.org/10.25557/2310-0435.2023.03.19-27; Лазуткина А.Ю. Формирование и прогрессирование микроальбуминурии. Артериальная гипертензия. 2024;30(6):562–576. https://doi.org/10.18705/1607-419X-2024-2418; Лазуткина А.Ю. Происхождение и прогрессирование креатининемии у мужчин трудоспособного возраста, работников локомотивных бригад. Терапия. 2024;10(9):88–101. https://doi.org/10.18565/therapy.2024.9.88-101; Лазуткина А.Ю. Четыре вида деструктивного влияния конфаундинг-эффектов кардиоренального континуума. Медицина. 2024;12(2):25–47. https://doi.org/10.29234/2308-9113-2024-12-2-25-47; Ожерельева Т.А. Уравнения структурного моделирования. Пер­спективы науки и образования. 2017;26(2):63–67.; Румянцев П.О., Саенко В.А., Румянцева У.В., Чекин С.Ю. Статистические методы анализа в клинической практике. Часть II. Анализ выживаемости и многомерная статистика. Проблемы эндокринологии. 2009;55(6):48–56. https://doi.org/10.14341/probl200955648-56; Корнышева Е.А., Платонов Д.Ю., Родионов А.А., Шабашов А.Е. Эпидемиология и статистика как инструменты доказательной медицины. 2-е изд., испр. и доп. Тверь: ТГМ; 2009.; Заболотских В.В., Васильев А.В., Терещенко Ю.П. Синергические эффекты при одновременном воздействии физических и химических факторов. Известия Самарского научного центра Российской академии наук. 2016;18(5–2):290–294.; Резник Е.В., Никитин И.Г. Кардиоренальный синдром у больных с сердечной недостаточностью как этап кардиоренального континуума (Часть I): определение, классификация, патогенез, диагностика, эпидемиология (обзор литературы). Архивъ внутренней медицины. 2019;9(1):5–22. https://doi.org/10.20514/2226-6704-2019-9-1-5-22; Лазуткина А.Ю. Старение сетчатки глаза. Сообщение 1. Национальный журнал глаукома. 2025;24(1):15–23. https://doi.org/10.53432/2078-4104-2025-24-1-15-23; Кочетов А.Г., Лянг О.В., Масенко В.П., Жиров И.В., Наконечников С. Н., Терещенко С.Н. Методы статистической обработки медицинских данных: методические рекомендации для ординаторов и аспирантов медицинских учебных заведений, научных работников. Москва: РКНПК; 2012.; Бабайлов В.К. Анализ и синтез. Бизнес Информ. 2012;(4):16–19.; Бабайлов В.К. Теория метода. Харкiв: ХНАДУ; 2011.; Синтез. URL: http://dic.academic.ru/dic.nsf/ruwiki/74900 [Дата обращения 27.02.25г.]; Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: Патогенетические основы превентивной нефрологии. Нефрология. 2005;9(3):7–15.; Шутов А.М., Серов В.А. Кардиоренальный континуум или кардиоренальный синдром? Клиническая нефрология. 2010;(1):44–48.; Кобалава Ж.Д., Дмитрова Т.Б. Кардиоренальный синдром. Русский медицинский журнал. Кардиология. 2003;11(12):699–702.; Комаров А.Л., Шахматова О.О., Илющенко Т.А., Джалилова Г.В., Деев А.Д., Панченко Е.П. Факторы, определяющие прогноз у больных со стабильной формой ишемической болезни сердца (по результатам пятилетнего проспективного наблюдения). Кардиология. 2012;(1):4–14.; Филиппов А.Е., Ханджян А.М., Солодухин К.А., Никифоров В.С., Бобкова О.А. Дисфункция эндотелия и факторы риска при ишемической болезни сердца. Клиническая медицина. 2006;84(2):28–32.; Мухин Н.А. (ред.) Нефрология: национальное руководство. Москва: ГЭОТАР-Медиа, 2009.; Сигитова О.Н., Бикмухамметова Э.И., Надеева Р.А. Микроальбуминурия – диагностическое и прогностическое значение при артериальной гипертонии. Артериальная гипертензия. 2009;15(6):627–632.; Kasumovic A, Matoc I, Rebic D, Avdagic N, Halimic T. Assessment of Retinal Microangiopathy in Chronic Kidney Disease Patients. Med. Arch. 2020;74(3):191–194. PMID: 28365183 https://doi.org/10.5455/medarh.2020.74.191-194; Balmforth C, van Bragt JJ, Ruijs T, Cameron JR, Kimmitt R, Moorhouse R, et al. Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. JCI Insight. 2016;1(20):e89173. PMID: 27942587 https://doi.org/10.1172/jci.insight.89173; Фурсова А.Ж., Васильева М.А., Дербенева А.С., Тарасов М.С., Чубарь Н.В., Никулич И.Ф. и др. Оптическая когерентная томография-ангиография в диагностике микроваскулярных изменений сетчатки при хронической болезни почек (клинические наблюдения). Вестник офтальмологии. 2021;137(3):97–104. https://doi.org/10.17116/oftalma202113703197; Кутырина И.М. Лечение артериальной гипертонии при хронических заболевания почек. РМЖ. 1997;5(23):7.; Weber JA, van Zanten AP. Interferences in current methods for measurements of creatinine. Clin Chem. 1991;37(5):695–700. PMID: 2032322; Коротаева Н.В., Настаушева Т.Л., Ипполитова Л.И. Функциональное состояние почек в неонатальном периоде у детей с очень низкой и экстремально низкой массой тела. Нефрология. 2022;26(4):89–96. https://doi.org/10.36485/1561-6274-2022-26-4-89-96; Янин В.Л., Углева Т.Н., Петухова С.Н., Биктимиров Т.Р., Алексеенко Л.А., Хадиева Е.Д. Функциональная и морфологическая характеристика почек новорожденных с экстремально низкой массой тела. FORCIPE. 2020;3(3):5–12.; Родригес Д.Э., Боброва Л.А., Козловская Н.Л., Столяревич Е.С. Тромботическая микроангиопатия у пациента с генетической формой тромбофилии как фактор риска прогрессирования IgA-нефропатии. Клиническая нефрология. 2017;(4):66–71.; Трифаненкова И.Г., Терещенко А.В. Флюоресцентная иридоангиография в диагностике активной ретинопатии недоношенных. Офтальмохирургия. 2020;(4):67–72. https://doi.org/10.25276/0235-4160-2020-4-67-72; Рогозина Л.А., Давыдкин И.Л., Данилова О.Е., Фатенков О.В., Гиматдинова Г.Р., Хайретдинов Р.К. Атипичный гемолитико-уремический синдром в клинической практике. Ульяновский медико-биологический журнал. 2023;(1):6-13. https://doi.org/10.34014/2227-1848-2023-1-6-13; Байко С.В., Сукало А.В. Факторы риска неблагоприятного исхода гемолитико-уремического синдрома у детей. Нефрология и диализ. 2016;18(4):404–414.; Попа А.В. Роль тромбофилии в развитии тромботической микроангиопатии при гемолитико-уремическом синдроме у детей: автореферат дис. … к.м.н. Москва; 2014. URL: https://viewer.rsl.ru/ru/rsl01005552004?page=1&rotate=0&theme=white [Дата обращения 27.02.25]; Боброва Л.А., Козловская Н.Л., Шкарупо В.В. и др. Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита. Нефрология и диализ. 2010;(1):25–33.; Loirat C. Post-diarrhea hemolytic-uremic syndrome: clinical aspects. Arch Pediatr. 2001;4:776s–784s. PMID: 11582927 https://doi.org/10.1016/s0929-693x(01)80196-2; Raife T, Montgomery R. New aspects in the pathogenesis and treatment of Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Rev Clin Exp Hematol. 2001;5(3):236–261. PMID: 11703817 https://doi.org/10.1046/j.1468-0734.2001.00044.x; Макарова И.Н. Функциональные взаимосвязи и взаимоотношения различных систем в организме как основа реабилитации. Физиотерапия, Бальнеология и Реабилитация. 2008;(2):36–46.; Драпкина О.М., Дроздова Л.Ю., Калинина А.М., Ипатов П.В., Егоров В.А., Иванова Е.С. и др. Организация проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения. Методические рекомендации. 2-е изд. Москва: ФГБУ «НМИЦ ТПМ» Минздрава России; 2020.; Лазуткина А.Ю. Метод определения экспозиции латентного чрезмерного потребления алкоголя в коллективах операторских профессий, влияние этого фактора на сердечно-сосудистую заболеваемость и смертность. Медицина. 2024;12(3):25–44. https://doi.org/10.29234/2308-9113-2024-12-3-25-44; Мельник А.А. Кардиоренальный синдром: диагностика и лечение. Почки. 2017;6(10):2–14. https://doi.org/10.22141/2307-1257.6.1.2017.93777; Ветлугина Т.П., Прокопьева В.Д., Епимахова Е.В., Мандель А.И., Бойко А.С. Провоспалительные цитокины, окисленные белки и липиды при алкогольной зависимости. Патогенез. 2022;20(3):73–74. https://doi.org/10.25557/2310-0435.2022.03.73-74; Чернов И.А., Кириллов Ю.А., Арешидзе Д.А., Козлова М.А., Макарцева Л.А., Штемплевская Е.В. Влияние этанола на развитие оксидативного стресса и эндотелиальной дисфункции. Медицинская наука и образование Урала. 2020;3(103):143–149. https://doi.org/10.36361/1814-8999-2020-21-3-143-149; Schachinger V, Britten MB, Zeiger AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899–1906. PMID: 10779454 https://doi.org/10.1161/01.cir.101.16.1899; Медведев С.А., Зверев Ю.П. Распространённость употребления алкоголя и его негативных последствий среди спортсменов игровых видов спорта. Клиническая практика. 2011;3(7):24–28.; Grant BF, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, et al. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiatry. 2017;74(9):911–923. PMID: 28793133 https://doi.org/10.1001/jamapsychiatry.2017.2161; Marshall EJ. Adolescent alcohol use: risks and consequences. Alcohol Alcohol. 2014;49(2):160–164. PMID: 24402246 https://doi.org/10.1093/alcalc/agt180; Martinsen M, Sundgot-Borgen J. Adolescent elite athletes’ cigarette smoking, use of snus, and alcohol. Scand J Med Sci Sports. 2014;24(2):439–446. PMID: 22830488 https://doi.org/10.1111/j.1600-0838.2012.01505.x; Королева Е.Д., Бутовский М.С., Малякин Г.И., Лазарев А.М., Телышев Д.В., Вахидов Т.М. Распространенность употребления алкоголя и предтренировочного кофеина и их влияние на травматизм и нарушения сна среди элитных молодых футболистов. Спортивная медицина: наука и практика. 2023;13(2):5–12. https://doi.org/10.47529/2223-2524.2023.2.4; Лазуткина А.Ю. Оценка качества скрининг-теста предикторов внезапной сердечной смерти. Современные проблемы здравоохранения и медицинской статистики. 2023;(3):149–165. https://doi.org/10.24412/2312-2935-2023-3-149-165; Пальчик А.Б., Шабалов Н.П. Токсические энцефалопатии новорожденных. 3-е изд. Москва: МЕДпресс-информ; 2013.; Габитова Н.Х, Черезова И.Н., Васина А.И. Токсическое действие хронической никотиновой и алкогольной интоксикации на новорожденного ребенка. Практическая медицина. 2023;(5):86–90. https://doi.org/10.32000/2072-1757-2023-5-86-90; Патент № 2051384 Российская Федерация МПК G01N 33/48 Боженов Ю.А., Ерохова З.Н. Способ диагностики внутриутробной алкогольной интоксикации у детей раннего возраста: 5047637/14; заявл. 13.04.1992; опубл. 27.12.1995 URL: https://rusneb.ru/catalog/000224_000128_0002051384_19951227_C1_RU/ [Дата обращения 27.02.25]; Породенко В.А., Быстрова Е.И., Ильина А.В. Активность алкогольокисляющих ферментных систем миокарда при хронической интоксикации этанолом. Кубанский научный медицинский вестник. 2008;3–4(102–103):137–140.; Породенко В.А., Корхмазов В.Т., Травенко Е.Н. Активность алкогольокисляющих ферментных систем сердца, печени и почки при остром отравлении этанолом. Кубанский научный медицинский вестник. 2010;3–4(117–118):160–162.; Халиков А.А., Кузнецов К.О., Искужина Л.Р., Халикова Л.В. Судебно-медицинские аспекты внезапной аутопсия-отрицательной сердечной смерти. Судебно-медицинская экспертиза. 2021;64(3):59–63. https://doi.org/10.17116/sudmed20216403159; https://www.jnmp.ru/jour/article/view/2068

Διαθεσιμότητα: https://www.jnmp.ru/jour/article/view/2068
https://doi.org/10.23934/2223-9022-2025-14-1-23-36

The Sudden Cardiac Death Continuum. Message 1 ; Континуум внезапной сердечной смерти. Сообщение 1

Συγγραφείς: A. Yu. Lazutkina, А. Ю. Лазуткина

Συνεισφορές: The study has no sponsorship, Исследование не имеет спонсорской поддержки

Πηγή: Russian Sklifosovsky Journal "Emergency Medical Care"; Том 13, № 4 (2024); 578-589 ; Журнал им. Н.В. Склифосовского «Неотложная медицинская помощь»; Том 13, № 4 (2024); 578-589 ; 2541-8017 ; 2223-9022

Θεματικοί όροι: факторы риска, chronic kidney disease, continuum, sudden cardiac death, predictors, cardiorenal syndrome, risk factors, хроническая болезнь почек, континуум, внезапная сердечная смерть, предикторы, кардиоренальный синдром

Περιγραφή αρχείου: application/pdf

Relation: https://www.jnmp.ru/jour/article/view/1999/1501; https://www.jnmp.ru/jour/article/view/1999/1661; Dzau VJ, Antman EM, Black HR, Hayes DL, Manson JE, Plutzky J, et al. The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease). Circulation. 2006;114(25):2850–2870. PMID: 17179034 https://doi.org/10.1161/circulationaha.106.655688; Степин В.С. (ред.) Новая философская энциклопедия: в 4-х томах. T. 3 Москва: Мысль; 2010. с. 73–76.; Ожерельева Т.А. Уравнения структурного моделирования. Перспективы науки и образования. 2017;26(2):63–67.; Лазуткина А.Ю., Горбунов В.В. Континуум внезапной сердечной смерти. Хабаровск: ДВГМУ; 2017.; Лазуткина А.Ю. Кардиореноцереброваскулярный континуум (Континуум хронических облитерирующих заболеваний артерий нижних конечностей & Возвращение к внезапной сердечной смерти и хронической болезни почек). Хабаровск: ДВГМУ; 2019.; Лазуткина А.Ю. Прогнозирование сердечно-сосудистых заболеваний и их исходов у работников локомотивных бригад Забайкальской железной дороги (Результаты 6-летнего проспективного наблюдения): автореф. дис канд. мед. наук. Чита; 2017. URL: https://www.dissercat.com/content/prognozirovanie-serdechno-sosudistykhzabolevanii-i-ikh-iskhodov-u-rabotnikov-lokomotivnykh/read (Дата обращения 27.11.2024); Приказ Минздравсоцразвития РФ № 796 от 19.12.2005 г. «Об утверждении перечня медицинских противопоказаний к работам, непосредственно связанным с движением поездов и маневровой работой». URL: https://base.garant.ru/12144914/ (Дата обращения 27.11.2024); Бритов А.Н., Поздняков Ю.М., Волкова Э.Г., Драпкина О.М., Еганян Р.А., Кисляк О.М. и др. Национальные рекомендации по кардиоваскулярной профилактике. Кардиоваскулярная терапия и профилактика. 2011;10(6, Прил. 2):2–64.; Подзолков В.И., Перепеч Н.Б., Перепеч Н.Б., Ощепкова Е.В., Остроумова О.Д., Оганов Р.Г. и др. Диагностика и лечение артериальной гипертензии: Российские рекомендации (третий пересмотр). Кардиоваскулярная терапия и профилактика. 2008;7(6, Прил. 2):1–32.; Окороков Н.А. Диагностика болезней внутренних органов: практическое руководство. Т. 6. Диагностика болезней сердца и сосудов (диагностика атеросклероза и ишемической болезни сердца). Москва: Медицинская литература; 2002.; Петри М.А., Сэбин К. Наглядная медицинская статистика: пер. с англ. 2-е изд., перераб. и доп. Москва: ГЭОТАР Медиа; 2010.; Анализ выживаемости и регрессия для цензурированных данных. В кн.: StatSoft: Statistica. Официальное руководство. В 5 томах. Том 3. Статистики. StatSoft, 1995. Гл. 10. с. 3473–3534.; Лазуткина А.Ю. Происхождение ретинопатии I–II степени. Аспирантский вестник Поволжья. 2023;23(4):38–43. https://doi.org/10.55531/2072-2354.2023.23.4.38-43; Лазуткина А.Ю. Предикторы креатининемии у работников локомотивных бригад: проспективное наблюдательное исследование. Терапия. 2024;10(3):52–60. https://doi.org/10.18565/therapy.2024.3.52-60; Лазуткина А.Ю. Происхождение и формирование ранних изменений сетчатки глаза под воздействием факторов атеросклероза. Атеросклероз. 2023;19(4):385–403. https://doi.org/10.52727/2078256X-2023-19-4-385-403; Лазуткина А.Ю. Предикторы микроальбуминурии у работников локомотивных бригад: проспективное наблюдательное исследование. CardioСоматика. 2023;14(1):27–36. https://doi.org/10.17816/CS321275; Лазуткина А.Ю., Горбунов В.В. Предикторы хронической болезни почек у работников локомотивных бригад. Клиническая нефрология. 2015;(2–3):21–26.; Румянцев П.О., Саенко В.А., Румянцева У.В., Чекин С.Ю. Статистические методы анализа в клинической практике. Часть II. Анализ выживаемости и многомерная статистика. Проблемы эндокринологии. 2009;55(6):48–56.; Лазуткина А.Ю. Четыре вида деструктивного влияния конфаундинг-эффектов кардиоренального континуума. Медицина. 2024;12(2):25–47. https://doi.org/10.29234/2308-9113-2024-12-2-25-47; Корнышева Е.А., Платонов Д.Ю., Родионов А.А., Шабашов А.Е. Эпидемиология и статистика как инструменты доказательной медицины. 2-е изд., исправ. и доп. Тверь: ТГМА; 2009.; Dougherty C. Introduction to econometrics. New York: Oxford University Press; 1992.; Заболотских В.В., Васильев А.В., Терещенко Ю.П. Синергические эффекты при одновременном воздействии физических и химических факторов. Известия Самарского научного центра Российской академии наук. 2016;18(5–2):290–294.; Бабайлов В.К. Анализ и синтез. Бизнес Информ. 2012;(4):16–19.; Бабайлов В.К. Теория метода. Харкiв: ХНАДУ; 2011.; Синтез. URL: http://dic.academic.ru/dic.nsf/ruwiki/74900 (Дата обращения 27.11.2024).; Лазуткина А.Ю. Предикторы сниженной скорости клубочковой фильтрации. Патогенез. 2023;21(2):55–61. https://doi.org/10.25557/2310-0435.2023.02.55-61; Лазуткина А.Ю. Патогенетические механизмы сниженной скорости клубочковой фильтрации. Патогенез. 2023;21(3):19–27. http:// doi.org/10.25557/2310-0435.2023.03.19-27; Schrier RW. Cardiorenal versus renocardiac syndrome: Is there a difference? Nat Clin Pract Nephrol. 2007;3(12):637. PMID: 18033224 https://doi.org/10.1038/ncpneph0673; Мельник А.А. Кардиоренальный синдром: диагностика и лечение. Почки. 2017;6(10):2–14. https://doi.org/10.22141/23071257.6.1.2017.93777; Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардиоренальный континуум: Патогенетические основы превентивной нефрологии. Нефрология. 2005;9(3):7–15.; Шутов А.М., Серов В.А. Кардиоренальный континуум или кардиоренальный синдром? Клиническая нефрология. 2010;(1):44–48.; Кобалава Ж.Д., Дмитрова Т.Б. Кардиоренальный синдром. Русский медицинский журнал. 2003;11(12):699–702.; Мухин Н.А. (ред.) Нефрология: национальное руководство. Москва: ГОЭТАР-Медиа; 2009.; Иванов Д.Д. Микроальбуминурия: взгляд нефролога. Здоровье Украины. 2008;21(1):18–19.; Сигитова О.Н., Бикмухамметова Э.И., Надеева Р.А. Микроальбуминурия – диагностическое и прогностическое значение при артериальной гипертонии. Артериальная гипертензия. 2009;15(6):627– 632.; Kasumovic A, Matoc I, Rebic D, Avdagic N, Halimic T. Assessment of Retinal Microangiopathy in Chronic Kidney Disease Patients. Med. Arch. 2020;74(3):191–194. PMID: 32801434 https://doi.org/10.5455/medarh.2020.74.191-194; Balmforth C, van Bragt JJ, Ruijs T, Cameron JR, Kimmitt R, Moorhouse R, et al. Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. JCI Insight. 2016:1(20): e89173. PMID: 27942587 https://doi.org/10.1172/jci.insight.89173; Фурсова А.Ж., Васильева М.А., Дербенева А.С., Тарасов М.С., Чубарь Н.В., Никулич И.Ф. и др. Оптическая когерентная томография-ангиография в диагностике микроваскулярных изменений сетчатки при хронической болезни почек (клинические наблюдения). Вестник офтальмологии. 2021;137(3):97–104. https://doi.org/10.17116/oftalma202113703197; Кутырина И.М. Лечение артериальной гипертонии при хронических заболевания почек. РМЖ. 1997;5(23):7.; Weber JA, van Zanten AP. Interferences in current methods for measurements of creatinine. Clin Chem. 1991;37(5):695–700. PMID: 2032322; Коротаева Н.В., Настаушева Т.Л., Ипполитова Л.И. Функциональное состояние почек в неонатальном периоде у детей с очень низкой и экстремально низкой массой тела. Нефрология. 2022;26(4):89–96. https://doi.org/10.36485/1561-6274-2022-26-4-89-96; Янин В.Л., Углева Т.Н., Петухова С.Н., Биктимиров Т.Р., Алексеенко Л.А., Хадиева Е.Д. Функциональная и морфологическая характеристика почек новорожденных с экстремально низкой массой тела. FORCIPE. 2020;3(3):5–12.; Родригес Д.Э., Боброва Л.А., Козловская Н.Л., Столяревич Е.С. Тромботическая микроангиопатия у пациента с генетической формой тромбофилии как фактор риска прогрессирования IgAнефропатии. Клиническая нефрология. 2017;(4):66–71.; Трифаненкова И.Г., Терещенко А.В. Флюоресцентная иридоангиография в диагностике активной ретинопатии недоношенных. Офтальмохирургия. 2020;(4):67–72. https://doi.org/10.25276/0235-4160-2020-4-67-72; Рогозина Л.А., Давыдкин И.Л., Данилова О.Е., Фатенков О.В., Гиматдинова Г.Р., Хайретдинов Р.К. Атипичный гемолитико-уремический синдром в клинической практике. Ульяновский медикобиологический журнал. 2023;(1):6–13. https://doi.org/10.34014/22271848-2023-1-6-13; Байко С.В., Сукало А.В. Факторы риска неблагоприятного исхода гемолитико-уремического синдрома у детей. Нефрология и диализ. 2016;18(4):404–414.; Попа А.В. Роль тромбофилии в развитии тромботической микроангиопатии при гемолитико-уремическом синдроме у детей: автореф. дис. … канд. мед. наук. Москва; 2014. URL: https://viewer.rsl.ru/ru/rsl01005552004?page=1&rotate=0&theme=white (Дата обращения 27.11.2024); Боброва Л.А., Козловская Н.Л., Шкарупо В.В., Варшавский В.А., Столяревич Е.С. Влияние генетической формы тромбофилии на клинико-морфологические проявления и характер течения хронического гломерулонефрита. Нефрология и диализ. 2010;12(1):25–33.; Loirat C. Post-diarrhea hemolytic-uremic syndrome: clinical aspects. Arch Pediatr. 2001;8(Suppl 4):776–784. PMID: 11582927 https://doi.org/10.1016/s0929-693x(01)80196-2; Raife T, Montgomery R. New aspects in the pathogenesis and treatment of Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Rev Clin Exp Hematol. 2001;5(3):536–561. PMID: 11703817 https://doi.org/10.1046/j.1468-0734.2001.00044.x; Макарова И.Н. Функциональные взаимосвязи и взаимоотношения различных систем в организме как основа реабилитации. Физиотерапия, Бальнеология и Реабилитация. 2008;(2):36–46.; Драпкина О.М., Дроздова Л.Ю., Калинина А.М., Ипатов П.В., Егоров В.А., Иванова Е.С. и др. Организация проведения профилактического медицинского осмотра и диспансеризации определенных групп взрослого населения. Методические рекомендации. 2-е изд. Москва: ФГБУ «НМИЦ ТПМ» Минздрава России; 2020.; Ветлугина Т.П., Прокопьева В.Д., Епимахова Е.В., Мандель А.И., Бойко А.С. Провоспалительные цитокины, окисленные белки и липиды при алкогольной зависимости. Патогенез. 2022;20(3):73–74. https://doi.org/10.25557/2310-0435.2022.03.73-74; Чернов И.А., Кириллов Ю.А., Арешидзе Д.А., Козлова М.А., Макарцева Л.А., Штемплевская Е.В. Влияние этанола на развитие оксидативного стресса и эндотелиальной дисфункции. Медицинская наука и образование Урала. 2020;21(3):143–149. https://doi.org/10.36361/1814-8999-2020-21-3-143-149; Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000;101(16):1899–1906. PMID: 10779454 https://doi.org/10.1161/01.cir.101.16.1899; Медведев С.А., Зверев Ю.П. Распространённость употребления алкоголя и его негативных последствий среди спортсменов игровых видов спорта. Клиническая практика. 2011;(3):24–28.; Петров Д.В. Диагностика, лечение и профилактика расстройств, вызванных употреблением алкоголя. Ярославль: ЯГМА; 2002.; Мягкова М.А., Пушкина В.В., Петроченко С.Н., Морозова В.С. Определение маркеров хронического злоупотребления алкоголем методом капиллярного электрофореза. Международный журнал прикладных и фундаментальных исследований. 2015;(12):1640–1643.; Лазуткина А.Ю. Метод определения экспозиции латентного чрезмерного потребления алкоголя в коллективах операторских профессий, влияние этого фактора на сердечно-сосудистую заболеваемость и смертность. Медицина. 2024;12(3):25–44. https://doi.org/10.29234/2308-9113-2024-12-3-25-44; Лазуткина А.Ю. Оценка качества скрининг-теста предикторов внезапной сердечной смерти. Современные проблемы здравоохранения и медицинской статистики. 2023;(3):149–165. https://doi.org/10.24412/2312-2935-2023-3-149-165; Лазуткина А.Ю. Определение экспозиции факторов риска сердечно-сосудистых заболеваний у работников локомотивных бригад Забайкальской железной дороги. Сибирский научный медицинский журнал. 2024;44(5):209–221. https://doi.org/10.18699/SSMJ20240525; https://www.jnmp.ru/jour/article/view/1999

Διαθεσιμότητα: https://www.jnmp.ru/jour/article/view/1999
https://doi.org/10.23934/2223-9022-2024-13-4-578-589

Propafenone in combination antiarrhythmic therapy for patients with catecholaminergic polymorphic ventricular tachycardia ; Применение пропафенона в составе комбинированной антиаритмической терапии у больных с катехоламинергической полиморфной желудочковой тахикардией

Συγγραφείς: E. K. Kulbachinskaya, L. S. Gordeev, V. V. Bereznitskaya, Е. К. Кульбачинская, Л. С. Гордеев, В. В. Березницкая

Πηγή: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 70, № 1 (2025); 42-49 ; Российский вестник перинатологии и педиатрии; Том 70, № 1 (2025); 42-49 ; 2500-2228 ; 1027-4065

Θεματικοί όροι: бета-адреноблокаторы, catecholaminergic polymorphic ventricular tachycardia, bidirectional ventricular tachycardia, flecainide, sudden cardiac death, beta-blockers, катехоламинергическая полиморфная желудочковая тахикардия, двунаправленная желудочковая тахикардия, флекаинид, внезапная сердечная смерть

Περιγραφή αρχείου: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/2138/1565; Roston T.M., Yuchi Z., Kannankeril P.J., Hathaway J., Vinocur J.M., Etheridge S.P., et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: Findings from an international multicentre registry. Europace 2018; 20(3): 541–547. DOI:10.1093/europace/euw389; Josephs K., Patel K., Janson C.M., Montagna C., McDonald V.T. Compound heterozygous CASQ2 mutations and long-term course of catecholaminergic polymorphic ventricular tachycardia. Mol Genet Genomic Med. 2017; 5(6): 788–794. DOI:10.1002/mgg3.323; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях. Альманах клинической медицины 2023; 51(3): 192–199. DOI 10.18786/2072–0505–2023–51–022; Webster G., Aburawi E.H., Chaix M.A., Chandler S., Foo R., Monwarul Islam A.K.M., et al. Life-threatening arrhythmias with autosomal recessive TECRL variants. Europace 2021; 23(5): 781–788. DOI:10.1093/europace/euaa376; Wang G., Zhao N., Zhong S., Wang Y., Li J. Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis. Medicine 2019; 98(34): p e16961. DOI:10.1097/MD.0000000000016961; Galimberti E.S., Knollmann B.C. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 2011; 51(5): 760–768. DOI:10.1016/j.yjmcc.2011.07.002; Marx A., Lange B., Nalenz C., Hoffmann B., Rostock T., Konrad T. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports 2019; 5(2): 74–77. DOI:10.1016/j.hrcr.2018.04.003; Li S., Lv T., Yang J., Li K., Yang Y., Zhang P. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol 2023; 50 (1): 39–49. DOI:10.1111/1440–1681.13722; Veith M., El-Battrawy I., Roterberg G., Raschwitz L., Lang S., Wolpert C., et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020; 9(4): 123–131. DOI:10.3390/jcm9040903; Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B.G., Behr E.R., Blom N.A., et al. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J, 2022. 43(40): p. 3997–4126. DOI:10.1161/CIR.0000000000000548; Duan H., Lu Y., Yan S., Qiao L., Hua Y., Li Y., et al. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. Medicine (Baltimore) 2018; 97(16): 63–68. DOI:10.1097/MD.0000000000010368; Friday K.P., Moak J.P., Fries M.H., Iqbal S.N. Catecholaminergic Ventricular Tachycardia, Pregnancy and Teenager: Are They Compatible? Pediatric Cardiology 2015; 36(7): 1542–1547. DOI:10.1007/s00246–015–1232–3; Hwang H.S., Hasdemir C., Laver D., Mehra D., Turhan K., Faggioni M., et al. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class i antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circulation: Arrhythmia and Electrophysiology 2011; 4(2): 128–135. DOI:10.1161/CIRCEP.110.959916; Lawrenz W., Krogmann O.N., Wieczorek M. Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene. Cardiol Young 2014; 24 (4): 741–744. DOI:10.1017/S1047951113001091; Kulbachinskaya E., Bereznitskaya V. Long-term clinical course of patients with catecholaminergic polymorphic ventricular tachycardia: A more than 10-year follow-up cohort study. Annals of Pediatric Cardiology 2024; 17 (3): 196–203. DOI:10.4103/apc.apc_101_24

Διαθεσιμότητα: https://www.ped-perinatology.ru/jour/article/view/2138
https://doi.org/10.21508/1027-4065-2025-70-1-42-49

Brugada syndrome: from genetic diagnostics to personalized therapy ; Синдром Бругада: от генетической диагностики к персонализированной терапии

Συγγραφείς: A. V. Iarmukhametova, A. S. Sergeev, A. P. Filatov, E. R. Shmatkova, K. Iu. Kopytova, A. A. Akhiyarova, A. F. Davletshin, K. A. Salakhova, А. В. Ярмухаметова, А. С. Сергеев, А. П. Филатов, Е. Р. Шматкова, К. Ю. Копытова, А. А. Ахиярова, А. Ф. Давлетшин, К. А. Салахова

Πηγή: Medical Genetics; Том 24, № 1 (2025); 13-22 ; Медицинская генетика; Том 24, № 1 (2025); 13-22 ; 2073-7998

Θεματικοί όροι: секвенирование нового поколения, pathogenic genetic variants, ventricular arrhythmias, sudden cardiac death, Next-Generation Sequencing, патогенные генетические варианты, желудочковые аритмии, внезапная сердечная смерть

Περιγραφή αρχείου: application/pdf

Relation: https://www.medgen-journal.ru/jour/article/view/2600/1843; Sieira J., Dendramis G., Brugada P. Pathogenesis and management of Brugada syndrome. Nat Rev Cardiol. 2016;13(12):744-756. https://doi.org/10.1038/nrcardio.2016.143.; Дульченко В.С., Василенко А.А., Магомедова А.Х., Хидирова Л.Д. Основные аспекты синдрома Бругада. Евразийский Кардиологический Журнал. 2020;1:130-135. https://doi.org/10.38109/2225-1685-2020-1-130-135.; Watanabe H., Minamino T. Genetics of Brugada syndrome. J Hum Genet. 2016;61(1):57-60. https://doi.org/10.1038/jhg.2015.97.; Sarquella-Brugada G., Campuzano O., Arbelo E., et al. Brugada syndrome: clinical and genetic findings. Genet Med. 2016;18(1):3-12. https://doi.org/10.1038/gim.2015.35.; Савилова В.В., Кондратьев А.И., Стоцкий А.О., и др. Внезапная смерть при синдроме Бругада: успешная реанимация, ЭКГ-диагностика и третичная профилактика. Вестник анестезиологии и реаниматологии. 2016;13(1):59-63. https://doi.org/10.21292/2078-5658-2016-13-1-59-63.; Juang J.J., Horie M. Genetics of Brugada syndrome. J Arrhythm. 2016;32(5):418-425. https://doi.org/10.1016/j.joa.2016.07.012.; Мирошникова В.В., Пчелина С.Н., Донников М.Ю., и др. Генетическое тестирование в кардиологии с помощью NGS панели: от оценки риска заболевания до фармакогенетики. Фармакогенетика и фармакогеномика. 2023;(1):7-19. https://doi.org/10.37489/2588-0527-2023-1-7-19.; Cerrone M., Costa S., Delmar M. The Genetics of Brugada Syndrome. Annu Rev Genomics Hum Genet. 2022;23:255-274. https://doi.org/10.1146/annurev-genom-112921-011200.; Полянская А. В. Синдром Бругада в клинической практике. Военная медицина. 2023;1(66):112-119. https://doi.org/10.51922/2074-5044.2023.1.112.; Juang J.J., Binda A., Lee S.J., et al. GSTM3 variant is a novel genetic modifier in Brugada syndrome, a disease with risk of sudden cardiac death. EBioMedicine. 2020;57:102843. https://doi.org/10.1016/j.ebiom.2020.102843.; Полякова Е.Б., Якшина А.Ю., Березницкая В.В., Щербакова Н.В. Генетически детерминированное прогрессирующее заболевание проводящей системы сердца у ребенка с вариантами гена SCN5A. Педиатрия. Журнал им. Г.Н. Сперанского. 2023;102(6):202-208. https://doi.org/10.24110/0031-403X-2023-102-6-202-208.; Комиссарова С.М., Чакова Н.Н., Ринейская Н.М., и др. Синдром Бругада: вариабельность клинических и генетических характеристик. Cardiac Arrhythmias. 2023;3(4):5-19. https://doi.org/10.17816/cardar626595.; Campuzano O, Sarquella-Brugada G, Cesar S, et al. Update on Genetic Basis of Brugada Syndrome: Monogenic, Polygenic or Oligogenic? Int J Mol Sci. 2020;21(19):7155. https://doi.org/10.3390/ijms21197155.; Зайцева А.К., Карпушев А.В., Михайлов Е.Н., и др. Молекулярные механизмы синдрома Бругада подтипа 1. Трансляционная медицина. 2017;4(4):23-35. https://doi.org/10.18705/2311-4495-2017-4-4-23-35.; Sanchez O., Campuzano O., Fernandez-Falgueras A., et al. Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome. Frontiers in Genetics. 2020; 11:590261. https://doi.org/10.3389/fgene.2020.590261.; Бородулин В.П., Бородулин Р.П. Влияние гена SCN5A на синдром врожденного синусового узла и синдром Бругада. В кн.: Наука молодых – будущее России: сборник научных статей 8-й Международной научной конференции перспективных разработок молодых ученых, Курск, 12–13 декабря 2023 года. Курск: ЗАО ≪Университетская книга≫. 2023:179-182.; Бокерия Л.А., Проничева И.В., Сергуладзе С.Ю., и др. Синдром Бругада и перекрестные синдромы сердечной натриевой каналопатии: различные маски мутаций гена SCN5A. Анналы аритмологии. 2018;15(1):40-54. https://doi.org/10.15275/annaritmol.2018.1.5.; Kinoshita K., Takahashi H., Hata Y., et al. SCN5A(K817E), a novel Brugada syndrome-associated mutation that alters the activation gating of NaV1.5 channel. Heart Rhythm. 2016;13(5):1113-1120. https://doi.org/10.1016/j.hrthm.2016.01.008.; Akai J., Makita N., Sakurada H., et al. A novel SCN5A mutation associated with idiopathic ventricular fibrillation without typical ECG findings of Brugada syndrome. FEBS Lett. 2000;479(1-2):29-34. https://doi.org/10.1016/s0014-5793(00)01875-5.; Yamagata K., Horie M., Aiba T., et al. Genotype-Phenotype Correlation of SCN5A Mutation for the Clinical and Electrocardiographic Characteristics of Probands With Brugada Syndrome: A Japanese Multicenter Registry. Circulation. 2017;135(23):2255-2270. https://doi.org/10.1161/CIRCULATIONAHA.117.027983.; Monasky M.M., Rutigliani C., Micaglio E., Pappone C. Commentary: Peptide-Based Targeting of the L-Type Calcium Channel Corrects the Loss-of-Function Phenotype of Two Novel Mutations of the CACNA1 Gene Associated With Brugada Syndrome. Front Physiol. 2021;12:682567. https://doi.org/10.3389/fphys.2021.682567.; Novelli V., Memmi M., Malovini A., et al. Role of CACNA1C in Brugada syndrome: Prevalence and phenotype of probands referred for genetic testing. Heart Rhythm. 2022;19(5):798-806. https://doi.org/10.1016/j.hrthm.2021.12.032.; Hu D., Barajas-Martinez H., Medeiros-Domingo A., et al. A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm. 2012;9(5):760-9. https://doi.org/10.1016/j.hrthm.2011.12.006.; Fukuyama M., Ohno S., Makiyama T., Horie M. Novel SCN10A variants associated with Brugada syndrome. Europace. 2016;18(6):905-11. https://doi.org/10.1093/europace/euv078.; Allegue C., Coll M., Mates .J, et al. Genetic Analysis of Arrhythmogenic Diseases in the Era of NGS: The Complexity of Clinical Decision-Making in Brugada Syndrome. PLoS One. 2015;10(7):e0133037. https://doi.org/10.1371/journal.pone.0133037.; Selga E., Campuzano O., Pinsach-Abuin M.L., et al. Comprehensive Genetic Characterization of a Spanish Brugada Syndrome Cohort. PLoS One. 2015;10(7):e0132888. https://doi.org/10.1371/journal.pone.0132888.; Kapplinger J.D., Tester D.J., Alders M., et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm. 2010;7(1):33-46. https://doi.org/10.1016/j.hrthm.2009.09.069.; Mademont-Soler I., Pinsach-Abuin M.L., Riuro H., et al. Large Genomic Imbalances in Brugada Syndrome. PLoS One. 2016;11(9):e0163514. https://doi.org/10.1371/journal.pone.0163514.; Tse G., Lee S., Liu T., et al. Identification of Novel SCN5A Single Nucleotide Variants in Brugada Syndrome: A Territory-Wide Study From Hong Kong. Front Physiol. 2020;11:574590. https://doi.org/10.3389/fphys.2020.574590.; Chung C., Bazoukis G., Matusik P., et al. Differences in the rate and yield of genetic testing in patients with brugada syndrome: A systematic review and analysis of cohort studies. Annals of Clinical Cardiology. 2023; 5(11):11-16. https://doi.org/10.4103/accj.accj_10_22; Andorin A., Behr E.R., Denjoy I., et al. Impact of clinical and genetic findings on the management of young patients with Brugada syndrome. Heart Rhythm. 2016;13(6):1274-82. https://doi.org/10.1016/j.hrthm.2016.02.013.; Ishikawa T., Kimoto H., Mishima H., et al. Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome. Eur Heart J. 2021;42(29):2854-2863. https://doi.org/10.1093/eurheartj/ehab254.; Le Scouarnec S., Karakachoff M., Gourraud J.B., et al. Testing the burden of rare variation in arrhythmia-susceptibility genes provides new insights into molecular diagnosis for Brugada syndrome. Hum Mol Genet. 2015;24(10):2757-63. https://doi.org/10.1093/hmg/ddv036.; Antzelevitch C., Patocskai B. Brugada Syndrome: Clinical, Genetic, Molecular, Cellular, and Ionic Aspects. Curr Probl Cardiol. 2016;41(1):7-57.; Iglesias D.G., Rubin J., Perez D., et al. Insights for Stratification of Risk in Brugada Syndrome. Eur Cardiol. 2019;14(1):45-49. https://doi.org/10.15420/ecr.2018.31.2.

Διαθεσιμότητα: https://www.medgen-journal.ru/jour/article/view/2600
https://doi.org/10.25557/2073-7998.2025.01.13-22

Судебно-медицинское значение определения сердечных тропонинов в биологических жидкостях трупа

Θεματικοί όροι: посмертный интервал, тропонины, внезапная сердечная смерть, сыворотка крови, судебно-медицинская экспертиза, судебная биохимия, перикардиальная жидкость, ишемия миокарда, чувствительность, специфичность

Περιγραφή αρχείου: application/pdf

Σύνδεσμος πρόσβασης: https://rep.vsu.by/handle/123456789/45158

Подкожные кардиовертеры-дефибрилляторы в сравнении с трансвенозными: 6-месячное наблюдение

Συγγραφείς: А.В. Верещагина, Т.М. Ускач, О.В. Сапельников, В.А. Аманатова, И.Р. Гришин

Πηγή: Патология кровообращения и кардиохирургия, Vol 27, Iss 1, Pp 17-29 (2023)

Θεματικοί όροι: внезапная сердечная смерть, кардиовертер-дефибриллятор, первичная профилактика, хроническая сердечная недостаточность, Surgery, RD1-811

Περιγραφή αρχείου: electronic resource

Relation: https://journalmeshalkin.ru/index.php/heartjournal/article/view/1175; https://doaj.org/toc/1681-3472; https://doaj.org/toc/2500-3119

Σύνδεσμος πρόσβασης: https://doaj.org/article/aaf97414ae1442e89b5d49cd29be97e0

Management of Catecholaminergic Polymorphic Ventricular Tachycardia ; Лечение катехоламинергической полиморфной желудочковой тахикардии

Συγγραφείς: Ekaterina K. Kulbachinskaya, Vera V. Bereznitskaya, Е. К. Кульбачинская, В. В. Березницкая

Συνεισφορές: Not specified., Отсутствует.

Πηγή: Current Pediatrics; Том 23, № 2 (2024); 63-70 ; Вопросы современной педиатрии; Том 23, № 2 (2024); 63-70 ; 1682-5535 ; 1682-5527

Θεματικοί όροι: имплантируемый кардиовертер-дефибриллятор, atenolol, propafenone, primary channelopathy, sudden cardiac death, left side sympathectomy, implantable cardioverter defibrillator, атенолол, пропафенон, первичная каналопатия, внезапная сердечная смерть, левосторонняя симпатэктомия

Περιγραφή αρχείου: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3449/1364; Pflaumer A, Davis AM. An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2019;28(3):366–369. doi: https://doi.org/10.1016/j.hlc.2018.10.016; Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126. doi: https://doi.org/10.1093/eurheartj/ehac262; Kurtzwald-Josefson E, Hochhauser E, Katz G, et al. Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice. J Appl Physiol (1985). 2012;113(11):1677–1683. doi: https://doi.org/10.1152/japplphysiol.00818.2012; Ostby SA, Bos JM, Owen HJ, et al. Competitive Sports Participation in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia: A Single Center’s Early Experience. JACC Clin Electrophysiol. 2016;2(3):253–262. doi: https://doi.org/10.1016/j.jacep.2016.01.020; Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–867l. doi: https://doi.org/10.1093/eurheartj/ehv316; Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41–e44. doi: https://doi.org/10.1016/j.hrthm.2016.09.012; Leren IS, Saberniak J, Majid E, et al. Nadolol decreases the incidence and severity of ventricular arrhythmias during exercise stress testing compared with β1-selective β-blockers in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2016;13(2):432–440. doi: https://doi.org/10.1016/j.hrthm.2015.09.029; Peltenburg PJ, Kallas D, Bos JM, et al. An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2022;145(5):333–344. doi: https://doi.org/10.1161/CIRCULATIONAHA.123.064786; Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119(18):2426–2434. doi: https://doi.org/10.1161/CIRCULATIONAHA.108.829267; Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Analysis of Therapeutic Strategies and Outcomes from an International Multicenter Registry. Circ Arrhythm Electrophysiol. 2015;8(3):633–642. doi: https://doi.org/10.1161/CIRCEP.114.002217; Sumitomo N, Harada K, Nagashima M, et al. Catecholaminergic polymorphic ventricular tachycardia: Electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart. 2003;89(1):66–70. doi: https://doi.org/10.1136/heart.89.1.66; Березницкая В.В., Кульбачинская Е.К., Школьникова М.А. Особенности клинических проявлений и эффективность антиаритмической терапии у больных с катехоламинергической полиморфной желудочковой тахикардией // Вестник аритмологии. — 2021.—Т.28.—№4.—С.62–69.—doi:https://doi.org/10.35336/VA-2021-4-62-69; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях // Альманах клинической медицины. — 2023. — Т. 51. — № 3. — С. 192–199. — doi: https://doi.org/10.18786/2072-0505-2023-51-022; Mazzanti A, Kukavica D, Trancuccio A, et al. Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With β-Blockers. JAMA Cardiol. 2022;7(5):504–512. doi: https://doi.org/10.1001/jamacardio.2022.0219; Veith M, El-Battrawy I, Roterberg G, et al. Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020;9(4):903. doi: https://doi.org/10.3390/jcm9040903; Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69–74. doi: https://doi.org/10.1161/01.cir.0000020013.73106.d8; Marai I, Khoury A, Suleiman M, et al. Importance of ventricular tachycardia storms not terminated by implantable cardioverter defibrillators shocks in patients with CASQ2 associated catecholaminergic polymorphic ventricular tachycardia. Am J Cardiol. 2012;110(1):72–76. doi: https://doi.org/110.1016/j.amjcard.2012.02.049; Kawata H, Ohno S, Aiba T, et al. Catecholaminergic polymorphic ventricular tachycardia (CPVT) associated with ryanodine receptor (RyR2) gene mutations: Long-term prognosis after initiation of medical treatment. Circ J. 2016;80(9):1907–1915. doi: https://doi.org/10.1253/circj.CJ-16-0250; Li Y, Peng X, Lin R, et al. The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia. Front Physiol. 2022;13:850117. doi: https://doi.org/10.3389/fphys.2022.850117; Salvage SC, Huang CL, Fraser JA, Dulhunty AF. How does flecainide impact RyR2 channel function? J Gen Physiol. 2022;154(9): e202213089. doi: https://doi.org/10.1085/jgp.202213089; Bannister ML, MacLeod KT, George CH. Moving in the right direction: elucidating the mechanisms of interaction between flecainide and the cardiac ryanodine receptor. Br J Pharmacol. 2022;179(11):2558–2563. doi: https://doi.org/10.1111/bph.15718; Kryshtal DO, Blackwell DJ, Egly CL, et al. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT. Circ Res. 2021;128(3):321–331. doi: https://doi.org/10.1161/CIRCRESAHA.120.316819; Kannankeril PJ, Moore JP, Cerrone M, et al. Efficacy of flecainide in the treatment of catecholaminergic polymorphic ventricular tachycardia a randomized clinical trial. JAMA Cardiology. 2017;2(7):759–766. doi: https://doi.org/10.1001/jamacardio.2017.1320; Khoury A, Marai I, Suleiman M, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10(11):1671–1675. doi: https://doi.org/10.1016/j.hrthm.2013.08.011; Watanabe H, Van Der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10(4):542–547. doi: https://doi.org/10.1016/j.hrthm.2012.12.035; Jacquemart C, Ould Abderrahmane F, Massin MM. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol. 2012;45(6):736–738. doi: https://doi.org/10.1016/j.jelectrocard.2012.05.002; Pott C, Dechering DG, Reinke F, et al. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: A case report and review of the current literature. Europace. 2011;13(6):897–901. doi: https://doi.org/10.1093/europace/euq517; Padfield GJ, AlAhmari L, Lieve KV, et al. Flecainide monotherapy is an option for selected patients with catecholaminergic polymorphic ventricular tachycardia intolerant of beta-blockade. Heart Rhythm. 2016;13(2):609–613. doi: https://doi.org/10.1016/j.hrthm.2015.09.027; Savio-Galimberti E, Knollmann BC. Channel activity of cardiac ryanodine receptors (RyR2) determines potency and efficacy of flecainide and R-propafenone against arrhythmogenic calcium waves in ventricular cardiomyocytes. PLoS One. 2015;10(6):e0131179. doi: https://doi.org/10.1371/journal.pone.0131179; Marx A, Lange B, Nalenz C, et al. A 35-year effective treatment of catecholaminergic polymorphic ventricular tachycardia with propafenone. HeartRhythm Case Reports. 2019;5(2):74–77. doi: https://doi.org/10.1016/j.hrcr.2018.04.003; Li S, Lv T, Yang J, et al. A gain of function ryanodine receptor 2 mutation (R1760W-RyR2) in catecholaminergic polymorphic ventricular tachycardia. Clin Exp Pharmacol Physiol. 2023;50(1):39–49. doi: https://doi.org/10.1111/1440-1681.13722; Vaksmann G, Klug D. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2018;41(10):1378–1380. doi: https://doi.org/10.1111/pace.13446; Kohli U, Aziz Z, Beaser AD, Nayak HM. A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2019;42(8):1146–1154. doi: https://doi.org/10.1111/pace.13668; Roston TM, Hart A, Krahn AD, Sanatani S. The challenge of implantable cardioverter-defibrillator programming and shock interpretation in treatment-refractory catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Med (Hagerstown). 2019;20(8):569–571. doi: https://doi.org/10.2459/JCM.0000000000000814; Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: Success depends on substrate. Circ Arrhythm Electrophysiol. 2013;6(3):579–587. doi: https://doi.org/10.1161/CIRCEP.113.000170; Eckert H, El-Battrawy I, Veith M, et al. Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Pers Med. 2022;12(4):536. doi: https://doi.org/10.3390/jpm12040536.; Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(12):1319–1321. doi: https://doi.org/10.1111/j.1540-8167.2008.01211.x; Itoh H, Murayama T, Kurebayashi N, et al. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation. J Electrocardiol. 2021;69:111-118. doi: https://doi.org/10.1016/j.jelectrocard.2021.09.015; Richardson E, Spinks C, Davis A, et al. Psychosocial Implications of Living with Catecholaminergic Polymorphic Ventricular Tachycardia in Adulthood. J Genet Couns. 2018;27(3):549-557. doi: https://doi.org/10.1007/s10897-017-0152-1; Roses-Noguer F, Jarman JWE, Clague JR, Till J. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2014;11(1):58-66. doi: https://doi.org/10.1016/j.hrthm.2013.10.027; Roston TM, Jones K, Hawkins NM, et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review. Heart Rhythm. 2018;15(12):1791-1799. doi: https://doi.org/10.1016/j.hrthm.2018.06.046; Van Der Werf C, Lieve KV, Bos JM, et al. Implantable cardioverter-defibrillators in previously undiagnosed patients with catecholaminergic polymorphic ventricular tachycardia resuscitated from sudden cardiac arrest. Eur Heart J. 2019;40(35):2953-2961. doi: https://doi.org/10.1093/eurheartj/ehz309; Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm. 2006;3(12):1486-1489.; Sy RW, Gollob MH, Klein GJ, et al. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2011;8(6):864-871. doi: https://doi.org/10.1016/j.hrthm.2011.01.048; De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical Management of Catecholaminergic Polymorphic Ventricular Tachycardia: The Role of Left Cardiac Sympathetic Denervation. Circulation. 2015;131(25):2185-2193. doi: https://doi.org/10.1161/CIRCULATIONAHA.115.015731; Schwartz PJ, Snebold NG, Brown AM. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold. Am J Cardiol. 1976;37(7):1034-1040. doi: https://doi.org/10.1016/0002-9149(76)90420-3; Yagishita D, Chui RW, Yamakawa K, et al. Sympathetic nerve stimulation, not circulating norepinephrine, modulates T-peak to T-end interval by increasing global dispersion of repolarization. Circ Arrhythm Electrophysiol. 2015;8(1):174-185. doi: https://doi.org/10.1161/CIRCEP.114.002195; Jonesco T. Traitement chirurgical de l'angine de poitrine par la resection dusympathique cervico-thoracique. Presse Med. 1921;20:30.; Moss AJ, McDonald J. Unilateral cervicothoracic sympathetic ganglionectomy for the treatment of long QT interval syndrome. N Engl J Med. 1971;285(16):903-904. doi: https://doi.org/10.1056/NEJM197110142851607; Schwartz PJ, Periti M, Malliani A. The long Q-T syndrome. Am Heart J. 1975;89(3):378-390. doi: https://doi.org/10.1016/0002-8703(75)90089-7; Schwartz PJ, Malliani A. Electrical alternation of the T-wave: clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J. 1975;89(1): 45-50. doi: https://doi.org/10.1016/0002-8703(75)90008-3; Wilde AAM, Bhuiyan ZA, Crotti L, et al. Left cardiac sympathetic denervation for catecholaminergic polymorphic ventricular tachycardia. N Engl J Med. 2008;358(19):2024-2029. doi: https://doi.org/10.1056/NEJMoa0708006; Atallah J, Fynn-Thompson F, Cecchin F, et al. Video-Assisted Thoracoscopic Cardiac Denervation: A Potential Novel Therapeutic Option for Children With Intractable Ventricular Arrhythmias. Ann Thorac Surg. 2008;86(5):1620-1625. doi: https://doi.org/10.1016/j.athoracsur.2008.07.006; Schwartz PJ, Ackerman MJ. Cardiac sympathetic denervation in the prevention of genetically mediated life-threatening ventricular arrhythmias. Eur Heart J. 2022;43(22):2096-2102. doi: https://doi.org/10.1093/eurheartj/ehac134; Cho Y. Left cardiac sympathetic denervation: An important treatment option for patients with hereditary ventricular arrhythmias. J Arrhythm. 2016;32(5):340-343. doi: https://doi.org/10.1016/j.joa.2015.08.002; Schwartz PJ, Locati EH, Moss AJ, et al. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report. Circulation. 1991;84(2):503-511. doi: https://doi.org/10.1161/01.cir.84.2.503; Li C, Hu D, Shang L, et al. Surgical left cardiac sympathetic denervation for long QT syndrome: effects on QT interval and heart rate. Heart Vessels. 2005;20(4):137-141. doi: https://doi.org/10.1007/s00380-005-0820-1; Waddell-Smith KE, Ertresvaag KN, Li J, et al. Physical and Psychological Consequences of Left Cardiac Sympathetic Denervation in Long-QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia. Circ Arrhythm Electrophysiol. 2015;8(5): 1151-1158. doi: https://doi.org/10.1161/CIRCEP.115.003159; Dusi V, De Ferrari GM, Pugliese L, Schwartz PJ. Cardiac Sympathetic Denervation in Channelopathies. Front Cardiovasc Med. 2019;6:27. doi: https://doi.org/10.3389/fcvm.2019.00027; Perez PR, Hylind RJ, Roston TM, et al. Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2023;32(7):790-797. doi: https://doi.org/10.1016/j.hlc.2023.01.018

Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/3449
https://doi.org/10.15690/vsp.v23i2.2740

Diagnosis of Catecholaminergic Polymorphic Ventricular Tachycardia ; Диагностика катехоламинергической полиморфной желудочковой тахикардии

Συγγραφείς: Ekaterina K. Kulbachinskaya, Vera V. Bereznitskaya, Е. К. Кульбачинская, В. В. Березницкая

Πηγή: Current Pediatrics; Том 23, № 4 (2024); 213-219 ; Вопросы современной педиатрии; Том 23, № 4 (2024); 213-219 ; 1682-5535 ; 1682-5527

Θεματικοί όροι: внезапная сердечная смерть, RYR2 gene, CASQ2 gene, primary channelopathies, sudden cardiac death, ген RYR2, ген CASQ2, первичные каналопатии

Περιγραφή αρχείου: application/pdf

Relation: https://vsp.spr-journal.ru/jour/article/view/3564/1384; Lahtinen AM, Havulinna AS, Noseworthy PA, et al. Prevalence of arrhythmia-associated gene mutations and risk of sudden cardiac death in the Finnish population. Ann Med. 2013;45(4):328–335. doi: https://doi.org/10.3109/07853890.2013.783995; Broendberg AK, Nielsen JC, Bjerre J, et al. Nationwide experience of catecholaminergic polymorphic ventricular tachycardia caused by RyR2 mutations. Heart. 2017;103(12):901–909. doi: https://doi.org/10.1136/heartjnl-2016-310509; Pflaumer A, Wilde AAM, Charafeddine F, Davis AM. 50 Years of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) — Time to Explore the Dark Side of the Moon. Heart Lung Circ. 2020;29(4):520–528. doi: https://doi.org/10.1016/j.hlc.2019.10.013; Kawata H, Ohno S, Aiba T, et al. Catecholaminergic polymorphic ventricular tachycardia (CPVT) associated with ryanodine receptor (RyR2) gene mutations: Long-term prognosis after initiation of medical treatment. Circ J. 2016;80(9):1907–1915. doi: https://doi.org/10.1253/circj.CJ-16-0250; Jiang H, Li XM, Ge HY, et al. Investigation of Catecholaminergic Polymorphic Ventricular Tachycardia Children in China: Clinical Characteristics, Delay to Diagnosis, and Misdiagnosis. Chin Med J (Engl). 2018;131(23):2864–2865. doi: https://doi.org/10.4103/0366-6999.246078; Swan H, Piippo K, Viitasalo M, et al. Arrhythmic disorder mapped to chromosome 1q42–q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol. 1999;34(7):2035–2042. doi: https://doi.org/10.1016/s0735-1097(99)00461-1; Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103(2): 196–200. doi: https://doi.org/10.1161/01.cir.103.2.196; Eldar M, Pras E, Lahat H. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in bedouin families from Israel. Cold Spring Harb Symp Quant Biol. 2002;67:333–337. doi: https://doi.org/10.1101/sqb.2002.67.333; Perez-Riera AR, Barbosa-Barros R, de Rezende Barbosa MPC, et al. Catecholaminergic polymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2018;23(4):e12512. doi: https://doi.org/10.1111/anec.12512; Roston TM, Yuchi Z, Kannankeril PJ, et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: Findings from an international multicentre registry. Europace. 2018;20(3):541–547. doi: https://doi.org/10.1093/europace/euw389; Ohno S, Hasegawa K, Horie M. Gender differences in the inheritance mode of RYR2 mutations in catecholaminergic polymorphic ventricular tachycardia patients. PLoS One. 2015;10(6):e0131517. doi: https://doi.org/10.1371/journal.pone.0131517; Steinberg C, Roston TM, van der Werf C, et al. RYR2- ryanodinopathies: from calcium overload to calcium deficiency. Europace. 2023;25(6):euad156. doi: https://doi.org/10.1093/europace/euad156; Lanner JT, Georgiou DK, Joshi AD, Hamilton SL. Ryanodine receptors: structure, expression, molecular details, and function in calcium release. Cold Spring Harb Symp Quant Biol. 2010;2(11):a003996. doi: https://doi.org/10.1101/cshperspect.a003996; Morano I. The Contractile Machines of the Heart. Adv Exp Med Biol. 2024;1441:417–433. doi: https://doi.org/10.1007/978-3-031-44087-8_21; Priori SG, Mazzanti A, Santiago DJ, et al. Precision Medicine in Catecholaminergic Polymorphic Ventricular Tachycardia: JACC Focus Seminar 5/5. J Am Coll Cardiol. 2021;77(20):2592–2612. doi: https://doi.org/10.1016/j.jacc.2020.12.073; Xiong J, Liu X, Gong Y, et al. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causingmutation in cardiac calcium release channel RyR2. J Mol Cell Cardiol. 2018;117:26–35. doi: https://doi.org/10.1016/j.yjmcc.2018.02.014; Gillis AM, Dobrev D. Targeting the RyR2 to Prevent Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2022;15(10):e011514. doi: https://doi.org/10.1161/circep.122.011514; Ormerod JOM, Ormondroyd E, Li Y, et al. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022;15(1):e003589. doi: https://doi.org/10.1161/circgen.121.003589; Roston TM, Wei J, Guo W, et al. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022;7(1): 84–92. doi: https://doi.org/10.1001/jamacardio.2021.4458; Sleiman Y, Lacampagne A, Meli AC. “Ryanopathies” and RyR2 dysfunctions: can we further decipher them using in vitro human disease models? Cell Death Dis. 2021;12(11):1041. doi: https://doi.org/10.1038/s41419-021-04337-9; Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2- Encoded Ryanodine Receptor/Calcium Release Channel in Patients Diagnosed Previously With Either Catecholaminergic Polymorphic Ventricular Tachycardia or Genotype Negative, Exercise-Induced Long QT Syndrome. A Comprehensive Open Reading Frame Mutational Analysis. J Am Coll Cardiol. 2009;54(22):2065–2074. doi: https://doi.org/10.1016/j.jacc.2009.08.022; Kapplinger JD, Pundi KN, Larson NB, et al. Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation. Circ Genom Precis Med. 2018;11(2):e001424. doi: https://doi.org/10.1161/CIRCGEN.116.001424; Kapplinger JD, Tester DJ, Ackerman MJ. Response by Kapplinger et al to Letter Regarding Article, “Yield of the RYR2 Genetic Test in Suspected Catecholaminergic Polymorphic Ventricular Tachycardia and Implications for Test Interpretation”. Circ Genom Precis Med. 2018;11(5):e002176. doi: https://doi.org/10.1161/CIRCGEN.118.002176; Ng K, Titus EW, Lieve KV, et al. An International Multicenter Evaluation of Inheritance Patterns, Arrhythmic Risks, and Underlying Mechanisms of CASQ2-Catecholaminergic Polymorphic Ventricular Tachycardia. Circulation. 2020;142(10):932–947. doi: https://doi.org/10.1161/circulationaha.120.045723; Кульбачинская Е.К., Березницкая В.В. CASQ2: клинико-генетические особенности катехоламинергической полиморфной желудочковой тахикардии в трех семьях // Альманах клинической медицины. — 2023. — Т. 51. — № 3. — С. 192–199. — doi: https://doi.org/10.18786/2072-0505-2023-51-022; Webster G, Aburawi EH, Chaix MA, et al. Life-threatening arrhythmias with autosomal recessive TECRL variants. Europace. 2021;23(5): 781–788. doi: https://doi.org/10.1093/europace/euaa376; Xie L, Hou C, Jiang X, et al. A compound heterozygosity of Tecrl gene confirmed in a catecholaminergic polymorphic ventricular tachycardia family. Eur J Med Genet. 2019;62(7):103631. doi: https://doi.org/10.1016/j.ejmg.2019.01.018; Moscu-Gregor A, Marschall C, Müntjes C, et al. Novel variants in TECRL cause recessive inherited CPVT type 3 with severe and variable clinical symptoms. J Cardiovasc Electrophysiol. 2020;31(6): 1527–1535. doi: https://doi.org/10.1111/jce.14446; Devalla HD, Gélinas R, Aburawi EH, et al. TECRL, a new life-threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVT. EMBO Mol Med. 2016;8(12):1390–1408. doi: https://doi.org/10.15252/emmm.201505719; Seidlmayer LK, Riediger F, Pagonas N, et al. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: A case report 11 Medical and Health Sciences 1102 Cardiorespiratory Medicine and Haematology. J Med Case Rep. 2018;12(1):298. doi: https://doi.org/10.1186/s13256-018-1825-6; Pflaumer A, Davis AM. An Update on the Diagnosis and Management of Catecholaminergic Polymorphic Ventricular Tachycardia. Heart Lung Circ. 2019;28(3):366–369. doi: https://doi.org/10.1016/j.hlc.2018.10.016; Vacanti G, Maragna R, Priori SG, Mazzanti A. Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases. Curr Opin Pediatr. 2017;29(5):552–559. doi: https://doi.org/10.1097/MOP.0000000000000537; Roston TM, Vinocur JM, Maginot KR, et al. Catecholaminergic Polymorphic Ventricular Tachycardia in Children: Analysis of Therapeutic Strategies and Outcomes from an International Multicenter Registry. Circ Arrhythm Electrophysiol. 2015;8(3): 633–642. doi: https://doi.org/10.1161/CIRCEP.114.002217; Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40): 3997–4126. doi: https://doi.org/10.1093/eurheartj/ehac262; Giordano U, Di Piazza MC, Bonomo V, et al. Catecholaminergic polymorphic ventricular tachycardia identified by 24 hours ecg monitor. Acta Med Mediterr. 2013;29(3):425–427.; Marjamaa A, Hiippala A, Arrhenius B, et al. Intravenous epinephrine infusion test in diagnosis of catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol. 2012;23(2):194–199. doi: https://doi.org/10.1111/j.1540-8167.2011.02188.x; Ковалёв И.А., Соловьёв В.М., Березницкая В.В. и др. Синдром недостаточности высвобождения кальция — редкий вариант катехоламинергической полиморфной желудочковой тахикардии // Педиатрия. Журнал им. Г.Н. Сперанского. — 2023. — Т. 102. — № 6. — С. 195–201. — doi: https://doi.org/10.24110/003-403X-2023-102-6-195-201; Moore JP. Slow and steady or fast and furious? Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc Electrophysiol. 2019;30(10):1930–1931. doi: https://doi.org/10.1111/jce.14041; Miyata K, Ohno S, Itoh H, Horie M. Bradycardia is a specific phenotype of catecholaminergic polymorphic ventricular tachycardia induced by RYR2 mutations. Intern Med. 2018;57(13):1813–1817. doi: https://doi.org/10.2169/internalmedicine.9843-17; Veith M, El-Battrawy I, Roterberg G, et al. Long-Term FollowUp of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. J Clin Med. 2020;9(4):903. doi: https://doi.org/10.3390/jcm9040903; Brunetti ND, Pellegrino PL, D’Arienzo G, et al. Catecholaminergic polymorphic ventricular tachycardia associated with sinus node dysfunction and junctional rhythm: Case report and literature review. J Electrocardiol. 2016;49(6):940–943. doi: https://doi.org/10.1016/j.jelectrocard.2016.07.024; Lawrenz W, Krogmann ON, Wieczorek M. Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene. Cardiol Young. 2014;24(4):741–744. doi: https://doi.org/10.1017/S1047951113001091; Lieve KVV, Verhagen JMA, Wei J, et al. Linking the heart and the brain: Neurodevelopmental disorders in patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2019;16(2):220–228. doi: https://doi.org/10.1016/j.hrthm.2018.08.025; Березницкая В.В., Кульбачинская Е.К., Школьникова М.А. Особенности клинических проявлений и эффективность антиаритмической терапии у больных с катехоламинергической полиморфной желудочковой тахикардией // Вестник аритмологии. — 2021. — Т. 28. — № 4. — С. 62–69. — doi: https://doi.org/10.35336/va-2021-4-62-69; Кульбачинская Е.К., Березницкая В.В. Лечение катехоламинергической полиморфной желудочковой тахикардии // Вопросы современной педиатрии. — 2024. — Т. 23. —№ 2. — С. 63–70. — doi: https://doi.org/10.15690/vsp.v23i2.2740; Nozaki Y, Kato Y, Uike K, et al. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation. Circ J. 2020; 84(2):226–234. doi: https://doi.org/10.1253/circj.CJ-19-0720; Roston TM, Guo W, Krahn AD, et al. A novel RYR2 loss-offunction mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia. J Electrocardiol. 2017;50(2):227–233. doi: https://doi.org/10.1016/j.jelectrocard.2016.09.006; Pérez Díaz P, Jurado Román A, Moreno Reig Á, et al. Polymorphic ventricular tachycardia and non-compacted myocardium: A new genetic variant? Revista Colombiana de Cardiologia. 2020;27(6):597–601. doi: https://doi.org/10.1016/j.rccar.2019.09.008; Ni M, Li Y, Wei J, et al. Increased Ca(2+) Transient Underlies RyR2-Related Left Ventricular Noncompaction. Circ Res. 2023;133(2): 177–192. doi: https://doi.org/10.1161/circresaha.123.322504; Duan H, Lu Y, Yan S, et al. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child. Medicine (Baltimore). 2018;97(16):e0368. doi: https://doi.org/10.1097/MD.0000000000010368; van der Werf C, Wilde AAM. Ventricular Tachycardias in Catecholaminergic Cardiomyopathy (Catecholaminergic Polymorphic Ventricular Tachycardia). In: Cardiac Electrophysiology: From Cell to Bedside. Elsevier; 2018. pp. 850–857.; Ma MG, Liu XR, Wu Y, et al. RYR2 Mutations Are Associated With Benign Epilepsy of Childhood With Centrotemporal Spikes With or Without Arrhythmia. Front Neurosci. 2021;15:629610. doi: https://doi.org/10.3389/fnins.2021.629610; Yap SM, Smyth S. Ryanodine receptor 2 (RYR2) mutation: A potentially novel neurocardiac calcium channelopathy manifesting as primary generalised epilepsy. Seizure. 2019;67:11–14. doi: https://doi.org/10.1016/j.seizure.2019.02.017; Hu J, Gao X, Chen L, et al. A novel mutation in ryanodine receptor 2 (RYR2) genes at c.12670G>T associated with focal epilepsy in a 3-year-old child. Front Pediatr. 2022;10:1022268. doi: https://doi.org/10.3389/fped.2022.1022268; Roston TM, Sanatani S. Beyond the exercise stress test: Does the cardiac ryanodine receptor affect intellectual function? Heart Rhythm. 2019;16(2):229–230. doi: https://doi.org/10.1016/j.hrthm.2018.09.003; Le Tanno P, Folacci M, Revilloud J, et al. Characterization of LossOf-Function KCNJ2 Mutations in Atypical Andersen Tawil Syndrome. Front Genet. 2021;12:773177. doi: https://doi.org/10.3389/fgene.2021.773177; Inoue YY, Aiba T, Kawata H, et al. Different responses to exercise between Andersen–Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. Europace. 2018;20(10): 1675–1682. doi: https://doi.org/10.1093/europace/eux351; Kimura H, Zhou J, Kawamura M, et al. Phenotype variability in patients carrying KCNJ2 mutations. Circ Cardiovasc Genet. 2012;5(3):344–353. doi: https://doi.org/10.1161/CIRCGENETICS.111.962316; Blich M, Marai I, Suleiman M, et al. Electrocardiographic comparison of ventricular premature complexes during exercise test in patients with CPVT and healthy subjects. Pacing Clin Electrophysiol. 2015;38(3):398–402. doi: https://doi.org/10.1111/pace.12574; Ozawa J, Ohno S, Fujii Y, et al. Differential diagnosis between catecholaminergic polymorphic ventricular tachycardia and long QT syndrome type 1 — Modified schwartz score. Circ J. 2018;82(9): 2269–2276. doi: https://doi.org/10.1253/circj.CJ-17-1032; Crotti L, Spazzolini C, Tester DJ, et al. Calmodulin mutations and life-threatening cardiac arrhythmias: Insights from the International Calmodulinopathy Registry. Eur Heart J. 2019;40(35):2964–2975. doi: https://doi.org/10.1093/eurheartj/ehz311; Tanaka Y, Kawabata M, Scheinman MM, Hirao K. Catecholaminergic Polymorphic Ventricular Tachycardia with QT Prolongation. Pacing Clin Electrophysiol. 2015;38(12):1499–1502. doi: https://doi.org/10.1111/pace.12735

Διαθεσιμότητα: https://vsp.spr-journal.ru/jour/article/view/3564
https://doi.org/10.15690/vsp.v23i4.2773

Arrhythmogenic Cardiomyopathy in 8-Year-Old Girl: Clinical Case. Difficult Path to Diagnosis ; Клинический случай аритмогенной кардиомиопатии у девочки 8 лет. Сложный путь к диагнозу

Συγγραφείς: Olga A. Kofeynikova, Darya Yu. Alexeeva, Evgeniya V. Characterova, Anna A. Kostareva, Elena S. Vasichkina, О. А. Кофейникова, Д. Ю. Алексеева, Е. В. Характерова, А. А. Костарева, Е. С. Васичкина

Συνεισφορές: The study was conducted with financial support of the Ministry of Science and Higher Education of the Russian Federation (Agreement №075-15-2022-301 from 20.04.2022)., Исследование выполнено при финансовой поддержке Министерства науки и высшего образования Российской Федерации (Соглашение № 075-15-2022-301 от 20.04.2022).

Πηγή: Pediatric pharmacology; Том 20, № 6 (2023); 574–579 ; Педиатрическая фармакология; Том 20, № 6 (2023); 574–579 ; 2500-3089 ; 1727-5776

Θεματικοί όροι: дети, dilated cardiomyopathy, sudden cardiac death, children, дилатационная кардиомиопатия, внезапная сердечная смерть

Περιγραφή αρχείου: application/pdf

Relation: https://www.pedpharma.ru/jour/article/view/2378/1548; Corrado D, Link MS, Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1):61–72. doi: https://doi.org/10.1056/NEJMra1509267; Basso C, Corrado D, Marcus FI, et al. Arrhythmogenic right ventricular cardiomyopathy. Lancet. 2009;373:1289–1300. doi: https://doi.org/10.1016/S0140-6736(09)60256-7; Towbin JA, McKenna WJ, Abrams DJ, et al. 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. Heart Rhythm. 2019;16(11):e301–e372. doi: https://doi.org/10.1016/j.hrthm.2019.05.007; Corrado D, Basso C. Arrhythmogenic left ventricular cardiomyopathy. Heart. 2022;108(9):733–743. doi: https://doi.org/10.1136/heartjnl-2020-316944; Mazić S, Lazović B, Delić M. Arrhythmogenic right ventricular cardiomyopathy as a cause of sudden death in young people--literature review. Med Pregl. 2012;65(9-10):396–404. doi: https://doi.org/10.2298/mpns1210396m; Cadrin-Tourigny J, Bosman LP, Wang W, et al. Sudden Cardiac Death Prediction in Arrhythmogenic Right Ventricular Cardiomyopathy: A Multinational Collaboration. Circ Arrhythm Electrophysiol. 2021;14(1):e008509. doi: https://doi.org/10.1161/CIRCEP.120.008509; Miles C, Finocchiaro G, Papadakis M, et al. Sudden Death and Left Ventricular Involvement in Arrhythmogenic Cardiomyopathy. Circulation. 2019;139(15):1786–1797. doi: https://doi.org/10.1161/CIRCULATIONAHA.118.037230; Sen-Chowdhry S, Syrris P, McKenna WJ. Role of Genetic Analysis in the Management of Patients With Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. J Am Coll Cardiol. 2007;50(19):1813–1821. doi: https://doi.org/10.1016/j.jacc.2007.08.008; Corrado D, Perazzolo Marra M, Zorzi A, et al. Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria. Int J Cardiol. 2020;319:106–114. doi: https://doi.org/10.1016/j.ijcard.2020.06.005; Molitor N, Duru F. Arrhythmogenic Right Ventricular Cardiomyopathy and Differential Diagnosis with Diseases Mimicking Its Phenotypes. J Clin Med. 2022;11(5):1230. doi: https://doi.org/10.3390/jcm11051230; Altmayer S, Nazarian S, Han Y. Left Ventricular Dysfunction in Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Can We Separate ARVC from Other Arrhythmogenic Cardiomyopathies? J Am Heart Assoc. 2020;9(23):e018866. doi: https://doi.org/10.1161/JAHA.120.018866; Cohen MI, Atkins MB. Arrhythmogenic right ventricular cardiomyopathy in the pediatric population. Curr Opin Cardiol. 2022;37(1):99–108. doi: https://doi.org/10.1097/HCO.0000000000000937; Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J. 2010;31(7):806–814. doi: https://doi.org/10.1093/eurheartj/ehq025; Corrado D, Zorzi A, Cipriani A, et al. Scarring/arrhythmogenic cardiomyopathy. Eur Heart J Suppl. 2023;25(Suppl C):C144–C154. doi: https://doi.org/10.1093/eurheartjsupp/suad017; Макаров Л.М. ЭКГ в педиатрии. — 3-е изд. — М.: Медпрактика-М; 2013. — 696 с.; Макаров Л.М. Нормативные параметры ЭКГ у детей: методические рекомендации. — М.: Медпрактика-М; 2018. — 17 с.; Zhang L, Liu L, Kowey PR, et al. The electrocardiographic manifestations of arrhythmogenic right ventricular dysplasia. Curr Cardiol Rev. 2014;10(3):237–245. doi: https://doi.org/10.2174/1573403x10666140514102928; Алексеева Д.Ю., Кофейникова О.А., Марапов Д.И., Васичкина Е.С. Электрокардиографические параметры и особенности желудочковых нарушений ритма при различных фенотипических формах аритмогенной кардиомиопатии в педиатрической популяции: систематический обзор и метаанализ // Российский кардиологический журнал. — 2022. — Т. 27. — № 3S. — С. 91–100. — doi: https://doi.org/10.15829/1560-4071-2022-5147; Bariani R, Rigato I, Cipriani A, et al. Myocarditis-like Episodes in Patients with Arrhythmogenic Cardiomyopathy: A Systematic Review on the So-Called Hot-Phase of the Disease. Biomolecules. 2022;12(9):1324. doi: https://doi.org/10.3390/biom12091324; Scheel PJ 3rd, Giuliano K, Tichnell C, et al. Heart transplantation strategies in arrhythmogenic right ventricular cardiomyopathy: a tertiary ARVC centre experience. ESC Heart Fail. 2022;9(2):1008–1017. doi: https://doi.org/10.1002/ehf2.13757; Christensen AH, Platonov PG, Jensen HK, et al. Genotype-phenotype correlation in arrhythmogenic right ventricular cardiomyopathy-risk of arrhythmias and heart failure. J Med Genet. 2022;59(9):858–864. doi: https://doi.org/10.1136/jmedgenet-2021-107911; Protonotarios A, Bariani R, Cappelletto C, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J. 2022;43(32):3053–3067. doi: https://doi.org/10.1093/eurheartj/ehac235; https://www.pedpharma.ru/jour/article/view/2378

Διαθεσιμότητα: https://www.pedpharma.ru/jour/article/view/2378
https://doi.org/10.15690/pf.v20i6.2664

MENTAL DISORDERS AND CARDIOVASCULAR DISEASES: GUIDELINES OF THE BAIKAL PSYCHOSOMATIC ASSOCIATION AND THE SIBERIAN PSYCHOSOMATIC ASSOCIATION ; ПСИХИЧЕСКИЕ РАССТРОЙСТВА И СЕРДЕЧНО-СОСУДИСТЫЕ БОЛЕЗНИ: КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ БАЙКАЛЬСКОЙ И СИБИРСКОЙ ПСИХОСОМАТИЧЕСКИХ АССОЦИАЦИЙ

Συγγραφείς: Farid I. Belialov, Alexey N. Sumin, Natalia P. Garganeeva, Natalia V. Lareva, Мarina M. Petrova, Olga V. Petrunko, Tatiana M. Poponina, Alexey N. Repin, Vasily S. Sobennikov, Фарид Исмагильевич Белялов, Алексей Николаевич Сумин, Наталья Петровна Гарганеева, Наталья Викторовна Ларева, Марина Михайловна Петрова, Ольга Вячеславна Петрунько, Татьяна Михайловна Попонина, Алексей Николаевич Репин, Василий Самуилович Собенников

Πηγή: Complex Issues of Cardiovascular Diseases; Том 13, № 3S (2024): приложение; 222-253 ; Комплексные проблемы сердечно-сосудистых заболеваний; Том 13, № 3S (2024): приложение; 222-253 ; 2587-9537 ; 2306-1278

Θεματικοί όροι: Рекомендации, Anxiety, Stress, Depressive disorder, Anxiety disorder, Post-traumatic stress disorder, Myocardial infarction, Coronary heart disease, Atrial fibrillation, Sudden cardiac death, Heart failure, Hypertension, Guideline, Тревога, Стресс, Депрессивное расстройство, Тревожное расстройство, Посттравматическое стрессовое расстройство, Инфаркт миокарда, Ишемическая болезнь сердца, Фибрилляция предсердий, Внезапная сердечная смерть, Сердечная недостаточность, Артериальная гипертензия

Περιγραφή αρχείου: application/pdf

Relation: https://www.nii-kpssz.com/jour/article/view/1566/945; World Health Organization. Mental Health Gap Action Programme (mhGAP) guideline for mental, neurological and substance use disorders. 2023. 152 с.; Байкальская психосоматическая ассоциация. Клинические рекомендации по психосоматической медицине. Иркутск. 2024. 35 с. URL: https:// therapy.irkutsk.ru/ispm/psomatic5.pdf.; Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452.; Российское общество психиатров. Депрессивный эпизод, рекуррентное депрессивное расстройство. 2021. 88 с.; Российское общество психиатров. Генерализованное тревожное расстройство. 2021. 101 с.; Albus C, Waller C, Fritzsche K, Gunold H, et al. Significance of psychosocial factors in cardiology: update 2018: Position paper of the German Cardiac Society. Clin Res Cardiol. 2019;108(11):1175-1196.; American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder. Third Edition. Am J Psychiatry. 2010;167(suppl):1-152.; Colquhoun DM, Bunker SJ, Clarke DM, et al. Screening, referral and treatment for depression in patients with coronary heart disease. Med J Aust. 2013 May 20;198(9):483-4.; Frost JL, Rich RL, Robbins CW, et al. Depression Following Acute Coronary Syndrome Events: Screening and Treatment Guidelines from the AAFP. Am Fam Physician. 2019 Jun 15;99(12).; Ladwig K, Baghai T, Doyle F, et al. Mental health-related risk factors and interventions in patients with heart failure: a position paper endorsed by the European Association of Preventive Cardiology (EAPC). European Journal of Preventive Cardiology. 2022;29:1124–1141.; Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a Risk Factor for Poor Prognosis Among Patients With Acute Coronary Syndrome: Systematic Review and Recommendations. Circulation. 2014;129:1350–1369.; Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008 Oct 21;118(17):1768-75.; National Heart Foundation of Australia. Screening, referral and treatment for depression in patients with coronary heart disease. MJA. 2013; 198(9): 1-7.; Visseren F, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;34:3227-3337.; Vaccarino V, Badimon L, Bremner J, et al. Depression and coronary heart disease: 2018 position paper of the ESC working group on coronary pathophysiology and microcirculation. European Heart Journal. 2020;17:1687-1696.; The American Psychiatric Publishing Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill. Third Edition. Edited by James L. Levenson. 2019. 1410 p.; Лебедева Е.В., Нонка Т.Г., Репин А.Н., и др. Современная психокардиология. Томск, 2019. 160 с.; Собенников В.С., Белялов Ф.И. Соматизация и психосоматические расстройства. Иркутск: РИО ИГИУВа, 2010. 223 с.; Психосоматические расстройства. Руководство для практических врачей. Под ред. А.Б.Смулевича. 2-е изд. М, 2019. 496 с.; Белялов Ф.И. Психосоматика. 9-е изд. Москва: ГЭОТАР-Медиа, 2022. 400 c.; World Health Organization. Clinical descriptions and diagnostic requirements for ICD-11 mental, behavioural and neurodevelopmental disorders. 2024. 834 p.; МКБ-11. Глава 6. Психические и поведенческие расстройства и нарушения нейропсихического развития. Статистическая классификация. М, 2021. 432 с.; Stein D, Szatmari P, Gaebel W, et al. Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Medicine. 2020;1:21.; Levis B, Benedetti A, Riehm K, et al. Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. The British Journal of Psychiatry. 2018;212:377-385.; Kwapong Y, Boakye E, Khan S, et al. Association of Depression and Poor Mental Health With Cardiovascular Disease and Suboptimal Cardiovascular Health Among Young Adults in the United States. Journal of the American Heart Association. 2023;3:e028332.; Bojanić I, Sund E, Sletvold H, et al. Prevalence trends of depression and anxiety symptoms in adults with cardiovascular diseases and diabetes 1995–2019: The HUNT studies, Norway. BMC Psychology. 2021;1:130.; Погосова Н.В., Бойцов С.А., Оганов Р.Г. и др. Клинико-эпидемиОлогическая программа изучения психосоциальных факторов риска в кардиологической практике у больных артериальной гипертонией и ишемической болезнью сердца (КОМЕТА): первые результаты российского многоцентрового исследования. Кардиология. 2018;58(9):47-58.; Karami N, Kazeminia M, Karami A, et al. Global prevalence of depression, anxiety, and stress in cardiac patients: A systematic review and meta-analysis. Journal of Affective Disorders. 2023;324:175-189.; Gaffey AE, Gathright EC, Fletcher LM, Goldstein CM. Screening for Psychological Distress and Risk of Cardiovascular Disease and Related Mortality: A Systematized Review, Meta-analysis, and Case for Prevention. J Cardiopulm Rehabil Prev. 2022 Nov 1;42(6):404-415.; Seldenrijk A, Vogelzangs N, Batelaan NM, et al. Depression, anxiety and 6-year risk of cardiovascular disease. Journal of Psychosomatic Research. 2015;78(2):123-129.; Nakamura S, Kato K, Yoshida A, et al. Prognostic Value of Depression, Anxiety, and Anger in Hospitalized Cardiovascular Disease Patients for Predicting Adverse Cardiac Outcomes. The American journal of cardiology. 2013;111[10]:1432-1436.; Fan AZ, Strine TW, Jiles R, et al. Psychological distress, use of rehabilitation services, and disability status among noninstitutionalized US adults aged 35 years and older, who have cardiovascular conditions, 2007. Int J Public Health. 2009;54 Suppl 1:100-5.; Charlson FJ, Moran AE, Freedman G, et al. The contribution of major depression to the global burden of ischemic heart disease: a comparative risk assessment. BMC Med. 2013; 11:250. 10.1186/1741-7015-11-250; Bekelman DB, Havranek EP, Becker DM, et al. Symptoms, depression, and quality of life in patients with heart failure. J Card Fail. 2007;13(8):643-648.; Gravely-Witte S, De Gucht V, Heiser W, et al. The impact of angina and cardiac history on health-related quality of life and depression in coronary heart disease patients. Chronic Illn. 2007;3(1):66-76.; Huang W, Aune D, Ferrari G, et al. Psychological Distress and All-Cause, Cardiovascular Disease, Cancer Mortality Among Adults with and without Diabetes. Clin Epidemiol. 2021;13:555-565.; Meier SM, Mattheisen M, Mors O, et al. Increased mortality among people with anxiety disorders: total population study. Br J Psychiatry. 2016;209(3):216-21.; Zhang Z, Jackson SL, Gillespie C, et al. Depressive Symptoms and Mortality Among US Adults. JAMA Netw Open. 2023;6(10):e2337011.; Péquignot R, Dufouil C, Pérès K, et al. Depression Increases the Risk of Death Independently From Vascular Events in Elderly Individuals: The Three-City Study. Journal of the American Geriatrics Society. 2019;3:546-552.; Shen R, Zhao N, Wang J, et al. Association between level of depression and coronary heart disease, stroke risk and all-cause and cardiovascular mortality: Data from the 2005–2018 National Health and Nutrition Examination Survey. Frontiers in Cardiovascular Medicine. 2022;9.; Tian F, Shen Q, Hu Y, et al. Association of stress-related disorders with subsequent risk of all-cause and cause-specific mortality: A population-based and sibling-controlled cohort study. The Lancet Regional Health – Europe. 2022;18:100402.; Mourad G, Jaarsma T, Hallert C, Strömberg A. Depressive symptoms and healthcare utilization in patients with noncardiac chest pain compared to patients with ischemic heart disease. Heart Lung. 2012 Sep-Oct;41(5):446-55.; Mourad G, Lundgren J, Andersson G, Johansson P. Healthcare use in patients with cardiovascular disease and depressive symptoms - The impact of a nurse-led internet-delivered cognitive behavioural therapy program. A secondary analysis of a RCT. Internet Interv. 2023 Dec 5;35:100696.; Ni J, Yan Y, Du W, et al. Depressive symptoms, alone or together with physical comorbidity, are predictive of healthcare use and spending in older adults. Journal of Psychosomatic Research. 2023;174:111482.; Stephenson J, Grabner M, Faries D, et al. The impact of anxiety on Healthcare Utilization and costs among respondents from the Co-Morbidities and Symptoms of depression (CODE) study. Value in Health. 2015;3:A119.; Horenstein A, Heimberg RG. Anxiety disorders and healthcare utilization: A systematic review. Clin Psychol Rev. 2020;81:101894.; Eisele M, Harder M, Rakebrandt A, et al. Association of depression and anxiety with adherence in primary care patients with heart failure—cross-sectional results of the observational RECODE-HF cohort study. Family Practice. 2020;5:695-702.; Crawshaw J, Auyeung V, Norton S, Weinman J. Identifying psychosocial predictors of medication non-adherence following acute coronary syndrome: A systematic review and meta-analysis. Journal of Psychosomatic Research. 2016;90:10-32.; Dempe C, Jünger J, Hoppe S, et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease. Journal of Psychosomatic Research. 2013;74(2):122-127.; Rasmussen A, Wiggers H, Jensen M, et al. Patient-reported outcomes and medication adherence in patients with heart failure. European Heart Journal - Cardiovascular Pharmacotherapy. 2021;4:287-295.; Curth N, Hjorthøj C, Brinck-Claussen U, et al. The effects of collaborative care versus consultation liaison for anxiety disorders and depression in Denmark: two randomised controlled trials. The British Journal of Psychiatry. 2023;223:430-437.; Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev. 2012 Oct 17;10:CD006525.; Sighinolfi C, Nespeca C, Menchetti M, et al. Collaborative care for depression in European countries: a systematic review and meta-analysis. J Psychosom Res. 2014;77(4):247-63.; Лебедева Е.В., Репин А.Н., Счастный Е.Д. и др. Методическое пособие по организации работы междисциплинарной команды при реабилитации пациентов с хронической ишемической болезнью сердца и депрессивными расстройствами. – Томск. 2012. 66 с.; Silverman JJ, Galanter M, Jackson-Triche M, et al. The American Psychiatric Association Practice Guidelines for the Psychiatric Evaluation of Adults. Am J Psych. 2015;172(8):798-802.; Correll CU, Galling B, Pawar A, et al. Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Psychiatry. 2018 Jun 1;75(6):555-565.; Albert N, Melau M, Jensen H, et al. Five years of specialised early intervention versus two years of specialised early intervention followed by three years of standard treatment for patients with a first episode psychosis: randomised, superiority, parallel group trial in Denmark (OPUS II). BMJ. 2017 Jan 12;356:i6681.; Olfson M, Blanco C, Marcus SC. Treatment of Adult Depression in the United States. JAMA Intern Med. 2016;176(10):1482-1491.; Linde K, Kriston L, Rücker G, et al. Efficacy and Acceptability of Pharmacological Treatments for Depressive Disorders in Primary Care: Systematic Review and Network Meta-Analysis. The Annals of Family Medicine. 2015;13(1):69-79.; Weisberg RB, Dyck I, Culpepper L, et al. Psychiatric Treatment in Primary Care Patients With Anxiety Disorders: A Comparison of Care Received From Primary Care Providers and Psychiatrists. Am J Psychiatry 2007;164:276-82.; Simon GE, Von Korff M, Rutter CM, Peterson DA. Treatment Process and Outcomes for Managed Care Patients Receiving New Antidepressant Prescriptions From Psychiatrists and Primary Care Physicians. Arch Gen Psychiatry. 2001;58:395-401.; Trautmann S, Beesdo-Baum K. The Treatment of Depression in Primary Care. Dtsch Arztebl Int. 2017 Oct 27;114(43):721-728.; Приказ Министерства здравоохранения Российской Федерации от 26.12.2023 N720н "Об утверждении Перечня медицинских противопоказаний для осуществления отдельных видов деятельности вследствие психического расстройства". https://webmed.irkutsk.ru/doc/order/mz720.pdf; Jha M, Qamar A, Vaduganathan M, et al. Screening and Management of Depression in Patients With Cardiovascular Disease. Journal of the American College of Cardiology. 2019;14:1827-1845.; US Preventive Services Task Force. Screening for Depression and Suicide Risk in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(23):2057–2067.; US Preventive Services Task Force. Screening for Anxiety Disorders in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(24):2163–2170.; Золотарева А.А. Адаптация русскоязычной версии шкалы генерализованного тревожного расстройства (Generalized Anxiety Disorder-7). Консультативная психология и психотерапия. 2023;31:31–46.; Погосова Н.В., Довженко Т.В., Бабин А.Г., и др. Русскоязычная версия опросников PHQ-2 и 9: чувствительность и специфичность при выявлении депрессии у пациентов общемедицинской амбулаторной практики. Кардиоваскулярная терапия и профилактика. 2014;13(3):18-24. https://doi.org/10.15829/1728-8800-2014-3-18-24; Морозова М.А., Потанин С.С., Бениашвили А.Г. и др. Валидация русскоязычной версии Госпитальной шкалы тревоги и депрессии в общей популяции. Профилактическая медицина. 2023;26(4):7‑14.; Белялов Ф.И. Прогнозирование и шкалы в медицине. 4-е изд. Москва: ГЭОТАР-Медиа, 2023. 416 с.; Wu Y, Levis B, Sun Y, et al. Accuracy of the Hospital Anxiety and Depression Scale Depression subscale (HADS-D) to screen for major depression: systematic review and individual participant data meta-analysis. BMJ. 2021 May 10;373:n972. doi:10.1136/bmj.n972.; Levis B, Benedetti A, Thombs BD; DEPRESsion Screening Data (DEPRESSD) Collaboration. Accuracy of Patient Health Questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019 Apr 9;365:l1476. doi:10.1136/bmj.l1476. Erratum in: BMJ. 2019 Apr 12;365:l1781.; Manea L, Gilbody S, McMillan D. A diagnostic meta-analysis of the Patient Health Questionnaire-9 (PHQ-9) algorithm scoring method as a screen for depression. Gen Hosp Psychiatry. 2015;37(1):67-75.; Christensen A, Dixon J, Juel K, et al. Psychometric properties of the Danish Hospital Anxiety and Depression Scale in patients with cardiac disease: results from the DenHeart survey. Health and Quality of Life Outcomes. 2020;1:9.; Thombs BD, Ziegelstein RC, Roseman M, et al. There are no randomized controlled trials that support the United States Preventive Services Task Force guideline on screening for depression in primary care: a systematic review. BMC Medicine. 2014;12:13.; Romera I, Montejo Á, Aragonés E, et al. Systematic depression screening in high-risk patients attending primary care: a pragmatic cluster-randomized trial. BMC Psychiatry. 2013;1:83.; O'Connor EA, Henninger ML, Perdue LA, et al. Anxiety Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2023 Jun 27;329(24):2171-2184.; Moore M, Ali S, Stuart B, et al. Depression management in primary care: an observational study of management changes related to PHQ-9 score for depression monitoring. Br J Gen Pract. 2012;62(599):e451-7.; Toussaint A, Hüsing P, Gumz A, Wingenfeld K, Härter M, Schramm E, Löwe B. Sensitivity to change and minimal clinically important difference of the 7-item Generalized Anxiety Disorder Questionnaire (GAD-7). J Affect Disord. 2020 Mar 15;265:395-401. doi:10.1016/j.jad.2020.01.032.; Murphy B, Le Grande M, Alvarenga M, et al. Anxiety and Depression After a Cardiac Event: Prevalence and Predictors. Frontiers in Psychology. 2020;10.; ICSI. Major Depression in Adults in Primary Care. 17th edition. 2016. 131 p.; Screening adults for depression in primary care: A position statement of the American College of Preventive Medicine. J Fam Pract. 2009;58(10):535-8.; Plummer F, Manea L, Trepel D, McMillan D. Screening for anxiety disorders with the GAD-7 and GAD-2: a systematic review and diagnostic metaanalysis. Gen Hosp Psychiatry. 2016;39:24–31.; Adzrago D, Walker T, Williams F, et al. Reliability and validity of the Patient Health Questionnaire-4 scale and its subscales of depression and anxiety among US adults based on nativity. BMC Psychiatry. 2024;1:213.; Reavell J, Hopkinson M, Clarkesmith D, Lane DA. Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis. Psychosom Med. 2018;80(8):742-753.; Holdgaard A, Eckhardt-Hansen C, Lassen C, et al. Cognitive-behavioural therapy reduces psychological distress in younger patients with cardiac disease: a randomized trial. European Heart Journal. 2023;11:986-996.; El Baou C, Desai R, Cooper C, et al. Psychological therapies for depression and cardiovascular risk: evidence from national healthcare records in England. European Heart Journal. 2023;18:1650-1662.; Cuijpers P, Miguel C, Harrer M, et al. Cognitive behavior therapy vs. control conditions, other psychotherapies, pharmacotherapies and combined treatment for depression: a comprehensive meta-analysis including 409 trials with 52,702 patients. World Psychiatry. 2023;22(1):105-115.; Ding N, Sang Y, Chen J, et al. Cigarette Smoking, Smoking Cessation, and Long-Term Risk of 3 Major Atherosclerotic Diseases. Journal of the American College of Cardiology. 2019;4:498-507.; Wu AD, Lindson N, Hartmann-Boyce J, et al. Smoking cessation for secondary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2022, Issue 8. Art. No.: CD014936.; Taylor GMJ, Lindson N, Farley A, et al. Smoking cessation for improving mental health. Cochrane Database of Systematic Reviews 2021, Issue 3. Art. No.: CD013522.; Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers. A Randomized Clinical Trial. JAMA Intern Med. 2018;178(5):622–631.; Auer R, Schoeni A, Humair J, et al. Electronic Nicotine-Delivery Systems for Smoking Cessation. N Engl J Med. 2024;7:601-610.; Lindson N, Butler AR, McRobbie H, et al. Electronic cigarettes for smoking cessation. Cochrane Database of Systematic Reviews 2024, Issue 1. Art. No.: CD010216.; Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews 2023, Issue 6. Art. No.: CD006103.; Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023;330(2):152–160.; Krittanawong C, Isath A, Rosenson R, et al. Alcohol Consumption and Cardiovascular Health. The American Journal of Medicine. 2022;10:1213-1230.e3.; Biddinger KJ, Emdin CA, Haas ME, et al. Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Netw Open. 2022;5(3):e223849.; Millwood I, Walters R, Mei X, et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: a prospective study of 500 000 men and women in China. The Lancet. 2019;10183:1831-1842.; Holmes MV, Dale CE, Zuccolo L, et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ. 2014 Jul 10;349:g4164.; Jayakody K, Gunadasa S, Hosker C. Exercise for anxiety disorders: systematic review. Br J Sports Med. 2014;48(3):187-96.; Hallgren M, Nguyen T, Herring M, et al. Associations of physical activity with anxiety symptoms and disorders: Findings from the Swedish National March Cohort. General Hospital Psychiatry. 2019;58:45-50.; Yu Q, Wong KK, Lei OK, et al. Comparative Effectiveness of Multiple Exercise Interventions in the Treatment of Mental Health Disorders: A Systematic Review and Network Meta-Analysis. Sports Med Open. 2022 Oct 29;8(1):135.; Cooney GM, Dwan K, Greig CA, et al. Exercise for depression. Cochrane Database Syst Rev. 2013;(9):CD004366.; Gordon BR, McDowell CP, Hallgren M, et al. Association of Efficacy of Resistance Exercise Training With Depressive Symptoms. Meta-analysis and Meta-regression Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2018;75(6):566–576.; Carmin C, Ownby R, Fontanella C, et al. Impact of Mental Health Treatment on Outcomes in Patients With Heart Failure and Ischemic Heart Disease. Journal of the American Heart Association. 2024;0:e031117.; van Dis EAM, van Veen SC, Hagenaars MA, et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–273.; Papola D, Ostuzzi G, Tedeschi F, et al. Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. The British Journal of Psychiatry. 2022;221:507-519.; Papola D, Miguel C, Mazzaglia M, et al. Psychotherapies for Generalized Anxiety Disorder in Adults: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials. JAMA Psychiatry. 2024;81(3):250–259.; Plessen CY, Karyotaki E, Miguel C, et al. Exploring the efficacy of psychotherapies for depression: a multiverse meta-analysis. BMJ Ment Health. 2023;26(1):e300626.; Kolovos S, Kleiboer A, Cuijpers P. Effect of psychotherapy for depression on quality of life: meta-analysis. The British Journal of Psychiatry. 2016;209(6):460.; Hofmann SG, Wu JQ, Boettcher H. Effect of cognitive-behavioral therapy for anxiety disorders on quality of life: a meta-analysis. J Consult Clin Psychol. 2014;82(3):375-91.; Karyotaki E, Efthimiou O, Miguel C, et al. Internet-Based Cognitive Behavioral Therapy for Depression: A Systematic Review and Individual Patient Data Network Meta-analysis. JAMA Psychiatry. 2021;78(4):361–371.; Hedman-Lagerlöf E, Carlbring P, Svärdman F, et al. Therapist-supported Internet-based cognitive behaviour therapy yields similar effects as face-to-face therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. World Psychiatry. 2023;2:305-314.; Ricci C, Wood A, Muller D, et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: EPIC-CVD case-cohort study. BMJ. 2018;361:k934.; Pearce M, Garcia L, Abbas A, et al. Association Between Physical Activity and Risk of Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(6):550–559.; Jones ME, Campbell G, Patel D, et al. Risk of Mortality (including Sudden Cardiac Death) and Major Cardiovascular Events in Users of Olanzapine and Other Antipsychotics. Cardiovasc Psychiatry Neurol. 2013;2013:647476.; Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.Clin Pharmacol Ther. 2016;99(3):306-14.; Weeke P, Jensen A, Folke F, et al. Antipsychotics and associated risk of out-of-hospital cardiac arrest. Clin Pharmacol Ther. 2014;96(4):490-7.; Piña I, Di Palo K, Ventura H, et al. Psychopharmacology and Cardiovascular Disease. Journal of the American College of Cardiology. 2018;20:2346-2359.; Белялов Ф.И. Лечение болезней в условиях коморбидности. 12-е изд. Москва: ГЭОТАР-Медиа; Fanoe S, Kristensen D, Fink-Jensen A, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal 2014;35:1306-1315.; Beach SR, Celano CM, Sugrue AM, et al. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update. Psychosomatics. 2018;59(2):105-122.; Castro VM, Clements CC, Murphy SN, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ 2013;346.; Kasper S, Gastpar M, Muller WE, et al. Lavender oil preparation Silexan is effective in generalized anxiety disorder - a randomized, double-blind comparison to placebo and paroxetine. Int J Neuropsychopharmacol. 2014;17(6):859-69.; Donelli D, Antonelli M, Bellinazzi C, et al. Effects of lavender on anxiety: A systematic review and meta-analysis. Phytomedicine. 2019;65:153099.; Zhao X, Zhang H, Wu Y, Yu C. The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. Adv Clin Exp Med. 2023;32(2):151-161.; Cui YH, Zheng Y. A meta-analysis on the efficacy and safety of St John's wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuropsychiatr Dis Treat. 2016;12:1715-23.; de Vries Y, Roest A, Bos E, et al. Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. The British Journal of Psychiatry. 2019;214:4-10.; Baldwin DS, Stein DJ, Dolberg OT, Bandelow B. How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol. 2009;24(4):269-75.; Cleare A, Pariante CM, Young AH, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2015;29(5):459-525.; Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022;54(1):80-97.; Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: A systematic review and meta-analysis. Int J Geriatr Psychiatry. 2018;33(12):1688-1708.; Rahman AA, Platt RW, Beradid S, et al. Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding. JAMA Netw Open. 2024;7(3):e243208.; Gandhi S, Shariff SZ, Al-Jaishi A, et al. Second-Generation Antidepressants and Hyponatremia Risk: Population-Based Cohort Study of Older Adults. Am J Kidn Dis. 2016;69(1):87-96.; Viramontes TS, Truong H, Linnebur SA, et al. Antidepressant-Induced Hyponatremia in Older Adults. Consult Pharm. 2016;31(3):139-50.; De Picker L, Van Den Eede F, Dumont G, et al. Antidepressants and the Risk of Hyponatremia: A Class-by-Class Review of Literature. Psychosomatics. 2014;55:536-547.; Ojero-Senard A, Benevent J, Bondon-Guitton E, et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology (Berl). 2017;234(20):3075-3081.; Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330-41.; Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014;75(5):e441-9.; Van Leeuwen E, Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database of Systematic Reviews 2021, Issue 4. Art. No.: CD013495.; Almuwaqqat Z, Jokhadar M, Norby FL, et al. Association of Antidepressant Medication Type With the Incidence of Cardiovascular Disease in the ARIC Study. J Am Heart Assoc. 2019 Jun 4;8(11):e012503.; Coupland C, Hill T, Morriss R, et al. Antidepressant use and risk of cardiovascular outcomes in people aged 20 to 64: cohort study using primary care database. BMJ. 2016;352.; Mease PJ, Zimetbaum PJ, Duh, et al. Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data. Ann Pharmacother. 2011;45(2):179-88.; Maslej MM, Bolker BM, Russell MJ, et al. The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis. Psychotherapy and Psychosomatics. 2017;86(5):268-282.; NICE. Generalised anxiety disorder and panic disorder in adults: management. January 2020. 43 p.; de las Cuevas C, Sanz E, de la Fuente J. Benzodiazepines: more "behavioural" addiction than dependence. Psychopharmacology (Berl). 2003;167(3):297-303.; Donnelly K, Bracchi R, Hewitt J, et al. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. PLoS One. 2017 Apr 27;12(4):e0174730.; Poly T, Islam M, Yang H, et al. Association between benzodiazepines use and risk of hip fracture in the elderly people: A meta-analysis of observational studies. Joint Bone Spine. 2020;3:241-249.; Kim JH, Song YK, Jang HY, et al. Major Adverse Cardiovascular Events in Antidepressant Users Within Patients With Ischemic Heart Diseases: A Nationwide Cohort Study. J Clin Psychopharmacol. 2020 Sep/Oct;40(5):475-481.; Andersson N, Wohlfahrt J, Feenstra B, et al. Cumulative Incidence of Thiazide-Induced Hyponatremia. Ann Intern Med. 2024;1:1-11.; Jang HY, Kim JH, Song YK, et al. Antidepressant Use and the Risk of Major Adverse Cardiovascular Events in Patients Without Known Cardiovascular Disease: A Retrospective Cohort Study. Front Pharmacol. 2020 Dec 10;11:594474.; Al Dawsari A, Bushell TJ, Abutheraa N, et al. Use of sedative-hypnotic medications and risk of dementia: A systematic review and meta-analysis. Br J Clin Pharmacol. 2022;88(4):1567-1589.; Stott J, Saunders R, Desai R, et al. Associations between psychological intervention for anxiety disorders and risk of dementia: a prospective cohort study using national health-care records data in England. The Lancet Healthy Longevity. 2023;1:e12-e22.; Osler M, Jorgensen M. Associations of Benzodiazepines, Z-Drugs, and Other Anxiolytics With Subsequent Dementia in Patients With Affective Disorders: A Nationwide Cohort and Nested Case-Control Study. AJP. 2020;6:497-505.; Ray WA, Stein CM, Murray KT, et al. Association of Antipsychotic Treatment With Risk of Unexpected Death Among Children and Youths. JAMA Psychiatry. 2019;76(2):162–171.; Suvisaari J, Partti K, Perala J, et al. Mortality and Its Determinants in People With Psychotic Disorder. Psychosom Med 2013;75(1):60-7.; Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs. 2014;28(10):887-920.; Huang K-L, Fang C-J, Hsu C-C, et al. Myocardial infarction risk and antipsychotics use revisited: a meta-analysis of 10 observational studies. Journal of Psychopharmacology. 2017;31(12):1544-1555.; Yu ZH, Jiang HY, Shao L, et al. Use of antipsychotics and risk of myocardial infarction: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):624-32.; Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis. The Lancet. 2019;10202:939-951.; Pillinger T, McCutcheon R, Vano L, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. The Lancet Psychiatry. 2020;1:64-77.; NHS Foundation. Guidance on the Use of Antipsychotics. 2018. 60 p.; The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Third edition. 2021. 299 p.; Российское общество психиатров. Паническое расстройство. 2021. 113 с.; Olariu E, Forero CG, Castro-Rodriguez JI, et al. Detection of anxiety disorders in primary care: a meta-analysis of assisted and unassisted diagnoses. Depress Anxiety. 2015;32(7):471-84.; Bandelow B, Reitt M, Röver C, et al. Efficacy of treatments for anxiety disorders: a meta-analysis. Int Clin Psychopharmacol. 2015;30(4):183-92.; Carpenter JK, Andrews LA, Witcraft SM, et al. Cognitive behavioral therapy for anxiety and related disorders: A meta-analysis of randomized placebo-controlled trials. Depress Anxiety. 2018;35(6):502-514.; Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. The Cochrane Database of Systematic Reviews 2007 Issue 1.; Parker E, Banfield M, Fassnacht D, et al. Contemporary treatment of anxiety in primary care: a systematic review and meta-analysis of outcomes in countries with universal healthcare. BMC Family Practice. 2021;1:92.; Bandelow B, Werner A, Kopp I, et al. The German Guidelines for the treatment of anxiety disorders: first revision. European Archives of Psychiatry and Clinical Neuroscience. 2022;4:571-582.; Bolgeo T, Di Matteo R, Simonelli N, et al. Psychometric properties and measurement invariance of the 7-item General Anxiety Disorder scale (GAD-7) in an Italian coronary heart disease population. J Affect Disord. 2023 Aug 1;334:213-219.; Guaiana G, Meader N, Barbui C, et al. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database of Systematic Reviews 2023, Issue 11. Art. No.: CD012729.; Chawla N, Anothaisintawee T, Charoenrungrueangchai K, et al. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022;376:e066084.; Carl E, Witcraft SM, Kauffman BY, et al. Psychological and pharmacological treatments for generalized anxiety disorder (GAD): a meta-analysis of randomized controlled trials. Cogn Behav Ther. 2020;49(1):1-21.; Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. The Lancet. 2019;10173:768-777.; Generoso MB, Trevizol AP, Kasper S, et al. Pregabalin for generalized anxiety disorder: an updated systematic review and meta-analysis. Int Clin Psychopharmacol. 2017;32(1):49-55.; Stubbs B, Vancampfort D, Rosenbaum S, et al. An examination of the anxiolytic effects of exercise for people with anxiety and stress-related disorders: A meta-analysis. Psychiatry Res. 2017;249:102-108.; Rebar AL, Stanton R, Geard D, et al. A meta-meta-analysis of the effect of physical activity on depression and anxiety in non-clinical adult populations. Health Psychol Rev. 2015;9(3):366-78.; Ramos-Sanchez CP, Schuch FB, Seedat S, et al. The anxiolytic effects of exercise for people with anxiety and related disorders: An update of the available meta-analytic evidence. Psychiatry Res. 2021;302:114046.; Donovan MR, Glue P, Kolluri S, Emir B. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Disord. 2010;123(1-3):9-16.; Batelaan NM, et al. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ. 2017;358.; Perna G, Alciati A, Riva A, et al. Long-Term Pharmacological Treatments of Anxiety Disorders: An Updated Systematic Review. Curr Psychiatry Rep. 2016;18(3):23.; Nelson H, Cantor A, Pappas M, et al. Screening for Anxiety in Adolescent and Adult Women. Annals of Internal Medicine. 2020;1:29-41.; Guaiana G, Barbui C, Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database of Systematic Reviews 2010, Issue 12.; Breilmann J, Girlanda F, Guaiana G, et al. Benzodiazepines versus placebo for panic disorder in adults. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD010677.; Guerlais M, Grall-Bronnec M, Feuillet F, et al. Dependence on prescription benzodiazepines and Z-drugs among young to middle-aged patients in France. Subst Use Misuse. 2015;50(3):320-7.; Martin JL, Sainz-Pardo M, Furukawa TA, et al. Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials. J Psychopharmacol. 2007;21(7):774-82.; Shinfuku M, Kishimoto T, Uchida H, et al. Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: a systematic review and meta-analysis. Int Clin Psychopharmacol. 2019;34(5):211-221. van Dis EAM, van Veen SC, Hagenaars MA, et al. Long-term Outcomes of Cognitive Behavioral Therapy for Anxiety-Related Disorders: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2020;77(3):265–273.; Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011;342.; Ahmed S, Bachu R, Kotapati P, et al. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. Front Psychiatry. 2019 May 7;10:228.; Kim HS, Kim EJ. Effects of Relaxation Therapy on Anxiety Disorders: A Systematic Review and Meta-analysis. Arch Psychiatr Nurs. 2018;32(2):278-284.; Wang J, Wu X, Lai W, et al. Prevalence of depression and depressive symptoms among outpatients: a systematic review and meta-analysis. BMJ Open. 2017 Aug 23;7(8):e017173.; Российское общество психиатров. Биполярное аффективное расстройство. 2021. 161 с.; Симуткин Г.Г., Бохан Н.А., Иванова С.А. Вероятностная диагностика биполярного аффективного расстройства: современные подходы, возможности и ограничения. Томск. 2023. 162 с.; Daveney J, Panagioti M, Waheed W, et al. Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis. General Hospital Psychiatry. 2019;58:71-76.; Yildiz A, Siafis S, Mavridis D, et al. Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a systematic review and network meta-analysis. The Lancet Psychiatry. 2023;9:693-705.; Cerimele JM, Chwastiak LA, Dodson S, et al. The Prevalence of Bipolar Disorder in Primary Care Patients With Depression or Other Psychiatric Complaints: A Systematic Review. Psychosomatics. 2013;54(6):515-24.; Amick HR, Gartlehner G, Gaynes BN, et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ. 2015;351.; Gartlehner G, Dobrescu A, Chapman A, et al. Nonpharmacologic and Pharmacologic Treatments of Adult Patients With Major Depressive Disorder: A Systematic Review and Network Meta-analysis for a Clinical Guideline by the American College of Physicians. Ann Intern Med. 2023;2:196-211.; Cuijpers P, Oud M, Karyotaki E, et al. Psychologic Treatment of Depression Compared With Pharmacotherapy and Combined Treatment in Primary Care: A Network Meta-Analysis. Ann Fam Med. 2021;19(3):262-270.; Krijnen-de Bruin E, Scholten W, Muntingh A, et al. Psychological interventions to prevent relapse in anxiety and depression: A systematic review and meta-analysis. PLoS One. 2022 Aug 12;17(8):e0272200.; Kuyken W, Hayes R, Barrett B, et al. Effectiveness and cost-effectiveness of mindfulness-based cognitive therapy compared with maintenance antidepressant treatment in the prevention of depressive relapse or recurrence. The Lancet. 2015;386:63-73.; Bockting CLH, Klein NS, Elgersma HJ, et al. Effectiveness of preventive cognitive therapy while tapering antidepressants versus maintenance antidepressant treatment versus their combination in prevention of depressive relapse or recurrence (DRD study): a three-group, multicentre, randomised controlled trial. Lancet Psychiatry. 2018;5(5):401-410.; Breedvelt J, Warren F, Segal Z, et al. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression: An Individual Participant Data Meta-analysis. JAMA Psychiatry. 2021;8:868-875.; Cuijpers P, Noma H, Karyotaki E, et al. A network meta-analysis of the effects of psychotherapies, pharmacotherapies and their combination in the treatment of adult depression. World Psychiatry. 2020;19(1):92-107.; Furukawa TA, Shinohara K, Sahker E, et al. Initial treatment choices to achieve sustained response in major depression: a systematic review and network meta-analysis. World Psychiatry. 2021;20(3):387-396.; Guidi J, Fava G. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021;3:261-269.; Noetel M, Sanders T, Gallardo-Gómez D, et al. Effect of exercise for depression: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2024;384:e075847.; Schuch F, Vancampfort D, Firth J, et al. Physical activity and sedentary behavior in people with major depressive disorder: A systematic review and meta-analysis. Journal of Affective Disorders. 2017;210:139-150.; Schuch F, Vancampfort D, Richards J, et al. Exercise as a treatment for depression: A meta-analysis adjusting for publication bias. Journal of Psychiatric Research. 2016;77:42-51.; Kvam S, Kleppe C, Nordhus I, et al. Exercise as a treatment for depression: A meta-analysis. Journal of Affective Disorders. 2016;202:67-86.; Haddad M, Walters P, Phillips R, et al. Detecting depression in patients with coronary heart disease: a diagnostic evaluation of the PHQ-9 and HADS-D in primary care, findings from the UPBEAT-UK study. PLoS One. 2013 Oct 10;8(10):e78493.; Yuan J, Ding R, Wang L, et al. Screening for depression in acute coronary syndrome patients: A comparison of Patient Health Questionnaire-9 versus Hospital Anxiety and Depression Scale-Depression. Journal of Psychosomatic Research. 2019;121:24-28.; Frasure-Smith N, Lesperance F. Depression and Anxiety as Predictors of 2-Year Cardiac Events in Patients With Stable Coronary Artery Disease. Arch Gen Psychiatry 2008;65:62-71.; Krittanawong C, Maitra N, Qadeer Y, et al. Association of Depression and Cardiovascular Disease. The American Journal of Medicine. 2023;9:881-895.; Harshfield E, Pennells L, Schwartz J, et al. Association Between Depressive Symptoms and Incident Cardiovascular Diseases. JAMA. 2020;23:2396-2405.; Lee S, Yun J, Ko S, et al. Impacts of gender and lifestyle on the association between depressive symptoms and cardiovascular disease risk in the UK Biobank. Scientific Reports. 2023;1:10758.; Rajan S, McKee M, Rangarajan S, et al. Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. JAMA Psychiatry. 2020;10:1052-1063.; Chen X, Liu Z, Yang Y, et al. Depression Status, Lifestyle, and Metabolic Factors With Subsequent Risk for Major Cardiovascular Events: The China Cardiometabolic Disease and Cancer Cohort (4C) Study. Front Cardiovasc Med. 2022 May 26;9:865063.; Wei J, Hou R, Zhang X, et al. The association of late-life depression with all-cause and cardiovascular mortality among community-dwelling older adults: systematic review and meta-analysis. British Journal of Psychiatry. 2019;215:449-455.; VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. 2022. 159 p.; Lewis G, Marston L, Duffy L, et al. Maintenance or Discontinuation of Antidepressants in Primary Care. N Engl J Med. 2021;14:1257-1267.; Kato M, Hori H, Inoue T, et al. Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis. Mol Psychiatry. 2021;26(1):118-133.; Zhou D, Lv Z, Shi L, et al. Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves. Psychol Med. 2022;52(1):48-56.; Liu X, Momen NC, Molenaar N, et al. Discontinuation of antidepressants: Is there a minimum time on treatment that will reduce relapse risk? J Affect Disord. 2021 Jul 1;290:254-260.; Leung LB, Chu K, Rose D, et al. Electronic Population-Based Depression Detection and Management Through Universal Screening in the Veterans Health Administration. JAMA Netw Open. 2022;5(3):e221875.; Brinck-Claussen UØ, Curth NK, Christensen K, et al. Improving the precision of depression diagnosis in general practice: a cluster-randomized trial. BMC Fam Pract. 2021 May 7;22(1):88.; Löwe B, Scherer M, Braunschneider L, et al. Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observer-blinded, randomised controlled trial in Germany. The Lancet Psychiatry. 2024.; Moradi Y, Albatineh A, Mahmoodi H, et al. The relationship between depression and risk of metabolic syndrome: a meta-analysis of observational studies. Clinical Diabetes and Endocrinology. 2021;1:4.; Amare AT, Schubert KO, Klingler-Hoffmann M, et al. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry. 2017 Jan 24;7(1):e1007.; Herring MP, Puetz TW, O'Connor PJ, et al. Effect of Exercise Training on Depressive Symptoms Among Patients With a Chronic Illness: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Arch Intern Med 2012;172(2):101-11.; Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391:1357–1366.; Li CT, Bai YM, Huang YL, et al. Association between antidepressant resistance in unipolar depression and subsequent bipolar disorder: cohort study. Br J Psychiatry 2012;200(1):45-51.; Российское общество психиатров. Посттравматическое стрессовое расстройство. 2023. 200 c.; Coventry PA, Meader N, Melton H, et al. Psychological and pharmacological interventions for posttraumatic stress disorder and comorbid mental health problems following complex traumatic events: Systematic review and component network meta-analysis. PLoS Med. 2020 Aug 19;17(8):e1003262.; Merz J, Schwarzer G, Gerger H. Comparative Efficacy and Acceptability of Pharmacological, Psychotherapeutic, and Combination Treatments in Adults With Posttraumatic Stress Disorder: A Network Meta-analysis. JAMA Psychiatry. 2019;76(9):904–913.; Lee DJ, Schnitzlein CW, Wolf JP, et al. Psychotherapy versus pharmacotherapy for posttraumatic stress disorder: systemic review and meta-analyses to determine first-line treatments. Depress Anxiety. 2016;33(9):792-806.; Lewis C, Roberts NP, Andrew M, et al. Psychological therapies for post-traumatic stress disorder in adults: systematic review and meta-analysis. Eur J Psychotraumatol. 2020 Mar 10;11(1):1729633.; Rauch SAM, Kim HM, Powell C, et al. Efficacy of Prolonged Exposure Therapy, Sertraline Hydrochloride, and Their Combination Among Combat Veterans With Posttraumatic Stress Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(2):117–126.; Phelps AJ, Lethbridge R, Brennan S, et al. Australian guidelines for the prevention and treatment of posttraumatic stress disorder: Updates in the third edition. Australian & New Zealand Journal of Psychiatry. 2022;56(3):230-247.; Zoellner L, Roy-Byrne P, Mavissakalian M, et al. Doubly Randomized Preference Trial of Prolonged Exposure Versus Sertraline for Treatment of PTSD. AJP. 2019;4:287-296.; Williams T, Phillips NJ, Stein DJ, Ipser JC. Pharmacotherapy for posttraumatic stress disorder (PTSD). Cochrane Database of Systematic Reviews 2022, Issue 3. Art. No.: CD002795.; de Moraes Costa G, Zanatta FB, Ziegelmann PK, et al. Pharmacological treatments for adults with post-traumatic stress disorder: A network meta-analysis of comparative efficacy and acceptability. J Psychiatr Res. 2020;130:412-420.; Cipriani A, Williams T, Nikolakopoulou A, et al. Comparative efficacy and acceptability of pharmacological treatments for post-traumatic stress disorder in adults: a network meta-analysis. Psychol Med. 2018;48(12):1975-1984.; LeardMann CA, Kelton ML, Smith B, et al. Prospectively assessed posttraumatic stress disorder and associated physical activity. Public Health Rep. 2011 May-Jun;126(3):371-83.; Jadhakhan F, Lambert N, Middlebrook N, et al. Is exercise/physical activity effective at reducing symptoms of post-traumatic stress disorder in adults — A systematic review. Frontiers in Psychology. 2022;13.; Björkman F, Ekblom Ö. Physical Exercise as Treatment for PTSD: A Systematic Review and Meta-Analysis. Mil Med. 2022 Aug 25;187(9-10):e1103-e1113.; Guina J, Rossetter SR, Derhodes BJ, et al. Benzodiazepines for PTSD: A Systematic Review and Meta-Analysis. J Psychiatr Pract. 2015;21(4):281-303.; Gates M, Holowka D, Vasterling J, et al. Posttraumatic Stress Disorder in Veterans and Military Personnel: Epidemiology, Screening, and Case Recognition. Psychological services. 2012;9:361-382.; ECNP/EBC. The size and burden of mental disorders and other disorders of the brain in Europe 2010. European Neuropsychopharmacology. 2011;21:655–679; Huo N, Vemuri P, Graff-Radford J, et al. Sex Differences in the Association Between Midlife Cardiovascular Conditions or Risk Factors With Midlife Cognitive Decline. Neurology. 2022 Feb 8;98(6):e623-e632.; Liang X, Huang Y, Han X. Associations between coronary heart disease and risk of cognitive impairment: A meta-analysis. Brain Behav. 2021;11(5):e02108.; Adelborg K, Horváth-Puhó E, Ording A, et al. Heart failure and risk of dementia: a Danish nationwide population-based cohort study. Eur J Heart Fail. 2017;19(2):253-260.; Li Chenglong, Zhu Yidan, Ma Yanjun, et al. Association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. Journal of the American College of Cardiology. 2022;14:1321-1335.; Kuźma E, Lourida I, Moore SF, et al. Stroke and dementia risk: A systematic review and meta-analysis. Alzheimers Dement. 2018;14(11):1416–1426.; Zuin M, Roncon L, Passaro A, et al. Risk of dementia in patients with atrial fibrillation: Short versus long follow-up. A systematic review and meta-analysis. International Journal of Geriatric Psychiatry. 2021;10:1488-1500.; Российское общество психиатров, Российская ассоциация геронтологов и гериатров. Когнитивные расстройства у лиц пожилого и старческого возраста. 2020. 239 с.; Patnode CD, Perdue LA, Rossom RC, et al. Screening for Cognitive Impairment in Older Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2020 Feb 25;323(8):764-785.; Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER). The Lancet. 2015;385:2255-2263.; Na R, Yang J, Yeom Y, et al. A Systematic Review and Meta-Analysis of Nonpharmacological Interventions for Moderate to Severe Dementia. Psychiatry Investig. 2019;16(5):325-335.; Woods B, Rai HK, Elliott E, et al. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews 2023, Issue 1. Art. No.: CD005562.; Kudlicka A, Martyr A, Bahar-Fuchs A, et al. Cognitive rehabilitation for people with mild to moderate dementia. Cochrane Database of Systematic Reviews 2023, Issue 6. Art. No.: CD013388.; Bahar-Fuchs A, Martyr A, Goh A, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No.: CD013069.; Kishi T, Matsunaga S, Oya K, et al. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. J Alzheimers Dis. 2017;60(2):401-425.; McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154.; Birks JS, Grimley Evans J. Rivastigmine for Alzheimer's disease. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD001191.; Vaci N, Koychev I, Kim C, et al. Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study. The British Journal of Psychiatry. 2021;218:261-267.; Matsunaga S, Kishi T, Iwata N, et al. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015;10(4):e0123289.; Saragih I, Tonapa S, Saragih I, et al. Effects of cognitive stimulation therapy for people with dementia: A systematic review and meta-analysis of randomized controlled studies. International Journal of Nursing Studies. 2022;128:104181.; Rojas-Fernandez CH. Little Evidence That Cholinesterase Inhibitors Prevent Progression of Mild Cognitive Impairment to Dementia, but They Are Associated With Adverse Effects. Evid Based Ment Health. 2013;16(2):39; Halling A, Berglund J. Association of diagnosis of ischaemic heart disease, diabetes mellitus and heart failure with cognitive function in the elderly population. Eur J Gen Pract. 2006;12(3):114-9.; Mulligan M, Murphy R, Reddin C, et al. Population attributable fraction of hypertension for dementia: global, regional, and national estimates for 186 countries. eClinicalMedicine. 2023;60.; McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2016, Issue 1.; Davis K, Bishara D, Perera G, et al. Benefits and Harms of Statins in People with Dementia: A Systematic Review and Meta-Analysis. J Am Geriatr Soc. 2020;68(3):650-658.; Parish S, Mafham M, Offer A, et al. Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal. 2022 ;43(21):2010-9.; Doyle F, McGee H, Conroy R, et al. Systematic Review and Individual Patient Data Meta-Analysis of Sex Differences in Depression and Prognosis in Persons With Myocardial Infarction: A MINDMAPS Study. Psychosomatic Medicine 2015;77:419–28.; Meijer A, Conradi HJ, Bos EH, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry 2013;203(2):90-102.; Li J, Ji F, Song J, et al. Anxiety and clinical outcomes of patients with acute coronary syndrome: a meta-analysis. BMJ Open. 2020 Jul 9;10(7):e034135.; Roest AM, Martens EJ, Denollet J, et al. Prognostic Association of Anxiety Post Myocardial Infarction With Mortality and New Cardiac Events: A Meta-Analysis. Psychosom Med 2010;72(6):563-9.; Kronish IM, Edmondson D, Moise N, et al. Posttraumatic stress disorder in patients who rule out versus rule in for acute coronary syndrome. Gen Hosp Psychiatry. 2018 Jul-Aug;53:101-107.; Edmondson D, Richardson S, Falzon L, et al. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review. PLoS One. 2012;7(6):e38915.; Gustad LT, Laugsand LE, Janszky I, et al. Symptoms of anxiety and depression and risk of acute myocardial infarction: the HUNT 2 study. Eur Heart J. 2014;35(21):1394-1403.; Rosengren A, Hawken S, Ounpuu S, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364(9438):953-62.; Jeffrey FS, Timothy C, Angelique Z, et al. Anxiety disorders increase risk for incident myocardial infarction in depressed and nondepressed Veterans Administration patients. American heart journal. 2010;159[5]:772-779.; Chen YH, Tsai SY, Lee HC, et al. Increased Risk of Acute Myocardial Infarction for Patients With Panic Disorder: A Nationwide Population-Based Study. Psychosom Med. 2009;71(7):798-804.; Flygare O, Boberg J, Rück C, et al. Association of anxiety or depression with risk of recurrent cardiovascular events and death after myocardial infarction: A nationwide registry study. International Journal of Cardiology. 2023;381:120-127.; Myers V, Gerber Y, Benyamini Y, et al. Post-myocardial infarction depression: Increased hospital admissions and reduced adoption of secondary prevention measures - A longitudinal study. Journal of Psychosomatic Research. 2012;2(1):5-10.; Kim JM, Stewart R, Bae KY, et al. Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study. Psychol Med. 2015;45(8):1641-52.; Taylor CB, Youngblood ME, Catellier D, et al. Effects of Antidepressant Medication on Morbidity and Mortality in Depressed Patients After Myocardial Infarction. Arch Gen Psychiatry. 2005;62:792-798.; Glassman AH, O'Connor CM, Califf RM, et al. Sertraline Treatment of Major Depression in Patients With Acute MI or Unstable Angina. JAMA. 2002;288:701-709.; van Melle JP, de Jonge P, Honig A, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry 2007;190:460-6.; Kim J, Stewart R, Lee Y, et al. Effect of Escitalopram vs Placebo Treatment for Depression on Long-term Cardiac Outcomes in Patients With Acute Coronary Syndrome. A Randomized Clinical Trial. JAMA. 2018;320(4):350–358.; Abdullah A, Eigbire G, Salama A, et al. Impact of delirium on patients hospitalized for myocardial infarction: A propensity score analysis of the National Inpatient Sample. Clin Cardiol. 2018;41(7):910-915.; Jäckel M, Zotzmann V, Wengenmayer T, et al. Incidence and predictors of delirium on the intensive care unit after acute myocardial infarction, insight from a retrospective registry. Catheterization and Cardiovascular Interventions. 2021;6:1072-1081.; Patil S, Gonuguntala K, Rojulpote C, et al. Delirium is an important predictor of mortality in elderly patients with ST-elevation myocardial infarction: insight from National Inpatient Sample database. Coron Artery Dis. 2020;31(8):665-670.; Kang H-J, Stewart R, Bae K-Y, et al. Effects of depression screening on psychiatric outcomes in patients with acute coronary syndrome: Findings from the K-DEPACS and EsDEPACS studies. Int J Card. 2015;190:114-121.; Kronish IM, Moise N, Cheung YK, et al. Effect of Depression Screening After Acute Coronary Syndromes on Quality of Life: The CODIACS-QoL Randomized Clinical Trial. JAMA Intern Med. 2020;180(1):45–53.; Sweda R, Siontis GCM, Nikolakopoulou A, et al. Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis. ESC Heart Fail. 2020 Sep 16;7(6):3610–20.; Ben-Shoshan J, Segman-Rosenstveig Y, Arbel Y, et al. Comparison of Triggering and Nontriggering Factors in ST-Segment Elevation Myocardial Infarction and Extent of Coronary Arterial Narrowing. Am J Card. 2016;117(8):1219-1223.; Tofler GH, Kopel E, Klempfner R, et al. Triggers and Timing of Acute Coronary Syndromes. Am J Card. 2017;119(10):1560-1565.; Chan B, Buckley T, Tofler G, et al. Emotional Stress and Physical Exertion as Triggers of Acute Myocardial Infarction. American Journal of Cardiology. 2023;203:285-287.; Smyth A, O’Donnell M, Lamelas P, et al. Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction. Circulation. 2016;134:1059-1067; Lissåker CT, Norlund F, Wallert J, et al. Persistent emotional distress after a first-time myocardial infarction and its association to late cardiovascular and non-cardiovascular mortality. Eur J Prev Cardiol. 2019;26(14):1510-1518.; Park Y, Bateman BT, Kim DH, et al. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ. 2018;360.; Kemp AH, Brunoni AR, Nunes MA, et al. The association between mood and anxiety disorders, and coronary heart disease in Brazil: a cross-sectional analysis on the Brazilian longitudinal study of adult health (ELSA-Brasil). Front Psychol. 2015;6:187.; Gan Y, Gong Y, Tong X, et al. Depression and the risk of coronary heart disease: a meta-analysis of prospective cohort studies. BMC Psychiatry. 2014;14(1):1-11.; Poole L, Steptoe A. Depressive symptoms predict incident chronic disease burden 10-years later: Findings from the English Longitudinal Study of Ageing (ELSA). Journal of Psychosomatic Research. 2018;113:30-36.; Herbst S, Pietrzak RH, Wagner J et al. Lifetime Major Depression is Associated With Coronary Heart Disease in Older Adults: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. Psychosom Med 2007;69:729-34.; Roest AM, Martens EJ, de Jonge P, et al. Anxiety and Risk of Incident Coronary Heart Disease: A Meta-Analysis. J Am Coll Cardiol 2010;56(1):38-46.; Emdin CA, Odutayo A, Wong CX, et al. Meta-Analysis of Anxiety as a Risk Factor for Cardiovascular Disease. Am J Card. 2016;118(4):511-519.; Tully PJ, Turnbull DA, Beltrame J, et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychol Med. 2015;45(14):2909-20.; Akosile W, Colquhoun D, Young R, et al. The association between post-traumatic stress disorder and coronary artery disease: a meta-analysis. Australas Psychiatry. 2018;26(5):524-530.; Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. American heart journal. 2013;166[5]:806-814.; Белялов Ф.И. Депрессия, тревога и стресс у пациентов с ишемической болезнью сердца. Терапевтический архив. 2017;89(8):104–109.; Derisi MM, Nasiri MJ, Aryan A, et al. Prevalence of psychiatric disorders in patients with ischemic heart disease: A systematic review and meta-analysis. J Res Med Sci. 2022 Feb 18;27:12.; Boyle SH, Samad Z, Becker RC, et al. Depressive Symptoms and Mental Stress-Induced Myocardial Ischemia in Patients With Coronary Heart Disease. Psychosom Med 2013;75(9):822-31.; Geovanini GR, Gowdak LHW, Pereira AC et al. OSA and depression are common and independently associated with refractory angina in patients with coronary artery disease. CHEST. 2014;146:73-80.; Schopfer DW, Regan M, Heidenreich PA, Whooley MA. Depressive Symptoms, Cardiac Disease Severity, and Functional Status in Patients With Coronary Artery Disease (from the Heart and Soul Study). Am J Card. 2016;118(9):1287-1292.; Papasavvas T, Alhashemi M, Micklewright D. Association Between Depressive Symptoms and Exercise Capacity in Patients With Heart Disease: A Meta-analysis. J Cardiopulm Rehabil Prev. 2017;37(4):239–49.; Lin S, Zhang H, Ma A. The association between depression and coronary artery calcification: A meta-analysis of observational studies. J Affect Disord. 2018;232:276-282.; Tusa N, Kautiainen H, Elfving P, et al. Depressive symptoms decrease health-related quality of life of patients with coronary artery disease and diabetes: a 12-month follow up study in primary care. Scand J Prim Health Care. 2023;41(3):276-286.; Martens EJ, de Jonge P, Na B, et al. Scared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study. Arch Gen Psychiatry 2010;67(7):750-8.; Celano CM, Millstein RA, Bedoya CA, et al. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015;170(6):1105-1115.; Vaccarino V, Sullivan S, Hammadah M, et al. Mental Stress–Induced-Myocardial Ischemia in Young Patients With Recent Myocardial Infarction. Circulation. 2018;137(8):794.; Wei J, Rooks C, Ramadan R, et al. Meta-analysis of mental stress-induced myocardial ischemia and subsequent cardiac events in patients with coronary artery disease. The American journal of cardiology 2014;114:187-192.; Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. Pharmacol Res. 2017;118:19-32.; Magán I, Jurado-Barba R, Casado L, et al. Efficacy of psychological interventions on clinical outcomes of coronary artery disease: Systematic review and meta-analysis. Journal of Psychosomatic Research. 2022;153:110710.; Doyle F, Freedland K, Carney R, et al. Hybrid Systematic Review and Network Meta-Analysis of Randomized Controlled Trials of Interventions for Depressive Symptoms in Patients With Coronary Artery Disease. Psychosomatic Medicine. 2021;83.; Dibben G, Faulkner J, Oldridge N, et al. Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis. European Heart Journal. 2023;6:452-469.; Hallgren M, Kraepelien M, Öjehagen A, et al. Physical exercise and internet-based cognitive–behavioural therapy in the treatment of depression: randomised controlled trial. The British Journal of Psychiatry 2015;207:227-234.; Blumenthal JA, Sherwood A, Babyak MA, et al. Exercise and Pharmacological Treatment of Depressive Symptoms in Patients With Coronary Heart Disease: Results From the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) Study. J Am Coll Cardiol. 2012;60(12):1053-1063.; Bauer LK, Caro MA, Beach SR, et al. Effects of Depression and Anxiety Improvement on Adherence to Medication and Health Behaviors in Recently Hospitalized Cardiac Patients. The American journal of cardiology. 2012;109[10]:1266-1271.; Kronish IM, Woodward M, Sergie Z, et al. Meta-Analysis: Impact of Drug Class on Adherence to Antihypertensives. Circulation 2011;123(15):1611-21.; Lapa ME, Swabe GM, Rollman BL, et al. Assessment of Depression and Adherence to Guideline-Directed Medical Therapies Following Percutaneous Coronary Intervention. JAMA Netw Open. 2022;5(12):e2246317.; Kronish IM, Rieckmann N, Halm EA et al. Persistent depression affects adherence to secondary prevention behaviors after acute coronary syndromes. J Gen Intern Med. 2006;21(11):1178-83.; Greaves D, Psaltis P, Ross T, et al. Cognitive outcomes following coronary artery bypass grafting: A systematic review and meta-analysis of 91,829 patients. International Journal of Cardiology. 2019;289:43-49.; van Dijk MR, Utens EM, Dulfer K, et al. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. Eur J Prev Cardiol. 2016;23(5):552-8.; Zhang WY, Nan N, Song XT, et al. Impact of depression on clinical outcomes following percutaneous coronary intervention: a systematic review and meta-analysis. BMJ Open. 2019 Aug 20;9(8):e026445.; Geulayov G, Novikov I, Dankner D, Dankner R. Symptoms of depression and anxiety and 11-year all-cause mortality in men and women undergoing coronary artery bypass graft (CABG) surgery. J Psychosom Res. 2018;105:106-114.; Stenman M, Holzmann MJ, Sartipy U. Association between preoperative depression and long-term survival following coronary artery bypass surgery - A systematic review and meta-analysis. Int J Cardiol. 2016;222:462-466.; Bouchard V, Robitaille A, Perreault S, et al. Psychological distress, social support, and use of outpatient care among adult men and women with coronary artery disease or other non-cardiovascular chronic disease. Journal of Psychosomatic Research. 2023;165:111131.; Rawashdeh SI, Ibdah R, Kheirallah KA, et al. Prevalence Estimates, Severity, and Risk Factors of Depressive Symptoms among Coronary Artery Disease Patients after Ten Days of Percutaneous Coronary Intervention. Clin Pract Epidemiol Ment Health. 2021 Sep 16;17:103-113.; Pedersen SS, Denollet J, van Gestel YR, et al. Clustering of psychosocial risk factors enhances the risk of depressive symptoms 12-months post percutaneous coronary intervention. Eur J Cardiovasc Prev Rehabil. 2008;15(2):203-9.; Williams B, Riangwiwat T, Voyce S, et al. Burden and Predictors of Chest Pain-Related Health-Care Utilization Following Percutaneous Coronary Intervention. American Journal of Cardiology. 2021;160:31-39.; de Jager T, Dulfer K, Radhoe S, et al. Predictive value of depression and anxiety for long-term mortality: differences in outcome between acute coronary syndrome and stable angina pectoris. Int J Card. 2018;250:43-48.; Zhang H, Shao B, Wang Q, et al. Alcohol Consumption and Risk of Atrial Fibrillation: A Dose-Response Meta-Analysis of Prospective Studies. Frontiers in Cardiovascular Medicine. 2022;9.; Yang L, Chen H, Shu T, et al. Risk of incident atrial fibrillation with low-to-moderate alcohol consumption is associated with gender, region, alcohol category: a systematic review and meta-analysis. EP Europace. 2022;5:729-746.; Larsson SC, Drca N, Wolk A. Alcohol Consumption and Risk of Atrial Fibrillation: A Prospective Study and Dose-Response Meta-Analysis. J Am Coll Cardiol. 2014;64(3):281-289.; Gehi AK, Sears S, Goli N, et al. Psychopathology and symptoms of atrial fibrillation: implications for therapy. J Cardiovasc Electrophysiol. 2012;23(5):473-8.; Thompson TS, Barksdale DJ, Sears SF, et al. The effect of anxiety and depression on symptoms attributed to atrial fibrillation. Pacing Clin Electrophysiol. 2014;37(4):439-46.; Akintade BF, Chapa D, Friedmann E, Thomas SA. The influence of depression and anxiety symptoms on health-related quality of life in patients with atrial fibrillation and atrial flutter. J Cardiovasc Nurs. 2015;30(1):66-73.; Bamgbade BA, Sanghai SR, McManus DD, et al. Psychosocial and cognitive multimorbidity and health-related quality of life and symptom burden in older adults with atrial fibrillation: The systematic assessment of geriatric elements in atrial fibrillation (SAGE-AF) cohort study. Arch Gerontol Geriatr. 2020 Sep-Oct;90:104117.; Taylor EC, O'Neill M, Hughes LD, Moss-Morris R. Atrial fibrillation, quality of life and distress: a cluster analysis of cognitive and behavioural responses. Qual Life Res. 2022;31(5):1415-1425.; von Eisenhart Rothe A, Hutt F, Baumert J et al. Depressed mood amplifies heart-related symptoms in persistent and paroxysmal atrial fibrillation patients: a longitudinal analysis. Europace 2015;17:1354-1362.; Yu S, Zhao Q, Wu P, et al. Effect of anxiety and depression on the recurrence of paroxysmal atrial fibrillation after circumferential pulmonary vein ablation. J Cardiovasc Electrophysiol. 2012;23 Suppl 1:S17-23.; Efremidis M, Letsas KP, Lioni L, et al. Association of quality of life, anxiety, and depression with left atrial ablation outcomes. Pacing Clin Electrophysiol. 2014;37(6):703-11.; Giannone M, Filippini T, Whelton P, et al. Atrial Fibrillation and the Risk of Early-Onset Dementia: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2022;14:e025653.; Koh Y, Lew L, Franke K, et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals . EP Europace. 2022;8:1229-1239.; Rosman L, Lampert R, Ramsey C, et al. Posttraumatic Stress Disorder and Risk for Early Incident Atrial Fibrillation: A Prospective Cohort Study of 1.1 Million Young Adults. Journal of the American Heart Association. 2019;19:e013741.; Voskoboinik A, Kalman J, De Silva A, et al. Alcohol Abstinence in Drinkers with Atrial Fibrillation. N Engl J Med. 2020;1:20-28.; Lee S, Choi E, Jung J, et al. Lower risk of stroke after alcohol abstinence in patients with incident atrial fibrillation: a nationwide population-based cohort study. European Heart Journal. 2021;46:4759-4768.; Lee J, Roh S, Yoon W, et al. Changes in alcohol consumption habits and risk of atrial fibrillation: a nationwide population-based study. European Journal of Preventive Cardiology. 2024;1:49-58.; Damanti S, Pasina L, Cortesi L, et al. Atrial Fibrillation: Possible Influences of Rate and Rhythm Control Strategy on Cognitive Performance. J Am Geriatr Soc. 2018;66(11):2178-2182.; Teppo K, Jaakkola J, Airaksinen K, et al. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. Journal of the American Heart Association. 2022;6:e024119.; Lapa ME, Swabe GM, Magnani JW. Association of Depression and Adherence to Oral Anticoagulation in Patients With Atrial Fibrillation. J Am Heart Assoc. 2023 Nov 20:e031281.; Colquhoun D, Malawaraarachchi N, Ferreira-Jardim A, et al. Poor adherence to anticoagulant therapy: a call to screen and treat depression in patients with atrial fibrillation. Heart, Lung and Circulation. 2015;24:S389-S390.; Lampert R, Burg M, Jamner L, et al. Effect of b-blockers on triggering of symptomatic atrial fibrillation by anger or stress. Heart Rhythm. 2019;8:1167-1173.; Kim D, Yang P, Sung J, et al. Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study. European Heart Journal. 2020;47:4483-4493.; Mark DB, Anstrom KJ, Sheng S, et al. Effect of Catheter Ablation vs Medical Therapy on Quality of Life Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial. JAMA. 2019;321(13):1275-1285.; Al-Kaisey Ahmed M, Parameswaran Ramanathan, Bryant Christina, et al. Impact of Catheter Ablation on Cognitive Function in Atrial Fibrillation. JACC: Clinical Electrophysiology. 2023;7Part2:1024-1034.; Harrison S, Buckley B, Austin P, et al. Catheter ablation and lower risk of incident dementia and mortality in older adults with atrial fibrillation. Journal of the American Geriatrics Society. 2023;11:3357-3366.; Thrall G, Lip GYH, Carroll D, et al. Depression, Anxiety, and Quality of Life in Patients With Atrial Fibrillation. Chest 2007;132:1259-64.; Wu H, Li C, Li B, et al. Psychological factors and risk of atrial fibrillation: A meta-analysis and systematic review. International Journal of Cardiology. 2022;362:85-92.; Shi S, Liu T, Liang J, Hu D, Yang B. Depression and Risk of Sudden Cardiac Death and Arrhythmias: A Meta-Analysis. Psychosomatic Medicine. 2017;79(2).; Kim Y, Lee K, Han K, et al. Association of Depression With Atrial Fibrillation in South Korean Adults. JAMA Network Open. 2022;1:e2141772-e2141772.; Cheng YF, Leu HB, Su CC, et al. Association Between Panic Disorder and Risk of Atrial Fibrillation: A Nationwide Study. Psychosom Med 2013;75(1):30-5.; Graff S, Fenger-Grøn M, Christensen B, et al. Long-term risk of atrial fibrillation after the death of a partner. Open Heart. 2016;3(1).; Wei D, Olofsson T, Chen H, et al. Death of a child and the risk of atrial fibrillation: a nationwide cohort study in Sweden. European Heart Journal. 2021;15:1489-1495.; Suzuki H, Ohira T, Takeishi Y, et al. Increased prevalence of atrial fibrillation after the Great East Japan Earthquake: Results from the Fukushima Health Management Survey. Int J Card. 2015;198:102-105.; Kupper N, van den Broek KC, Widdershoven J, Denollet J. Subjectively reported symptoms in patients with persistent atrial fibrillation and emotional distress. Front Psychol. 2013;4:192.; Perret-Guillaume C, Briancon S, Wahl D, et al. Quality of Life in elderly inpatients with atrial fibrillation as compared with controlled subjects. J Nutr Health Aging. 2010;14(2):161-6.; Sadlonova M, Salzmann S, Senges J, et al. Generalized anxiety is a predictor of impaired quality of life in patients with atrial fibrillation: Findings from the prospective observational ARENA study. Journal of Psychosomatic Research. 2024;176:111542.; Gardarsdottir M, Sigurdsson S, Aspelund T, et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. EP Europace. 2018;8:1252-1258.; Singh-Manoux A, Fayosse A, Sabia S, et al. Atrial fibrillation as a risk factor for cognitive decline and dementia. Eur Heart J. 2017;38(34):2612-2618.; Marcus G, Vittinghoff E, Whitman I, et al. Acute Consumption of Alcohol and Discrete Atrial Fibrillation Events. Ann Intern Med. 2021;11:1503-1509.; Gallagher C, Hendriks JML, Elliott AD, et al. Alcohol and incident atrial fibrillation – A systematic review and meta-analysis. Int J Card. 2017;246:46-52.; Stecker EC, Reinier K, Marijon E, et al. Public health burden of sudden cardiac death in the United States. Circ Arrhythm Electrophysiol. 2014;7(2):212-7.; Ray WA, Chung CP, Murray KT, et al. Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. The New England Journal of Medicine 2009;360(3):225-35.; Murray-Thomas T, Jones ME, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol. 2013;2013:247486.; Wang M, Szepietowska B, Polonsky B, et al. Risk of Cardiac Events Associated With Antidepressant Therapy in Patients With Long QT Syndrome. Am J Card. 2018;121(2):182-187.; Schwartz PJ, Priori SG, Spazzolini C, et al. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001 Jan 2;103(1):89-95.; Hintsa T, Määttänen I, Hintsanen M, et al. Work stress and the long QT syndrome: high job strain and effort-reward imbalance at work associated with arrhythmic risk in the long QT syndrome. J Occup Environ Med. 2013;55(12):1387-93.; Shimizu W, Noda T, Takaki H, et al. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1(3):276-83.; Ghezzi E, Sharman R, Selvanayagam J, et al. Burden of mood symptoms and disorders in implantable cardioverter defibrillator patients: a systematic review and meta-analysis of 39 954 patients. EP Europace. 2023;25(6):euad130.; Miller J, Thylén I, Elayi S, et al. Multi-morbidity burden, psychological distress, and quality of life in implantable cardioverter defibrillator recipients: Results from a nationwide study. Journal of Psychosomatic Research. 2019;120:39-45.; Januszkiewicz Ł, Barra S, Providencia R, et al. Long-term quality of life and acceptance of implantable cardioverter-defibrillator therapy: results of the European Heart Rhythm Association survey. EP Europace. 2022;5:860-867.; Белялов Ф.И. Белялов Ф.И. Аритмии сердца. 9-e изд. Москва: ГЭОТАР-Медиа, 2023. с. 412–415 с.; Jeon SH, Jaekal J, Lee SH, et al. Effects of nortriptyline on QT prolongation: a safety pharmacology study. Hum Exp Toxicol. 2011;30(10):1649-56.; Polcwiartek C, Kragholm K, Schjerning O, et al. Cardiovascular safety of antipsychotics: a clinical overview. Expert Opin Drug Saf. 2016;15(5):679-88.; Fayssoil A, Issi J, Guerbaa M, et al. Torsade de pointes induced by citalopram and amiodarone. Ann Cardiol Angeiol (Paris). 2011;60(3):165-8.; Bundgaard J, Thune J, Nielsen J, et al. The impact of implantable cardioverter-defibrillator implantation on health-related quality of life in the DANISH trial. EP Europace. 2019;6:900-908.; Pan Y., Cai W., Cheng Q., Dong W., An T., Wang J. Association between anxiety and hypertension: a systematic review and meta-analysis of epidemiological studies. Neuropsychiatr Dis Treat. 2015;11:1121-1130 https://doi.org/10.2147/NDT.S77710; Wu E-L, Chien IC, Lin C-H. Increased risk of hypertension in patients with anxiety disorders: A population-based study. Journal of Psychosomatic Research. 2014;77(6):522-527.; Meng L, Chen D, Yang Y, et al. Depression increases the risk of hypertension incidence: a meta-analysis of prospective cohort studies. J Hypertens. 2012;30(5):842-51.; Wu E-L, Chien IC, Lin C-H, Chou Y-J, Chou P. Increased risk of hypertension in patients with major depressive disorder: A population-based study. Journal of Psychosomatic Research. 2012;73(3):169-174.; Lim L, Solmi M, Cortese S, et al. Association between anxiety and hypertension in adults: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2021;131:96-119.; Abouzeid M, Kelsall HL, Forbes AB, et al. Posttraumatic stress disorder and hypertension in Australian veterans of the 1991 Gulf War. Journal of Psychosomatic Research. 2012;72(1):33-38.; Sumner JA, Kubzansky LD, Roberts AL, et al. Post-traumatic stress disorder symptoms and risk of hypertension over 22 years in a large cohort of younger and middle-aged women. Psychol Med. 2016;46(15):3105-3116.; Abell J, Kivimäki M, Dugravot A, et al. Association between systolic blood pressure and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to define hypertension. European Heart Journal. 2018;33:3119-3125.; Emdin C, Rothwell P, Salimi-Khorshidi G, et al. Blood Pressure and Risk of Vascular Dementia. Stroke. 2016;6:1429-1435.; Cunningham EL, Todd SA, Passmore P, et al. Pharmacological treatment of hypertension in people without prior cerebrovascular disease for the prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews 2021, Issue 5. Art. No.: CD004034.; Hughes D, Judge C, Murphy R, et al. Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. JAMA. 2020;323(19):1934–1944.; Forette F, Seux ML, Staessen JA, et al. The Prevention of Dementia With Antihypertensive Treatment. Arch Intern Med. 2002;162:2046-52.; Peters R, Xu Y, Fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022 Dec 21;43(48):4980-4990.; Wang L, Liu Q, Sun D, et al. Effects of Combination Treatment in Hypertensive Patients with Depression: A Systematic Review and Meta-Analysis of 27 Randomized Controlled Trials. Ther Clin Risk Manag. 2022 Mar 5;18:197-211.; Graham N, Ward J, Mackay D, et al. Impact of major depression on cardiovascular outcomes for individuals with hypertension: prospective survival analysis in UK Biobank. BMJ Open. 2019 Sep 30;9(9):e024433.; Ogedegbe G, Pickering TG, Clemow L, et al. The Misdiagnosis of Hypertension: The Role of Patient Anxiety. Arch Intern Med 2008;168(22):2459-65.; Spruill TM, Pickering TG, Schwartz JE, et al. The impact of perceived hypertension status on anxiety and the white coat effect. Ann Behav Med. 2007;34(1):1-9.; Jhalani J, Goyal T, Clemow L, et al. Anxiety and outcome expectations predict the white-coat effect. Blood Press Monit. 2005;10(6):317-9.; Li Z., Li Y., Chen L., Chen P., Hu Y. Prevalence of Depression in Patients With Hypertension: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015 Aug;94(31):e1317. doi:10.1097/MD.0000000000001317.; Williamson JD, Pajewski NM, Auchus AP, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial. JAMA. 2019;321(6):553–561.; Stuhec M, Keuschler J, Serra-Mestres J, Isetta M. Effects of different antihypertensive medication groups on cognitive function in older patients: A systematic review. European Psychiatry. 2017;46:1-15.; den Brok M, van Dalen J, Abdulrahman H, et al. Antihypertensive Medication Classes and the Risk of Dementia: A Systematic Review and Network Meta-Analysis. J Am Med Dir Assoc. 2021;22(7):1386-1395.e15.; Chen YJ, Li LJ, Tang WL, et al. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database Syst Rev. 2018 Nov 14;11(11):CD008170.; Breeden M, Gillis A, Salas J, et al. Antidepressant treatment and blood pressure control in patients with comorbid depression and treatment resistant hypertension. Journal of Psychosomatic Research. 2022;153:110692.; Turvey CL, Schultz K, Arndt S, et al. Prevalence and correlates of depressive symptoms in a community sample of people suffering from heart failure. J Am Geriatr Soc 2002;50(12):2003-8.; Chobufo M, Khan S, Agbor V, et al. 10-Year trend in the prevalence and predictors of depression among patients with heart failure in the USA from 2007-2016. International Journal of Cardiology. 2020;301:123-126.; Angermann CE, Gelbrich G, Stork S, et al. Somatic correlates of comorbid major depression in patients with systolic heart failure. Int J Cardiol. 2011;147(1):66-73.; Khodneva Y, Goyal P, Levitan E, et al. Depressive Symptoms and Incident Hospitalization for Heart Failure: Findings From the REGARDS Study. Journal of the American Heart Association. 2022;7:e022818.; Gustad LT, Laugsand LE, Janszky I, Dalen H, Bjerkeset O. Symptoms of anxiety and depression and risk of heart failure: the HUNT Study. Eur J Heart Fail 2014;16:861–870.; Garfield LD, Scherrer JF, Hauptman PJ, et al. Association of Anxiety Disorders and Depression With Incident Heart Failure. Psychosomatic Medicine. 2014;76(2):128-36.; Lossnitzer N, Herzog W, Stork S, et al. Incidence rates and predictors of major and minor depression in patients with heart failure. Int J Cardiol. 2013;167(2):502-7.; Kewcharoen J, Tachorueangwiwat C, Kanitsoraphan C, et al. Association between depression and increased risk of readmission in patients with heart failure: a systematic review and meta-analysis. Minerva Cardiol Angiol. 2021;69(4):389-397.; Machado MO, Veronese N, Sanches M, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med 2018;16:112; Patel N, Chakraborty S, Bandyopadhyay D, et al. Association between depression and readmission of heart failure: A national representative database study. Prog Cardiovasc Dis. 2020 Sep-Oct;63(5):585-590. doi:10.1016/j.pcad.2020.03.014.; Gathright EC, Goldstein CM, Josephson RA, Hughes JW. Depression increases the risk of mortality in patients with heart failure: A meta-analysis. J Psychosom Res. 2017;94:82-89.; IsHak WW, Hamilton MA, Korouri S, et al. Comparative Effectiveness of Psychotherapy vs Antidepressants for Depression in Heart Failure: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2352094. doi:10.1001/jamanetworkopen.2023.52094; Angermann CE, Gelbrich G, Sto¨rk S, et al. Effect of escitalopram on all cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF Randomized Clinical Trial. JAMA 2016;315:2683–2693.; O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and Efficacy of Sertraline for Depression in Patients With Heart Failure: Results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) Trial. J Am Coll Cardiol 2010;56(9):692-9.; Hedrick R, Korouri S, Tadros E, et al. The impact of antidepressants on depressive symptom severity, quality of life, morbidity, and mortality in heart failure: a systematic review. Drugs Context 2020;9:2020-5-4; He W, Zhou Y, Ma J, Wei B, Fu Y. Effect of antidepressants on death in patients with heart failure: a systematic review and meta-analysis. Heart Fail Rev 2020;25:919–926.; Jeyanantham K, Kotecha D, Thanki D, Dekker R, Lane DA. Effects of cognitive behavioural therapy for depression in heart failure patients: a systematic review and meta-analysis. Heart Fail Rev 2017;22:731–741.; Chernoff RA, Messineo G, Kim S, et al. Psychosocial Interventions for Patients With Heart Failure and Their Impact on Depression, Anxiety, Quality of Life, Morbidity, and Mortality: A Systematic Review and Meta-Analysis. Psychosom Med. 2022 Jun 1;84(5):560-580. doi:10.1097/PSY.0000000000001073.; Tu R-H, Zeng Z-Y, Zhong G-Q, et al. Effects of exercise training on depression in patients with heart failure: a systematic review and meta-analysis of randomized controlled trials. Eur J Heart Fail 2014;16:749–757; Das A, Roy B, Schwarzer G, et al. Comparison of treatment options for depression in heart failure: A network meta-analysis. J Psychiatr Res. 2019;108:7-23.; Blumenthal JA, Babyak MA, O’Connor C, et al. Effects of Exercise Training on Depressive Symptoms in Patients With Chronic Heart Failure: The HF-ACTION Randomized Trial. JAMA. 2012;308(5):465-474.; Suzuki T, Shiga T, Kuwahara K, et al. Impact of clustered depression and anxiety on mortality and rehospitalization in patients with heart failure. J Cardiol. 2014;64(6):456-62.; Alhurani AS, Dekker RL, Abed MA, et al. The Association of Co-morbid Symptoms of Depression and Anxiety With All-Cause Mortality and Cardiac Rehospitalization in Patients With Heart Failure. Psychosomatics. 2015;56:371-380.; Sato Y, Yoshihisa A, Hotsuki Y, et al. Associations of Benzodiazepine With Adverse Prognosis in Heart Failure Patients With Insomnia. Journal of the American Heart Association. 2020;7:e013982.; Chuang C, Hsiao FC, Cheng YW, et al. Benzodiazepines in Patients with Heart Failure and Reduced Ejection Fraction. Acta Cardiol Sin. 2022;38(5):573-583.; Zwas DR, Keren A, Amir O, Gotsman I. Treatment of Heart Failure Patients with Anxiolytics Is Associated with Adverse Outcomes, with and without Depression. J Clin Med. 2020 Dec 7;9(12):3967. doi:10.3390/jcm9123967.; Ribeirinho-Soares P, Madureira S, Elias C, et al. Benzodiazepine use and mortality in chronic heart failure. Pol Arch Intern Med. 2023; 133: 16464.; 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42:3599–726.

Διαθεσιμότητα: https://www.nii-kpssz.com/jour/article/view/1566
https://doi.org/10.17802/2306-1278-2024-13-3S-222-253

Long QT Syndrome in Children

Πηγή: Педиатрия. Восточная Европа. :107-118

Θεματικοί όροι: внезапная сердечная смерть, ECG, синдром удлиненного интервала QT, бета-адреноблокаторы, дети, кардиовертер-дефибриллятор, corrected QT interval, ЭКГ, sudden cardiac death, 3. Good health, canalopathy, 03 medical and health sciences, beta-blockers, 0302 clinical medicine, children, cardioverter-defibrillator, каналопатии, long QT syndrome, корригированный интервал QT

Spatial QRS-T Angle in Risk Assessment of the Life-Threatening Arrhythmic Events

Πηγή: Кардиология в Беларуси. :620-628

Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, прогнозирование, внезапная сердечная смерть, аритмия, угол QRS-T, prognosis, arrhythmia, QRS-T angle, vector electrocardiography, sudden cardiac death, 3. Good health, векторная электрокардиография

Сравнительный анализ нарушений сердечно-сосудистой системы у пациентов с хроническим миелолейкозом на фоне лечения ингибиторами тирозинкиназы

Συγγραφείς: E. I. Emelina, IE Lazarev, Galina Gusarova, OYu Vinogradova, Anna G. Turkina, Anastasiya Bykova, G. E. Gendlin, EYu Chelysheva, Immunology, Samory Mashela str., Moscow, Russian Federation, EG Arshanskaya, Igor G. Nikitin, L M Makeeva

Πηγή: Клиническая онкогематология, Vol 13, Iss 1 (2020)

Θεματικοί όροι: удлинение интервала QTc, 03 medical and health sciences, иматиниб, 0302 clinical medicine, нилотиниб, хронический миелолейкоз, внезапная сердечная смерть, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, дазатиниб, RC254-282, 3. Good health

Σύνδεσμος πρόσβασης: http://bloodjournal.ru/wp-content/uploads/2019/12/10.pdf
https://doaj.org/article/3a198ed8936c4a4b95770e0a6ac2e590

Исход жизнеугрожающей сердечной аритмии при интенсивных физических нагрузках: клинический случай ; Outcome of life-threating cardiac arrhythmia during intensive physical loads: clinical case

Συγγραφείς: Chigareva, M. L., Mironov, V. A., Akimova, A. V., Чигарева, М. Л., Миронов, В. А., Акимова, А. В.

Πηγή: Сборник статей

Θεματικοί όροι: RHYTHM DISTURBANCES, SUDDEN CARDIAC DEATH, PHYSICAL ACTIVITY, CONNECTIVE TISSUE DYSPLASIA, НАРУШЕНИЯ РИТМА, ВНЕЗАПНАЯ СЕРДЕЧНАЯ СМЕРТЬ, ФИЗИЧЕСКИЕ НАГРУЗКИ, ДИСПЛАЗИЯ СОЕДИНИТЕЛЬНОЙ ТКАНИ

Περιγραφή αρχείου: application/pdf

Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/13404

Διαθεσιμότητα: http://elib.usma.ru/handle/usma/13404

Arrhythmic Mitral Valve Prolapse: New Menaces of the Known Disease ; Аритмогенный пролапс митрального клапана: новые угрозы известного заболевания

Συγγραφείς: D. A. Kuzhel, G. V. Matyushin, E. A. Savchenko, Д. А. Кужель, Г. В. Матюшин, Е. А. Савченко

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 19, No 1 (2023); 77-82 ; Рациональная Фармакотерапия в Кардиологии; Vol 19, No 1 (2023); 77-82 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: внезапная сердечная смерть, mitral annular disjunction, sudden cardiac death, митрально-аннулярное разъединение

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2884/2397; Barlow JB, Pocock WA. The significance of late systolic murmurs and mid-late systolic clicks. Md State Med J. 1963;12:76-7.; Criley JM, Lewis KB, Humphries JO, et al. Prolapse of the mitral valve: clinical and cine-angiocardiographic findings. Br Heart J. 1966;28(4):488-96. DOI:10.1136/hrt.28.4.488.; Feigenbaum H. Acquired valvular heart disease. In: Feigenbaum H. Echocardiography. 5th ed. Philadelphia: Lea & Febiger; 1995.; Levy D, Savage D. Prevalence and clinical features of mitral valve prolapse. Am Heart J. 1987;113(5):1281-90. DOI:10.1016/0002-8703(87)90956-2.; Mantegazza V, Volpato V, Gripari P, et al. Multimodality imaging assessment of mitral annular disjunction in mitral valve prolapse. Heart. 2020;107(1):25-32. DOI:10.1136/heartjnl-2020-317330.; Savage DD, Garrison RJ, Devereux RB, et al. Mitral valve prolapse in the general population. 1. epidemiologic features: the Framingham study. Am Heart J. 1983;106(3):571-6. DOI:10.1016/0002-8703(83)90704-4.; Freed LA, Levy D, Levine RA, et al. Prevalence and clinical outcome of mitral-valve prolapse. N Engl J Med. 1999;341(1):1-7. DOI:10.1056/NEJM199907013410101.; Martini B, Basso C, Thiene G. Sudden death in mitral valve prolapse with Holter monitoring-documented ventricular fibrillation: evidence of coexisting arrhythmogenic right ventricular cardiomyopathy. Int J Cardiol. 1995;49(3):274-8. DOI:10.1016/0167-5273(95)02294-7.; Nalliah CJ, Mahajan R, Elliott AD, et al. Mitral valve prolapse and sudden cardiac death: a systematic review and meta-analysis. Heart. 2019;105(2):144-51. DOI:10.1136/heartjnl-2017-312932.; Coutsoumbas GV, Di Pasquale G. Mitral valve prolapse with ventricular arrhythmias: does it carries a worse prognosis? Eur Heart J Suppl. 2021;23(Suppl):E77-E82. DOI:10.1093/eurheartj/suab096.; Sriram CS, Syed FF, Ferguson ME, et al. Malignant bileaflet mitral valve prolapse syndrome in patients with otherwise idiopathic out-of-hospital cardiac arrest. J Am Coll Cardiol. 2013;62(3):222-30. DOI:10.1016/j.jacc.2013.02.060.; Henle J. Handbuch der systematischen Anatomie des Menschen. v. 3 pt. 1. Germany: Vieweg; 1876.; Zimmerman J. The functional and surgical anatomy of the heart. Ann R Coll Surg. 1966;39(6):348-66.; McAlpine WA. Heart and Coronary Arteries: An Anatomical Atlas for Clinical Diagnosis, Radiological Investigation, and Surgical Treatment. New York, NY: Springer-Verlag; 1975.; Toh H, Mori S, Izawa Y, et al. Prevalence and extent of mitral annular disjunction in structurally normal hearts: comprehensive 3D analysis using cardiac computed tomography. Eur Heart J Cardiovasc Imag. 2021;22(6):614-22. DOI:10.1093/ehjci/jeab022.; Bharati S, Granston AS, Liebson PR, et al. The conduction system in mitral valve prolapse syndrome with sudden death. Am Heart J. 1981;101(5):667-70. DOI:10.1016/0002-8703(81)90235-0.; Hutchins GM, Moore GW, Skoog DK. The association of floppy mitral valve with disjunction of the mitral annulus fibrosis. N Engl J Med. 1986;314(9):535-40. DOI:10.1056/NEJM198602273140902.; Basso C, Marra MP, Rizzo S, et al. Arrhythmic Mitral Valve Prolapse and Sudden Cardiac Death. Circulation. 2015;132(7):556-66. DOI:10.1161/circulationaha.115.016291.; Dejgaard LA, Skjølsvik ET, Lie ØH, et al. The mitral annulus disjunction arrhythmic syndrome. J Am Coll Cardiol. 2018;72(14):1600-9. DOI:10.1016/j.jacc.2018.07.070.; Bennett S, Thamman R, Griffiths T, et al. Mitral annular disjunction: a systematic review of the literature. Echocardiography. 2019;36(8):1549-58. DOI:10.1111/echo.14437.; van Wijngaarden AL, de Riva M, Hiemstra YL, et al. Parameters associated with ventricular arrhythmias in mitral valve prolapse with significant regurgitation. Heart. 2021;107(5):411-8. DOI:10.1136/heartjnl-2020-317451.; Han HC, Ha FJ, Teh AW, et al. Mitral valve prolapse and sudden cardiac death: a systematic review. J Am Heart Assoc. 2018;7(23):e010584. DOI:10.1161/JAHA.118.010584.; Chivulescu M, Aabel E, Dejgaard L, et al. Cardiac Arrest in a Patient With Arrhythmic Mitral Valve Prolapse Syndrome. Multiple Possible Etiologies. J Am Coll Cardiol Case Rep. 2021;3(16):1769-73. DOI:10.1016/j.jaccas.2021.08.019.; Essayagh B, Iacuzio L, Civaia F, et al. Usefulness of 3-tesla cardiac magnetic resonance to detect mitral annular disjunction in patients with mitral valve prolapse. Am J Cardiol. 2019;124(11):1725-30. DOI:10.1016/j.amjcard.2019.08.047.; Широбоких О. Е., Былова Н. А. Пролапс митрального клапана и внезапная сердечная смерть: кто в группе риска? Архивъ Внутренней Медицины. 2016;3(29):25-9. DOI:10.20514/2226-6704-2016-6-3-25-29.; Bains S, Tester DJ, Asirvatham SJ, et al. A novel truncating variant in FLNC-encoded filamin C may serve as a proarrhythmic genetic substrate for arrhythmogenic bileaflet mitral valve prolapse syndrome. Mayo Clin Proc. 2019;94(5):906-13. DOI:10.1016/j.mayocp.2018.11.028.; Muthukumar L, Rahman F, Jan M.F, et al. The Pickelhaube Sign: Novel Echocardiographic Risk Marker for Malignant Mitral Valve Prolapse Syndrome. JACC Cardiovasc Imaging. 2017;10(9):1078-80. DOI:10.1016/j.jcmg.2016.09.016.; Cipriani A, Bauce B. Ventricular arrhythmias in mitral valve prolapse: new explanations for an old problem. Heart. 2021;107(5):353-4. DOI:10.1136/heartjnl-2020-318086.; Haugaa K. Improving the imaging diagnosis of mitral annular disjunction. Heart. 2021;107(1):4-5. DOI:10.1136/heartjnl-2020-317667.; Villatore A, Sala S, Stella S, et al. Autoimmune Myocarditis and Arrhythmogenic Mitral Valve Prolapse: An Unexpected Overlap Syndrome. J Cardiovasc Dev Dis. 2021;8(11):151. DOI:10.3390/jcdd8110151.; Constant Dit Beaufils AL, Huttin O, Jobbe-Duval A, et al. Replacement myocardial fibrosis in patients with mitral valve prolapse: relation to mitral regurgitation, ventricular remodeling and arrhythmia. Circulation. 2021;143(18):1763-74. DOI:10.1161/CIRCULATIONAHA.120.050214.; Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. ESC Scientific Document Group. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2015;36(41):2793-867. DOI:10.1093/eurheartj/ehv316.; Лебедев Д. С., Михайлов Е. Н., Неминущий Н. М., и др. Желудочковые нарушения ритма. Желудочковые тахикардии и внезапная сердечная смерть. Клинические рекомендации 2020. Российский Кардиологический Журнал. 2021;26(7):4600. DOI:10.15829/1560-4071-2021-4600.; Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guide-lines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91-e220. DOI:10.1016/j.jacc.2017.10.054.; Pelliccia A, Sharma S, Gati S, et al. ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. DOI:10.1093/eurheartj/ehaa605.; Higuchi K, Bhargava M. Management of premature ventricular complexes. Heart 2022;108(7):565-72. DOI:10.1136/heartjnl-2020-318628.; https://www.rpcardio.com/jour/article/view/2884

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2884
https://doi.org/10.20996/1819-6446-2023-01-05

Sudden cardiac death in myocarditis ; Внезапная сердечная смерть при миокардите

Συγγραφείς: Taradin G.G., Ignatenko G.A., Kugler T.E.

Συνεισφορές: 1

Πηγή: Almanac of Clinical Medicine; Vol 51, No 2 (2023); 99-109 ; Альманах клинической медицины; Vol 51, No 2 (2023); 99-109 ; 2587-9294 ; 2072-0505

Θεματικοί όροι: myocarditis, etiology, sudden cardiac death, arrhythmia, ventricular tachycardia, COVID-19, SARS-CoV-2, миокардит, этиология, внезапная сердечная смерть, аритмия, желудочковая тахикардия

Περιγραφή αρχείου: application/pdf

Relation: https://almclinmed.ru/jour/article/view/7700/1561; https://almclinmed.ru/jour/article/view/7700/1567; https://almclinmed.ru/jour/article/downloadSuppFile/7700/104638; https://almclinmed.ru/jour/article/downloadSuppFile/7700/104639; https://almclinmed.ru/jour/article/downloadSuppFile/7700/104640; https://almclinmed.ru/jour/article/downloadSuppFile/7700/104641; https://almclinmed.ru/jour/article/downloadSuppFile/7700/104642; https://almclinmed.ru/jour/article/downloadSuppFile/7700/104643; https://almclinmed.ru/jour/article/view/7700

Διαθεσιμότητα: https://almclinmed.ru/jour/article/view/7700
https://doi.org/10.18786/2072-0505-2023-51-010

Профилактика внезапной сердечной смерти у детей и подростков на уроках физкультуры ; Prevention of sudden death in children during physical training classes

Συγγραφείς: Сухарева, Г. Э., Трофимова, И. А., Чеботарь, П. С., Suchareva, G., Trofimova, I., Chebotar, P.

Θεματικοί όροι: SUDDEN CARDIAC DEATH, PHYSICAL TRAINING CLASSES, CHILDREN AND ADOLESCENTS, QUESTIONING, PREVENTION, ВНЕЗАПНАЯ СЕРДЕЧНАЯ СМЕРТЬ, ФИЗКУЛЬТУРА, ДЕТИ И ПОДРОСТКИ, АНКЕТИРОВАНИЕ, ПРОФИЛАКТИКА ДЕТСКОЙ СМЕРТНОСТИ

Περιγραφή αρχείου: application/pdf

Relation: Проблемы качества физкультурно-оздоровительной и здоровьесберегающей деятельности образовательных организаций : сборник материалов 9-й Всероссийской научно-практической конференции. - 2019

Διαθεσιμότητα: https://elar.uspu.ru/handle/ru-uspu/34037